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Besides neurodegeneration, cerebrovascular disease (CeVD) is also considered a 
major cause and contributor to cognitive decline and dementia. Damage to the 
cerebral small and large blood vessels has been implicated in CeVD pathology. 
Magnetic Resonance Imaging (MRI) correlates of cerebral small vessel diseases 
include lacunes and white matter hyperintensities which have been widely linked to 
stroke, cognitive decline, dementia and mortality. However, these lesions do not fully 
capture the burden of CeVD in the brain. In this context, cerebral microbleeds and 
microinfarcts have emerged as the new imaging markers of CeVD pathology. 
Moreover, large vessel disease such as intracranial stenosis has increasingly gained 
importance in Asian population due to higher prevalence of vascular risk factors. 
Advancement in MRI quantitative segmentation of the brain parenchyma (cortex and 
subcortical regions) has also revealed subtle neuronal damage in cognitive 
impairment and dementia. However, the data on the determinants and the 
consequences of these CeVD markers and involutional changes are lacking.   
Despite advances in neuroimaging techniques, damage to the cerebral small vessels is 
difficult to visualize in-vivo. Retina as an extension of the brain, can serve as a 
complimentary technique to study subtle and early microvascular and neuronal 
damage involved in CeVD and cognitive impairment. Retinal microvascular (vessel 
calibers) and neuronal changes (thinning of retinal nerve fiber layer) have been linked 
to cognitive impairment, dementia and poor cognitive performance on the 
neuropsychological testing. However, association of other retinal quantitative 
parameters such as fractal dimension, tortuosity and ganglion cell inner plexiform 
layer with CeVD and involutional changes remains to be explored.  
Hence, the major objective of this proposal is to examine cerebral and retinal imaging 
biomarkers for cognitive impairment and dementia. Based on this objective advanced 
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cerebral and retinal imaging techniques are applied in two observational studies to 
demonstrate the following;  
1) Role of cerebral small vessel diseases (cerebral microbleeds and microinfarcts) in 
cognitive impairment and dementia, 
2) Role of large vessel disease (intracranial stenosis) in cognitive impairment and 
dementia,  
3) Role of involutional changes (cortical thinning and subcortical structure volumes) 
in cognitive impairment and dementia,  
4) Association of retinal microvascular and neuronal layers changes with CeVD, 
involutional changes and cognitive impairment. 
The major findings from this thesis are:  
1) Cerebral small vessel diseases (cerebral microbleeds and microinfarcts) are 
associated with cognitive impairment and poor performance on neuropsychological 
assessment. 
2) Large vessel disease (intracranial stenosis) is highly prevalent in Chinese and is 
associated with cognitive impairment and dementia in the presence of ischemia. 
3) Cortical thinning and decreasing subcortical structure volumes are associated with 
reduced performance in global and domain specific cognitive scores. 
4) Retinal microvascular changes (fractals and tortuosity) are associated with 
cerebrovascular diseases on MRI scans and preclinical cognitive impairment. 
5) Retinal neuronal damage reflected by thinning of ganglion cell inner plexiform 
layer is associated with cerebral atrophy on MRI scans.  
In conclusion, both cerebral and retinal parameters may serve as: 
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- Surrogate markers to study the exact role of microvascular pathology and 
involutional changes 
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CHAPTER 1:  





1.  INTRODUCTION 
1.1  Aging, Dementia and Cerebrovascular Diseases 
The world population is aging rapidly. The less economically developed countries 
gain about 10 hours per day in life expectancy1 while the global maximum life 
expectancy continues to increase linearly as it has over the last 160 years due to better 
health care, sanitation, education and economic wellbeing.2 People aged 60 years and 
over make up 12.3% of the global population which is expected to increase up to 22% 
by 2050. The World Health Organization (WHO) has projected that by 2025, about 
three quarters of world population aged 60 years and above will be living in 
developed countries.3 As a result of the rapid demographic aging, the burden from 
common age related diseases such as dementia is therefore expected to rise 
dramatically.4 This will not only affect the quality of life of patients and their care 
givers but will also increase the health care costs. World Alzheimer Report has 
pointed out that the annual societal and economic cost of dementia has increased by 
35% from its previous estimate of 604 billion USD.5 Asia and Europe are the two 
main regions where a number of countries will face an increase in aging population in 
the near future.6 As nearly 60% of the total world population of 7 billion is living in 
Asia, the burden of dementia will have major implications on the Asian continent 
compared to Europe and United States.7 Specifically, it is expected that not only will 
there be a rise in the proportion of persons aged ≥ 60 years among the total Asian 
population from 10% in 2010 to 24% in 2050, but also the absolute number of elderly 
will dramatically increase from 414 million to 1.2 billion.7, 8  
The most common type of dementia is Alzheimer’s disease (AD) followed by 
vascular dementia and other rare causes such as Fronto-Temporal Dementia and 
Lewy Body Dementia.9 There is increasing evidence that before a clinical diagnosis 
of AD is made, early signs of the disease are already present. Mild cognitive 




transitional stage between normal cognitive function and AD. Persons diagnosed with 
MCI or CIND are in general, at high risk of conversion to AD paralleled by increased 
decline in disability and mortality.10, 11 However, the mechanism behind this increased 
risk remains unknown. 
Besides neurodegeneration, cerebrovascular diseases (CeVD) such as strokes and 
white matter lesions are considered a major cause and contributor to cognitive decline 
and dementia in aging population.12 Autopsy studies have shown that the vascular 
pathology commonly co-exist in subjects diagnosed with AD and may even trigger or 
potentiate the existing neurodegenerative process.13 This is possibly because both 
CeVD and AD share common vascular risk factors such as hypertension, 
hyperlipidemia and diabetes.14 Overt clinical symptoms of CeVD and dementia 
reflect irreversible brain damage thereby highlighting the importance of early markers 
of vascular pathology and involutional changes. These markers of microvascular 
damage and involutional changes may allow early identification of at-risk patients 
and hence could be a potential target for early intervention. Moreover, these 
biomarkers may also serve as surrogate markers of disease progression providing 
information on prognosis and treatment efficacy.  
1.2  Magnetic Resonance Imaging Correlates of Cerebrovascular Diseases 
Non-invasive neuroimaging techniques such as magnetic resonance imaging (MRI) 
play an important role in identifying both clinical and subclinical structural brain 
changes. Over the last two decades, MRI has been increasingly utilized in unraveling 
the role of cerebrovascular disease pathology involved in cognitive impairment and 
dementia. Manifestations of CeVD on MRI commonly include subcortical infarcts, 
lacunes, white matter hyperintensities (WMH), cerebral microbleeds, enlarged 
perivascular spaces and even brain atrophy. An extensive work on infarcts and WMH 




advancements in conventional MRI hard and soft wares, it is possible to visualize 
other important markers of CeVD which includes cerebral microbleeds and 
microinfarcts. Moreover, there is an increasing focus on large vessel diseases (extra 
and intracranial stenosis) in Asians due to higher prevalence of vascular risk factors. 
Besides these visible vascular diseases on MRI, it is also feasible to quantitatively 
assess underlying subtle changes involved in involutional changes which include 
cortical thickness and volumes of the brain parenchyma.  
However, conventional MRI correlates of these CeVD do not fully capture the burden 
of vascular pathology in the brain as other small parenchymal lesions and 
vasculopathologic changes remain undetected in-vivo. As an expensive technique, 
MRI cannot feasibly be applied to large population based studies. Furthermore, there 
are several contraindications to MRI which includes pacemakers, metallic implants 
and claustrophobia which makes it less practicable in the elderly. 
1.3  Retinal Imaging – A Complimentary Technique to Study Cerebral 
Microvascular and Involutional Changes 
Retina shares several embryological, physiological and anatomical features with 
cerebral microcirculation while maintaining a close contact via optic nerve. In 
contrast to MRI, retinal imaging remains a time efficient and less expensive 
technique. Hence retinal imaging can be utilized as a complimentary technique to 
non-invasively assess subtle microvascular and involutional changes in the brain. 
These retinal changes may serve as biomarker of preclinical stages of the disease and 
might also predict the onset of the disease.  
Systemic vascular diseases such as hypertension, hyperlipidemia and diabetes not 
only affects the cerebral microvessels but also the retinal vasculature which are 
visible on fundus photography as retinopathy signs- the end stage of retinal 




and other cardiovascular events. With the advent of the geometric computer based 
methods, it is now possible to quantify retinal vascular parameters which reflect early 
changes in the retinal vascular network. Compared to the qualitative retinopathy 
signs, changes in retinal microvessels can even be assessed in the absence of visible 
pathology and hence can provide insight into the role of microvascular pathology in 
the preclinical stages of the CeVD and cognitive impairment.  
Apart from retinal microvessels, retinal axonal and ganglion cells are connected to the 
central nervous system through the optic nerve. Structural changes to the optic nerve 
can be non-invasively measured using high resolution techniques which can quantify 
retinal nerve fiber thickness. Neurodegeneration can directly affect the retinal axons 
and cell bodies or vice versa through transneuronal degeneration. Retinal neuronal 
loss can be found in dementia, stroke and other neurodegenerative diseases 
(Parkinson’s disease and multiple sclerosis). So far, these studies have not been able 
to provide conclusive answers. Therefore, three dimensional architecture of the retina 
still remains to be analyzed. 
2.  OBJECTIVE AND SPECIFIC AIMS  
This thesis intends to explore whether both brain and retina can serve as biomarkers 
for cerebrovascular and involutional changes involved in cognitive impairment and 
dementia. 
Hence, the major objective of this thesis is to examine the age-related structural 
changes in the brain and retina related to cognition using novel structural 
cerebral magnetic resonance (MR) and retinal imaging markers. Based on the 
overall objective, the following specific aims will be addressed in this thesis; 
Specific aim 1 – Brain markers of small vessel disease 




1b. To determine the clinical relevance of cerebral cortical microinfarcts on 3 Tesla in 
a memory clinic population. 
1c. To study the determinants and consequences of cerebral cortical microinfarcts on 
3 Tesla in a subsample of population based study. 
Specific aim 2 – Brain marker of large vessel disease 
2a. To examine the association of Intracranial stenosis (ICS) with cognitive 
impairment and to show whether this association is mediated by MRI markers in a 
subsample of population based study. 
2b.  To examine the association of intracranial stenosis with cognitive impairment, 
dementia and their subtypes in a memory clinic population. 
Specific aim 3 – Brain markers of involutional changes 
3a.  To study the determinants and consequences of cortical thickness. 
3b. To study the risk factors of subcortical structures on neuroimaging and their 
association with cognitive impairment and dementia. 
Specific aim 4 – Retinal markers of cerebrovascular disease and involutional 
changes 
4a. To examine the link between quantitative retinal vascular parameters and MRI 
markers. 
4b. To examine the association of quantitative retinal vascular parameters and 
preclinical cognitive impairment. 






3. OUTLINE OF THE THESIS 
The work described in this thesis is summarized in 14 chapters. The first 3 chapters of 
this thesis include scope of the study, aims and objectives, literature review and 
methodology. In chapters 4 to 13, the whole thesis is divided into three main parts; 1) 
Brain markers of cerebrovascular diseases, 2) Brain markers of involutional changes, 
and 3) Retinal markers of cerebrovascular diseases and involutional changes. The 
final chapter 14 covers the synthesis with future implications.  
Chapter 1 describes the scope of the study, objective and specific aims which this 
thesis attempts to study. 
Chapter 2 compiles the literature review related to established cerebrovascular 
disease markers of cognitive impairment and dementia and how the other MRI 
markers additionally add to the cerebrovascular disease burden and affect cognition. 
Moreover, I also describe how retinal imaging helps to study microvascular and 
involutional changes in the brain.  
Chapter 3 describes the study methodology in detail which consists of study 
population, study design, risk factors, determinants and outcomes of interest 
examined in each study. Retinal imaging, neuroimaging and cognitive assessments 
common among different studies are described in detail. Study specific determinants 
and imaging (brain and retina) unique to each study are further described in each 
chapter. 
Part I includes the next five chapters on the brain markers of cerebrovascular diseases  
Chapter 4 examines the effects of cerebral microbleeds on cognition from a 





Chapter 5 investigates the feasibility of detection of cerebral cortical microinfarcts 
(CMIs) on 3Tesla MRI and further determines the clinical relevance of this emerging 
new marker of CeVD in dementia. This is performed in a memory clinic setting. 
Chapter 6 explores the determinants and consequences of CMIs. The association of 
CMIs with brief cognitive tests and cognitive domains are examined using data from 
the EDIS study. 
Chapter 7 investigates the association of intracranial stenosis (ICS) with cognitive 
impairment and whether these associations are mediated by MRI markers. This is 
again performed in the EDIS cohort. 
Chapter 8 further investigates the role of ICS in cognitive impairment and dementia.  
The association of ICS with vascular vs. non-vascular subtypes of cognitive 
impairment is also explored. This is a case control study recruiting cases from the 
memory clinic and controls from both community and memory clinic. 
Part II includes two chapters on brain markers of involutional changes. 
Chapter 9 aims to identify the risk factors of cortical thickness (a reflection of 
cerebral involutional changes) and its eventual effects on cognition. Correlations of 
cortical thickness with varying severity of cognitive impairment and cognitive 
performance are performed in the EDIS cohort. 
Chapter 10 further explores the subcortical structure volumes in cognitive 
impairment and dementia. Major determinants and consequences of subcortical 
structures are reported from EDIS study whereas the findings on specific pattern of 
subcortical volume reduction in vascular vs. non vascular cognitive impairment is 
examined in memory clinic data. 





Chapter 11 investigates the association of the retinal vascular parameters with 
cerebral small vessel diseases. This is performed in the EDIS study where the 
subjects have both retinal and neuroimaging gradings. 
Chapter 12 examines the association of retinal vascular parameters with preclinical 
stages of cognitive impairment. These associations are explored with both the clinical 
outcomes and neuropsychological assessments in participants from EDIS study. 
Chapter 13 examines whether thinning of the retinal neuronal layers is associated 
with global and regional cerebral atrophy on MRI among participants of the EDIS 
study.   
Chapter 14 includes a synthesis of the main findings of the chapters 4 – 13, with a 
discussion on the implications of these markers in cerebrovascular diseases and 
cognitive impairment. Finally limitations and future perspectives from this thesis are 
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CHAPTER 1 – FIGURE  
 
Figure 1: Markers of cerebrovascular diseases and involutional changes 
In the Alzheimer’s pathological cascade, amyloid and tau deposition takes place in the early 
stages of the disease followed by brain and retinal changes before the development of clinical 
symptoms. These brain and retinal changes may occur concurrently and hence certain 
biomarkers on cerebral and retinal imaging can reflect the microvascular and involutional 
changes in the brain. Manifestations of cerebrovascular diseases on MRI include infarcts, 
white matter hyperintensities, microbleeds, microinfarcts and intracranial stenosis. Retinal 
mircovascular damage is reflected by changes in calibers, fractional dimension and tortuosity. 
Neuronal damage in the brain can be measured by cortical thickness and subcortical structures 




















1. PREVALENCE OF DEMENTIA AND COGNITIVE IMPAIRMENT- 
FACTS AND FIGURES 
Dementia is one of the most important neurological disorders in the elderly. A recent 
WHO publication has reported that there are currently 35.6 million people living with 
dementia worldwide; this number is expected to triple by 2050.1 The prevalence of 
dementia rapidly increases from 2-3% in ages 70-75 years to 20-25% in ages 80 and 
above. Moreover, whilst approximately 60% of patients with dementia were living in 
developing countries in 2001, this is expected to rise to 71% by 2040.2 This is due to 
the non-uniform increase in the number of dementia patients with four fold increase 
in Asia compared to two fold increase in Europe and USA.2 The prevalence of 
dementia in Caucasian population ranges from 5.4% in those aged >60 years to 
68.3% at age 90 years and above. With respect to the pre-clinical stages of dementia 
[cognitive impairment no dementia (CIND)], the overall prevalence ranges from 
14.9% to 22.2% in Caucasians.2 Previous studies from Asian population have 
reported the corresponding figures to be 2.6-60.5% for dementia3, 4 and 7.2-22.2% for 
CIND.5, 6  
Our recent findings from Singapore population have shown an overall age 
standardized prevalence of cognitive impairment to be 15.2% in Chinese7 and 25.5% 
in Malays.8 These results on ethnic differences have implications beyond Singapore 
as they constitute the major ethnic groups in South East Asia such as Malaysia and 
Indonesia. This higher prevalence of cognitive impairment among Asia Pacific 
regions will put a significant burden on the health care systems in these regions.8 
Hence it is important to target research efforts on Asian populations so as to identify 
novel markers for pre-clinical cognitive impairment and dementia which are 
economically feasible for predicting and monitoring disease progression.  





Dementia- a clinical syndrome – is characterized by slow and progressive loss of 
memory and other cognitive abilities (such as language, comprehension, attention, 
judgment) which are sufficiently severe to interfere with a person’s everyday 
activities. A clinical diagnosis of dementia is based on the Diagnostic and Statistical 
Manual of Mental Disorders – 4th edition (DSM-IV). According to this criteria, the 
development of multiple cognitive deficits is necessary for diagnosis of dementia 
which includes 1) memory impairment and 2) any one of the followings; language 
problems, inability to identify familiar objects/faces, impaired ability to carry out 
motor activities, disturbance in planning, organizing and sequencing, 3) significant 
impairment in social and occupational functioning, 4) sudden or gradual onset with 
progression in cognitive decline.9 The history of multiple cognitive deficits is usually 
collected from both the patients and caregivers and is also confirmed on the objective 
neuropsychological testing (either brief or detailed tests).  
Mostly dementia is underdiagnosed due to overlapping symptoms with other 
neurological and psychiatric disorders. Moreover, as memory problems are 
considered a normal part of aging process especially in the Asian population, 
dementia is often overlooked or identified at the later stage of the disease.10  
2.2  Types of Dementia  
Alzheimer’s Disease  
Alzheimer’s disease (AD) – the most common type of dementia accounts for 60-80% 
of all dementia cases.11 AD is clinically diagnosed by gradual onset and slow 
progression of cognitive symptoms predominantly memory and one or more other 
cognitive domains together with functional loss. It is distinguished from other types 
of dementia and neurological disorders by lack of substantial cerebrovascular 
diseases on MRI scans. The pathophysiology of AD has been related to the deposition 




In normal conditions, amyloid ß peptides are formed during the metabolism of 
amyloid precursor protein and are rapidly removed from the brain. Due to reduced 
clearance of Aß peptides, they aggregate to form oligomers and eventually deposit in 
the brain in the form of plaques.13 On the other hand, tau protein is a microtubule 
associated protein involved in stabilizing microtubules in neurons. Abnormal 
phosphorylation of tau proteins leads to microtubule instability and their aggregation 
in the form of neurofibrillary tangles. Both amyloid and tau proteins damage neuronal 
synapses and causes neuronal cell death.14 These pathological changes are more 
common in early onset AD than in persons with late onset AD. Grossly, AD is 
characterized by loss of neuronal cell bodies and dendrites (gray matter) together with 
loss of axonal myelin sheath (white matter) of the brain.   
Vascular Dementia 
Vascular dementia (VaD) on the other hand, occurs after stroke and is the second 
most common type of dementia. Clinical history is uniquely represented by sudden 
onset of cognitive deficits after stroke with no recovery or continued deterioration 
after 3 months of clinical stroke, or abrupt deterioration of cognitive function with 
fluctuating or step wise progression in cognitive decline. VaD is primarily due to 
vascular damage and it is mostly correlated with the presence of cerebrovascular 
lesions on MRI scans.15 These lesions may appear in the form of multiple infarcts, 
strategic single infarcts, small vessel diseases, hypoperfusion, hemorrhage or any 
combination thereof.   
2.3   Cerebrovascular Disease and Alzheimer’s Disease 
Despite the clinical classification of AD and VaD, increasing evidences suggest that 
the cerebrovascular disease and AD pathology have significant overlap and similar 
brain structures might be damaged in both AD and CeVD.16, 17 Neuropathological 




one-third cases18 and conversely about a half of dementia subjects with CeVD also 
have underlying AD pathology on autopsy.19 This CeVD can be additive with AD 
pathology in impairing cognitive function and increasing the likelihood of dementia.  
2.4  Cognitive Impairment 
Pathological cascade of AD takes place years before the onset of clinical symptoms. 
By the time clinical cognitive deficits appear, irreversible neuronal damage has 
already taken place. Hence it is imperative to identify patients at risk of converting to 
dementia so that early treatment could be targeted at this stage where there is still a 
chance of preserving cognitive function and functional independence. 
Mild Cognitive Impairment 
Mild cognitive impairment (MCI) is considered a transitional stage to dementia 
particularly AD. MCI is characterized by subjective/informant complaints of memory 
problems, impairment in at least one domain in neuropsychological assessment and 
difficulty in performing activities without loss of functional independence.20, 21 The 
annual conversion rate of MCI subjects to dementia is about 5-10% and hence is the 
potential target group for early intervention.22, 23   
Cognitive Impairment No Dementia 
Cognitive impairment no dementia (CIND) is a relatively recent concept and is 
defined based on the impairment in any objective cognitive domains in 
neuropsychological assessment.24 Unlike MCI, CIND subjects do not necessarily 
have to have subjective complaints. CIND has been regarded as an unstable group 
with some persons progressing rapidly into dementia while others experience a more 
indolent course.24, 25 Limited data is available on the subtypes of CIND based on the 
severity and their associated risk factors. 




It is increasingly being recognized that systemic vascular diseases such as 
hypertension, hypercholesterolemia and diabetes are the major risk factors for both 
cognitive impairment and dementia.26, 27 It has been suggested that mid-life 
hypertension increases atherosclerosis and lipohyalinosis of the small vessels in the 
brain thus leading to cognitive dysfunction. The relationship between cholesterol and 
dementia is linked to the increased production of amyloid proteins in brain leading to 
neuronal death. Type-II diabetes mellitus on the hand is suggested to play an 
important role in cognitive decline by promoting ischemic cerebral changes 
secondary to hyperglycemia and function as a modulatory factor in association with 
other co-morbid conditions as hypertension and hyperlipidemia.28 This suggests that 
these vascular risk factors act synergistically and promote cerebrovascular diseases 
through microvascular damage and increase the risk of cognitive impairment and 
dementia. 
3.  CEREBROVASCULAR DISEASES 
Cerebrovascular diseases encompass both small and large vessel diseases. 
Cerebral Small Vessel Diseases 
Cerebral small vessel diseases are a group of pathological disorders such as 
arteriosclerosis, atherosclerosis, vasculitis, micro-aneurysms, fibrinoid necrosis that 
affects the small vessels (arteries, arterioles, veins and capillaries) in the brain.29 
These pathological changes dysregulate cerebral blood flow causing local ischemia. 
Disruption of the blood brain barrier results in the leakage of blood and plasma into 
perivascular tissue causing microhemorrhages, edema and tissue damage which is 
visible as ischemic infarcts. Cumulative tissue damage leads to rarefraction and 
demyelination as seen in white matter lesions.30 However, unlike large vessels, 
cerebral small vessels cannot be visualized in vivo. Therefore, lesions in the brain 




markers of small vessel diseases. These markers are identified as lacunes, white 
matter hyperintensities, microbleeds and enlarged perivascular spaces on MRI. In 
order to differentiate these markers on neuroimaging and to have unified definitions 
for grading these lesions, STandards for ReportIng Vascular changes on 
nEuroimaging (STRIVE)31 criteria has been recommended which are as follows;  
Lacunar Infarcts  
Lacunar infarcts are defined as round or ovoid lesions, 3-15 mm in diameter, with 
low signal on T1weighted image and Fluid Attenuated Inversion Recovery (FLAIR); 
a high signal on T2 weighted image, and a hyperintense rim with center following the 
cerebrospinal fluid intensity.  
White Matter Hyperintensities (WMH) 
WMH are defined as signal abnormalities of variable sizes in white matter, 
hyperintense on T2-weighted image or FLAIR, without cavitation.  
Both lacunes and WMH are endemic in the elderly population with a prevalence of 
up to a quarter for infarcts and 96% for any severity of WMH in persons ≥ 60 years. 
Several studies have also shown association of lacunes and WMH with risk of 
stroke32 and development of cognitive impairment and dementia.33-35 These lesions 
are also associated with cognitive decline36, 37 and all-cause mortality35, 38, 39 (Table 2 
– 1a). Hence an extensive work is available on these established markers of CeVD.  
In the past decade, another marker that has been suggested to reflect cerebral small 
vessel disease is the presence of cerebral microbleeds. 
Cerebral Microbleeds (CMBs) 
CMB is defined as focal, rounded areas of hypointensity (T1 and T2 weighted 
images), 2-10 mm in diameter with blooming on T2*-weighted scans, which 




healthy populations the reported prevalence of CMBs ranges from 3.8% to 38.3%,40 
whereas in patients with stroke the corresponding figures may be as high as 50-
70%.41, 42 CMBs in the deep subcortical regions have been linked to hypertension 
whereas those in lobar are believed to be related to cerebral amyloid angiopathy 
(CAA). This amyloid plaque deposits in leptomeningeal and cortical arteries leading 
to vessel occlusion and reduction in microvessel density.43, 44 There is a considerable 
debate on the exact role of CMB in the pathophysiology of cognitive impairment and 
dementia.  The effect of CMB on cognition has been variable. Some studies have 
reported significant association,45 whereas others have either failed to find an 
independent association of CMB and cognitive decline 46-48 or found a striking effect 
on a specific domain (executive function, processing speed) with no effect on other 
cognitive domains49, 50 or brief test51 (Table 2 – 1b). These differences might be due 
to different cognitive tests used (brief tests vs. detailed) and varying criteria to define 
CMBs. 
Despite the extensive literature on cerebrovascular diseases on MRI, there is still 
debate that these MRI correlates of small vessel diseases do not fully capture the 
vascular damage in the brain parenchyma. In this context, cortical cerebral 
microinfarcts have gained increasing attention. 
Cortical Cerebral Microinfarcts (CMIs) 
Over the past decade, several neuropathological studies have suggested that CMIs are 
also manifestations of small vessel disease in addition to the established markers.52, 53 
They are reported to be the most wide spread form of brain infarction and are 
involved in the pathway between small vessel disease and cognitive impairment.54, 55 
CMIs are a common lesion in the elderly and are often seen in autopsy studies 
performed on both healthy elderly and patients with dementia. They are reported to 




patients with vascular dementia.55 CMIs are most commonly present in the cortex but 
may also appear in the subcortical regions.56 Microscopically, these lesions appear as 
sharply delineated areas of tissue necrosis.57 As CMIs can only be confirmed in 
pathological specimen of autopsied brain, this has its limitations as only small 
samples of brain tissue can be assessed and thus may not represent the true burden of 
such lesions. 
With the advancement of high resolution MRI scanners, it is now possible to detect 
CMIs in-vivo using 7T MRI.58 These lesions appear as perpendicular lesions in the 
cortical ribbon, <5mm in size, hyperintense on Fluid Attenuated Inversion Recovery 
(FLAIR) and T2 sequences and hypointense on T1 weighted images. They are 
distinguished from other hemorrhagic lesion, a vessel, or an artifact if they also 
appear as hypo or iso-intense lesions on FLAIR and T2 images. However, high 
resolution 7T scanning remains an expensive technique with limited accessibility in 
clinical settings. Furthermore there are challenges in terms of image homogeneity and 
strict safety regulations due to high strength magnetic field which restricts patients 
with metallic implants and stents to undergo 7T MRI which may still be possible with 
lower field strength 3T scanning. Hence it is of note that two recent reports have now 
shown that the CMIs are also visible on 3T mainly because of the availability of 
ultrahigh resolution 3T machines58, 59 in both clinical and research settings. However 
limited data exist on the risk factors60 and consequences of CMIs on 3T MRI scans 61 
(Table 2 – 2). 
Cerebral Large Vessel Diseases 
Besides the small blood vessels, large vessel diseases such as atherosclerosis obstruct 
the lumen of both extracranial and intracranial arteries and are major risk factors of 
stroke and mortality. Mounting evidences suggest that the coronary artery disease,62, 




thromboembolism which results in cardioembolic stroke.67 Postmortem studies have 
shown that severe arterial atherosclerosis of the Circle of Willis is also a common 
finding in dementia with reported prevalence of 53% in VaD, 30% in AD patients and 
20% in non-demented brains68, 69 (Table 2 - 3a). It has been hypothesized that Circle 
of Willis occlusion can lead to hypoperfusion with selective neuronal loss and may 
even trigger the neurodegenerative process by promoting amyloid accumulation.68 
Ante mortem studies have suggested that extracranial large artery disease is 
associated with cognitive impairment and poorer performance on several cognitive 
tests.70-73 Moreover, limited data has also reported cognitive alterations in patients 
with stroke, transient ischemic attack and internal carotid occlusion.74, 75  The effects 
of large artery stenosis on cognitive decline and risk of dementia has been 
contradictory with some reporting significant association whereas others do not 76 
(Table 2 - 3b). This disparity among studies are due to different imaging modalities 
used (transcranial doppler, magnetic resonance angiography, duplex ultrasound) to 
assess carotid stenosis. Furthermore, they are largely focused on the extracranial 
carotid artery stenosis rather than intracranial stenosis. It has been reported that ICS 
in stroke patients vary among different ethnicities with a higher prevalence in 
Chinese (40-50%) compared to Caucasians (8-10%)77-79 (Table 2 - 3a). Hence, data 
on ICS from asymptomatic and community-based subjects – especially of Asian 
populations - are largely lacking. Moreover, its association with vascular vs. non-
vascular cognitive impairment and dementia subtypes has not been explored 
previously.   
4.  NEURODEGENERATION 
Neurodegeneration is an umbrella term for progressive loss of structure and function 
of a neuron including neuronal death. Overt pathology in neurodegeneration is 
characterized by focal loss of neurons with reactive gliosis.80 Neurodegeneration 




AD and other dementias. It involves both cortical and subcortical structures 
(hippocampus) and remains the strongest predictor of MCI conversion to AD81, 82 and 
tracking disease progression.83, 84 Quantitative structural imaging has provided more 
insights in region specific atrophy thus assisting in early diagnosis and in increasing 
diagnostic confidence. Recent reports have suggested that brain changes, particularly 
reduction in gray matter volumes are present even during normal aging 85-89 (Table 2 
- 4c). In this regard, cortical thickness provides an advantage of capturing the 
physical property of the brain that can be measured in an individual in vivo90, with 
thinning of the cortex corresponding to pathologic observations including cellular 
shrinkage, neuronal loss, and reduction of intracortical myelin.  
A consistent pattern of cortical thinning in AD comprises the medial temporal lobes; 
inferior and anterior temporal association cortices; superior, inferior, and medial 
parietal association cortices; along with superior and inferior frontal association 
regions91-94 (Table 2 - 4a). Dickerson and colleagues have demonstrated that a set of 
regions with cortical thinning specific to AD can reliably be used to predict 
progression to AD in subjects with MCI  and in older individuals without cognitive 
impairment.95, 96 In addition, a few studies have also suggested preclinical cognitive 
impairment to be associated with worse performance on cognitive testing97, 98 (Table 
2 - 4b). However, limited data remains on the determinants of cortical thinning99 and 
its effects on cognition from elderly population in Asia.100, 101  
Besides the cortical thickness, computational segmentations can also quantify 
subcortical structures volumes which include accumbens, amygdala, caudate, 
pallidum, putamen, thalamus, hippocampus and more recently brainstem.102 Atrophy 
of these subcortical structures has been reported in a wide range of neurological and 
psychiatric disorders.103-106 Some studies have now suggested smaller volumes of 
several subcortical structures in AD107-111 (Table 2 - 5). There is only a scant 




no cognitive impairment with a primary focus on age and sex effects88, 112-115 (Table 2 
- 5). Moreover, the specific pattern of subcortical atrophies in vascular vs. non 
vascular cognitive impairment remains unclear.116  
5.  LIMITATIONS OF NEUROIMAGING 
 
Despite the rapid advancement in neuroimaging techniques in facilitating the 
diagnosis of different dementia subtypes and providing invaluable tools in advancing 
our understanding of cerebrovascular pathophysiology, it remains an expensive 
technique with several contraindications for the elderly with metallic implants. 
Moreover, quantitative structural imaging techniques require specialized skills in 
standardizing and co-registering the images with constant visual inspection and 
manual editing. Hence, this MRI processing becomes a long and tedious procedure 
and is only available in selected research settings with image analysis expertise. 
These techniques are therefore, not suitable candidates for more widespread screening 
of patients at risk of cerebrovascular disease. 
6.  RETINA – WINDOW TO THE BRAIN 
6.1  Homology in Retinal and Cerebral Microvasculature 
Retina and brain are highly metabolically active tissues with high demands on 
metabolic substrates such as oxygen via the specialized vascular network. Since both 
organs share similar pattern of vascularization (macro and microvascular blood 
supply), there is also a similarity in their regulatory processes.117-119 Aging affects 
both retinal and cerebral microvasculature by reducing blood flow and exhibiting 
decreased oxygen and glucose demand.120-123 Similarly both retinal and cerebral 
microcirculations also exhibit morphological changes in hypertension, diabetes, 
stroke and other hereditary conditions such as cerebral autosomal-dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and 




Retinopathy is the end organ damage in retina and is reflected on the retinal 
photography as generalized and focal retinal arteriolar narrowing, arteriovenous 
nicking (from intimal thickening), media wall hyperplasia, hyaline degeneration, and 
vessel wall necrosis. These are typically seen in the two most important 
cardiovascular risk factors i.e. hypertension and diabetes.125, 126 Both conditions cause 
endothelial dysfunction and blood retinal barrier break down leading to retinal 
haemorrhages, micoraneurysms, exudates and nerve fiber layer ischemia (cotton wool 
spots).127, 128 Narrowing and occlusion of the small arterioles lead to vessel collapse 
and reduced network density129 while capillary occlusion leads to 
neovascularization.130 Similar microvascular changes occur in brain with luminal 
narrowing (replacement of tunica media and internal elastic lamina with fibrous 
tissue),131 increased vessel tortuosity and vessel permeability (break down of blood 
brain barrier).132 Thus, these diseases on pathology have illustrated that the events 
occurring in the retinal circulation are indeed, mirrored by the cerebral circulation.  
6.2  Possible Early Retinal Microvascular Changes 
As retinopathy reflects the severe late stages of retinal damage, it is imperative to 
identify the early changes taking place in retinal vessels before the development of 
the retinopathy signs. Over the last decade, computer-based retinal image analysis 
technique has enabled us to quantify possible early changes which might serve as 
potential biomarker for alterations in retinal microvasculature. It is based on the 
prevailing hypothesis that the design of the retinal vascular tree obeys simple 
physiological and physical principle that optimizes the operation of the system. 
Singapore I Vessel Assessment (SIVA) system has the ability to provide in-depth 
visualization of the retinal vasculature.  




Retinal arteriolar and venular calibers, which are calculated as the central retinal 
arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE), have 
emerged as a marker for preclinical stages of the diseases such as hypertension, 
diabetes, myocardial infarction and stroke.133-136 However, as both of these calibers 
are affected by different pathological mechanisms, they are usually analyzed 
separately.137, 138 Arteriolar calibers are largely affected by blood pressure, 
hypertension whereas venular calibers are sensitive to changes in blood glucose, 
diabetes, inflammation, dyslipidemia and smoking.137 Caliber measurements are 
affected by pulse period and single measurement reflects significant variability across 
pulse cycle. Hence there is a need for other potential parameters which are less time 
dependent.139 
Retinal Fractal Dimension 
Fractal dimension uses a mathematical concept to characterize the complexity of 
natural branching vascular networks, such as those seen in the retinal, coronary and 
pulmonary vascular systems. It captures the optimality and efficiency of blood 
distribution. Fractal analysis has been used in many aspects of medicine to detect 
changes in the retinal vasculature during early stages of retinal diseases, such as 
diabetic retinopathy and glaucoma.140 Studies show that fractal dimension increases in 
eyes with new vessels, and decreases with regression of these new vessels. Fractal 
analysis thus may offer new insights into systemic microvasculogenesis.141, 142 
Retinal Vascular Tortuosity 
Retinal vessel tortuosity reflects the curvature of the vessel path and reflects vessel 
integrity and barrier dysfunction. Increased retinal tortuosity has been linked to 
retinopathy of prematurity, hypertension and diabetes.143  




Several population based studies such as Atherosclerosis Risk In Communities 
(ARIC) study, the Cardiovascular Health Study and the Rotterdam Scan Study, which 
are based on healthy middle-aged and elderly population, have shown that the 
retinopathy signs were associated not only with incident stroke, but also with 
subclinical MRI-defined changes, including cerebral infarction, progression of white 
matter lesions, multiple cerebral microbleeds and atrophy (Table 2 - 6a).144-153 These 
associations were independent of other cardiovascular risk factors suggesting that 
these retinal signs may provide additional information on cerebral small vessel 
diseases. 
Previous studies have also shown that narrower arteriolar and wider venular calibers 
are associated with incident stroke.134, 135, 151, 154 With respect to the other markers of 
cerebrovascular diseases, the similar caliber parameters were also linked to incident 
lacunar infarcts, and white matter lesions progression151, 155, 156(Table 2 - 6b). 
However, conflicting results remain in terms of newer vascular parameters i.e. fractal 
dimension.157 Furthermore, the effects of vessel tortuosity on MRI markers of 
cerebrovascular diseases and cognitive impairment remain to be explored. Limited 
studies on HERNS and CADASIL have suggested that the reduced fractal dimension 
and increased vessel tortuosity coexist with microvascular pathology in the brain such 
as microbleeds and white matter lesions.158, 159 However no studies have yet examined 
the association of all retinal microvascular changes (arteriolar caliber, venular caliber, 
fractal dimension and tortuosity) with the cerebrovascular diseases in the preclinical 
stages of dementia.   
Retinal Vascular Changes in Cognitive Impairment and Dementia 
Several population based studies have shown that retinopathy signs are associated 
with AD and vascular dementia in hypertensive groups50, 160, 161 and are even linked to 




were also associated with cognitive impairment in some studies whereas others failed 
to find clear association50, 162 (Table 2 - 6c). These discrepancies might be due to the 
differences in brief cognitive tests [Mini Mental Status Examination (MMSE) vs. 
Abbreviated Mental Test (AMT)]162, 163 and limitation to specific cognitive domains 
(psychomotor speed, executive function and visual memory).50, 164   
With regards to the early changes in retinal vasculature, Rotterdam scan study has 
reported that wider venular and smaller arteriolar caliber is associated with incident 
dementia.165 Another study has reported a link between smaller venular caliber and 
AD.166 Reduction in fractal dimension was associated with cognitive impairment in 
Singapore Malay Eye Study (SiMES) and the Australian Imaging, Biomarker & 
Lifestyle Flagship Study of Ageing (AIBL) studies (Table 2 – 6d).167, 168 However, it 
remains unknown if retinal microvascular changes are also associated with preclinical 
stages of cognitive impairment measured on a detailed neuropsychological 
assessment.  
6.3  Homology in Retinal and Cerebral Neuronal Layers 
Retina is a direct extension of the mesencephalon and is connected to the brain via the 
optic nerve. Retinal ganglion cells receive information from the photoreceptors in the 
eye and share morphological characteristics with the cerebral neurons in having the 
cell body, dendrites and myelinated axons. These axonal processes relay information 
to the visual cortex in the occipital lobe. Damage to either retinal or cerebral neurons 
results in degeneration in anterograde or retrograde direction due to lack of 
regenerative ability in axons.169 Hence the degeneration in the brain is reflected as 
retinal neuronal loss or vice versa.  
Optical Coherence Tomography 
Optical coherence tomography (OCT) is a non-invasive, non-contact optical imaging 




biopsy like cross-sectional images (10-20μm) using optical backscattering of light 
analogous to ultrasonography. First generation OCTs [time domain (TD) OCTs] are 
capable of measuring the retinal nerve fiber layer thickness (RNFL) and have been 
successfully used in research settings to measure the optic nerve damage in glaucoma 
and optic neuritis.171, 172 Second generation OCTs [spectral domain (SD) OCTs] are 
now able to measure thickness of retinal sublayers, the ganglion cell inner plexiform 
layer (GC-IPL) which is directly posterior and exterior to RNFL.173, 174 
RNFL consists of unmyelinated axons of the retinal ganglion cells and is thickest at 
the peripapillary region around the optic disc. GC-IPL contains the cell bodies and 
dendrites of the retinal ganglion cells, and is thickest at the macular region. Damage 
to the retinal neuronal layers affects the dendrites prior to the ganglion cell body, 
hence GC-IPL is more sensitive to neuronal damage compared to RNFL.175, 176  
Retinal Neuronal Changes in Cognitive Impairment and Dementia 
Several small studies using TD- OCT have shown that retinal nerve fiber thickness is 
reduced in subjects with AD and MCI.166, 177-181 Conversely, studies using the SD- 
OCT have shown either in-consistent or mixed results with cognitive performance.182-
184 More recent studies have shown that both RNFL and GC-IPL thickness is reduced 
in AD patients (Table 2 – 7).185 However, these were limited by small numbers and 
did not take into account the other cardiovascular risk factors. 
Besides the cognitive impairment and dementia, retinal neuronal changes (RNFL and 
GC-IPL) have also been reported in other neurodegenerative diseases such as 
multiple sclerosis and Parkinson’s disease.186-188 However, there is no data on the GC-
IPL thinning in relation to cerebral atrophy among subjects with preclinical cognitive 




Hence the main focus of this thesis is to examine how the age-related structural 
changes in the brain and retina are related to cerebrovascular diseases on MRI 
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CHAPTER 2 – TABLES 
 
Authors and Study Study type and population Cerebrovascular 
disease markers 
Outcome/Evaluation Findings with effect measure and 95% 
confidence interval or p value 
Vermeer S, et al. 2003 32  
(Rotterdam Scan Study) 
Prospective population based study; 
n= 1015; ages 60-90 years  
Silent brain infarcts 
and white matter 
hyperintensities 
Risk of stroke - Silent brain infarcts, HR: 3.5 (2.0 , 6.0) 
- White matter hyperintensities, HR: 3.5 (1.4 , 8.6) 
Vermeer S, et al. 2003 33 
(Rotterdam Scan Study) 
Prospective longitudinal population 
based study;  
n= 1015; ages 60-90 years 
Silent brain infarcts Risk of dementia and cognitive decline   HR: 2.26 (1.09 , 4.70) 
Vermeer S, et al. 2007 38 
(Review) 
Population and hospital based, case 
series; 
 n= 105; 
ages 34-97 years 
Silent brain infarcts Physical, cognitive disabilities, risk of stroke - Associated with physical, depressive symptoms, 
worse cognitive ability, subsequent stroke, risk of 
dementia 
Benjamin P, et al. 2014 34 
(St George’s Cognition and 
Neuroimaging in Stroke 
(SCANS) study) 
Cross sectional study; 
 n= 120; ages ≥ 60 years 
Lacunes count Cognitive tests:  Trail making test, Modified 
Wis- consin Card Sorting Test, Phonemic 
Fluency, Wechsler Adult Intelligence Scale-
III, Digit symbol substitution, Speed of 
Information Processing Task, Grooved 
Pegboard Task, Digit Span Task, Wechsler 
Memory Scale-III, Logical Memory and 
Visual Reproduction 
- Executive function, ß: −0.377 (p= 0.001)  
- Processing speed, ß: −0.430 (p= 0.001)  
- Working memory, ß: −0.207 (p= 0.028)  
- Episodic memory, ß: −0.189 (p= 0.045) 
Debette S, et al. 2010 35 
(Systemic review) 
Longitudinal studies; n= 53 articles White matter 
hyperintensities 
Dementia, mortality - Incident dementia, HR: 1.9 (1.3 , 2.8) 
- Mortality, HR: 2.0 (1.6 , 2.7) 
Mortamais M, et al. 2013 37 
(Review) 




Risk of dementia, risk of conversion to 
dementia and cognitive decline 
- Risk of dementia, HR: 2.9 (1.3 , 6.3) 
- Conversion to AD, HR: 1.2 (0.7 , 2.2) 
- Conversion to other dementias, HR 5.8 (1.2 – 26.6) 
- Cognitive decline, HR: 3.30 (1.33 , 8.22) 
Prins ND, et al. 2015 39 
(Review) 




Risk of dementia, cognitive decline, 
disability 
- WMH severity and progression linked to cognitive 
decline and dementia risk 
- Large confluent WMH with normal cognition can 
lead to disability within one year of assessment,  
HR: 2.36 (1.65, 3.81) 
Table 2 – 1 (a): Association of established cerebral small vessel disease markers (infarcts and white matter hyperintensities) with stroke and cognition 




Table 2 – 1 (b): Association of cerebral small vessel disease marker (cerebral microbleeds) with cognition 
  
Authors and Study Study type and population Cerebrovascular disease 
markers 
Outcome/Evaluation Findings with effect measure and 95% confidence 
interval or p value 
Werring DJ, et al. 2004 49 Case-control hospital based 
study; n= 55; age ≥ 60 years 
Cerebral microbleeds Cognitive dysfunction 
assessed by detailed 
neuropsychological tests 
- Microbleed an independent predictor of executive 
function impairment OR: 1.32 (1.01 , 1.70) 
- Modest correlation with other domains  
Spearman’s r = 0.44, (p = 0.03) 
Qui C, et al. 2010 50 
(AGES-Reykjavik Study) 
Cross-sectional study;  
n= 3906; age= 76 years 
Cerebral microbleeds California Verbal Learning 
Test, Digit Symbol 
Substitution Test, Salt house 
Figure Comparison Test, 
Stroop Test, Digit backwards 
People with multiple (≥2) CMBs had lower Z scores 
on tests of processing speed (ß: -0.25 (-0.37, -0.12) 
and executive function (ß: -0.19 (-0.31, -0.07) 
van Es AC, et al. 2011189 
(PROSPER study) 
Hospital based study; 
 n= 439; 
age 70-82 years 
Cerebral microbleeds MMSE, Picture Word 
Learning Test (immediate 
and delayed), Letter Digit 
Coding Test, Stroop Color 
Word Test 
Only infratentorial MBs associated with lower score 
on the Immediate Picture-Word Learning test 
(p=<0.01) and delayed Picture-Word Learning 
(p=0.01) 
Lei C, et al. 2013 45 
(Systemic review) 
Cross sectional studies; 
 n= 7 articles 
Cerebral microbleeds  Cognitive function using 
brief and detailed tests 
- Cerebral microbleeds (presence vs. absence),  
OR: 3.06 (1.59 , 5.89)  
- Cerebral microbleeds (count), ß: -1.06 (-2.10 , -0.02) 
Poels MMF, et al. 2012190 
(Rotterdam Scan Study) 
Prospective population based 
study; 
n= 3979; age 60-90years 
Cerebral microbleeds MMSE, Word Verbal 
Learning Test, Stroop test, 
Letter-Digit Substitution 
Task, Purdue Pegboard test, 
Word Fluency Test 
Higher number of microbleeds was associated with 
lower MMSE score (ß: -0.54) and worse performance 
on tests of information processing speed (ß: -0.46) and 
motor speed (ß: -0.42) 
van der Vlies A, et al. 2012 
48 
Prospective memory clinic study; 
n= 221; age ≥ 60 years 
Cerebral microbleeds Cognitive decline using mini 
mental status examination 
(MMSE) 
Microbleeds not associated with cognition 
- Baseline MMSE score, ß: 0.34 (p= 0.65) 
- Rate of decline, ß: 0.09 (p= 0.79) 




Table 2 – 2: Studies with prevalence and association of cerebral small vessel disease (microinfarcts) with other neuroimaging correlates and cognition 




Methodology Diagnosis/Evaluation Findings with effect measure and 95% confidence 
interval or p value 
Postmortem 
Launer LJ, et al. 201152 
(Honolulu Asia Aging Study) 
Hospital based 
neuropathological study;  
n=436; age > 73 years 
Cerebral 
microinfarcts  




- Microinfarcts associated with poorer performance in 
cognitive testing in non-demented group, β: −0.103 
(p=0.003) 
- No association in demented group, β: −0.56, 
(p=0.104) 









Autopsy Dementia and non-
dementia  
- Prevalence of microinfarcts in non-demented 24%, 
AD 43% and VaD 62% 
- Microinfarcts associated with clinical diagnosis of 
dementia, neuropathological confirmed AD, clinical 
diagnosis of VaD and cognitive dysfunction 
- Microinfarcts associated with other cerebrovascular 
diseases (infarcts, leukoencephalopathy and CAA) 







Autopsy Dementia and non-
dementia 
Microinfarcts disrupt important cognitive networks 
and account for some of the neurological dysfunction 
associated with other MRI lesions such as lacunar 
infarcts and white matter hyperintensities 
Antemortem 
van Veluw  SJ, et al 2013 58 Hospital based study;  
n= 24;  
age 65-80 years 
Cerebral cortical 
microinfarcts  
7T and 3T imaging Dementia and non-
dementia 
CMIs can be detected noninvasively using 7T and on 
3T MRI. Histopathologic validation of these lesions 
with similar characteristics on ex vivo MRI confirmed 
these lesions as CMIs 
Ii Y, et al. 2013 59 Hospital based study; 
n= 70;  
age 41-86 years 
Cerebral cortical 
microinfarcts  
3T imaging Cognitively impaired Multiple small CMIs visible in intracortical regions on 
3T  
van Rooden S, et al 2014 61 
 
Hospital based study;  
n= 32;  
age > 50 years 
Cerebral cortical 
microinfarcts  
7T imaging AD and controls/ MMSE Patients with AD have more microinfarcts than 
controls on 7T and is associated with worse global 
performance on MMSE (p= 0.009) 
van Dalen JW, et al 2015 60  Population based study;  
n= 194; age 72-80 years 
Cerebral cortical 
microinfarcts  
3T imaging Non demented 
hypertensive  
Prevalence of CMIs on 3T is 6%. Age and history of 
stroke are the major risk factors.  
T= Tesla; AD= Alzheimer’s disease; MMSE= Mini Mental Status Examination; β = mean difference; VaD=Vascular dementia; CAA= cerebral amyloid angiopathy; MRI= Magentic resonance 




Table 2 – 3 (a): Studies with prevalence of cerebral large vessel disease -extra and intracranial arterial stenosis in asymptomatic, stroke & demented subject 
Authors and 
Study 




Methodology Diagnosis/Evaluation Findings with effect measure and 95% confidence 
interval or p value 
Postmortem 
Roher, et al. 2003 
68 
Neuropathological study;  
n= 54;  




Autopsy AD and non-dementia - Average stenosis in AD is 30% and in non-demented 
brains is 20%.  
- Atherosclerosis-induced brain hypoperfusion contributes to 
the clinical and pathological manifestations of AD 




controls n= 92, cases n= 
305; 




Autopsy  Dementia  and non-
dementia 
- AD vs. controls, OR: 1.31 (1.04 ,1.69)  
- VaD vs. controls, OR: 2.50 (1.52, 4.10) 
Antemortem 
Huang YN, et al. 
1997 77 
Hospital based study; n= 
96; 






doppler and duplex 
ultrasound 
Transient ischemic attack - Extracranial stenosis was 19% and intracranial stenosis 
was 51%.  
- Stenosis of internal carotid and middle cerebral arteries is 
common in Chinese  
Li H, et al. 2003 78 
(Review) 







Stroke  - Intracranial stenosis in Asians is 30-83% and in whites it is 
8-10%. 
- Extracranial stenosis in Asians is 6-33% whereas in whites 
it is 85%  
Wong KS, et al. 
2007 191  
Population based study;  
n= 642;  








- Prevalence of intracranial stenosis was 6.9%.  
- Significant risk factors were hypertension, glycosuria, heart 
disease and history of stroke 
De Silva DA et al. 
2009 192 
Hospital based study;  
AD n= 56,  
VaD n= 47;  








AD and VaD Prevalence of intracranial stenosis among VaD patients was 
53%, significantly higher than AD patients  
(18%; P = < 0.001) 





Table 2 – 3 (b): Studies showing association of cerebral large vessel disease- extra cranial arterial stenosis with cognition in stroke, asymptomatic 
and symptomatic subjects 
Authors and 
Study 




Methodology Diagnosis/Evaluation Findings with effect measure and 95% confidence 
interval or p value 




cases n= 39; 
controls n= 46; 







Transient ischemic attack 
 
Cognitive tests include: Standard 
progressive matrices, Wechsler memory 
scale, Verbal learning and memory test; 
Visual retention test, Modified card sorting 
test, Trail making test, Word production 
test, Reaction time 
Patients with carotid artery occlusion and ipsilateral TIA 
performed worse on cognitive testing compared to controls 
Silvestrini M, et al. 
2009 75 
Hospital based 
study; n= 102 








Cognitive tests include: Phonemic Verbal 
Fluency, Category Verbal Fluency, 
Coloured Progressive Matrices, Complex 
Figure Copy Test 
Subjects with stenosis had significantly worse 
performance on phonemic verbal fluency compared to 
controls (p= <0.05) 




study; n= 64; age 






Symptomatic and asymptomatic  Patients with severe stenosis of one or both carotid arteries 
were impaired in cognitive functioning (p=0.042) 
Bossema ER, et al. 




cases n= 60, 
controls n= 23  






Symptomatic and asymptomatic subjects 
 
Cognitive tests include: Digit Span, Word 
Learning Test, Doors Test, Verbal Fluency, 
Trail Making Test, Motor Planning Test, 
Finger Tapping Test 
 
Subjects underwent carotid endarterectomy 
Significant improvements up to 1 year were demonstrated 
for the  
- Retrieval of verbal material  (p=0.008),  
- Planning speed of movement (p=0.02), 
- Finger tapping (p=0.04) 




Table 2 – 3 (b) continued: Studies showing association of cerebral large vessel disease (extra cranial arterial stenosis) with cognition in stroke, 
asymptomatic and symptomatic subjects 
  




Methodology Diagnosis/Evaluation Findings with effect measure and 95% confidence 
interval or p value 






cases n= 189, 
controls n= 201 








Digit Span Forward and 
Backward Test, Seashore Rhythm Test, 
Trail Making Test (Parts A and B), 
Grooved Pegboard, Verbal and Visual 
Paired Associates immediate 
and 30-minute delayed recall,  Controlled 
Oral Word Association Test, Wechsler 
Adult Intelligence Scale 
Patients with stenosis perform worse in the following 
tests; 
- Seashore Rhythm,  OR: 2.28 (1.67, 4.47) 
- Trail Making Test A, OR:3.88 (1.85, 8.14) 
- Trail Making Test B, OR:4.21 (1.94, 9.14) 
- Verbal Pair Association, immediate recall,  
  OR: 2.83 (1.43, 5.62) 
- Visual Pair Association, immediate recall,  
  OR: 3.21 (1.58, 6.49) 
- Grooved Pegboard Test, OR: 4.38 (1.93, 9.91) 
 
Landgraff NC, et al. 
2010 72 
Hospital based 











Cognitive tests include RBANS testing 
for immediate memory, visuospatial/ 
constructional, language, attention and 
delayed memory 
- In complete occluded group significant cognitive 
deficits were found in all domains except immediate 
memory  
- In the moderately stenotic group, there was 
significant cognitive decline in all domains  
- In the severely stenotic group, there was significant 
cognitive deficit in all domains with the exception of 
language 













measured by Pulse 





Cognitive tests include MMSE, Letter-
Digit Substitution Task, Stroop Test and 
Word Fluency Test 
Arterial stiffness is not associated with cognitive 
decline and risk of dementia, HR: 0.91 (0.75 , 1.10) 





Table 2 – 4 (a): Studies showing cerebral thickness/volume in cognitive impairment and Alzheimer’s dementia 
Authors and 
Study 






Findings with effect measure and 95% confidence interval or p 
value 
Karas GB, et al. 
2004 193 
Hospital based study; AD = 33, 
controls = 14, MCI = 22 
age ≥ 70 years; 
 
Caucasians 







- AD subjects had lower mean global GM volume compared to 
controls (p= < 0.001) 
- Global GM volume in the MCI group was intermediate between 
AD and controls (p=<0.001) 
- VBM showed MCI had local reductions in gray matter in the 
medial temporal lobe, the insula, and thalamus compared to controls 
- MCI subjects had more GM in the parietal association areas, 
anterior and the posterior cingulate compared to AD 
Trivedi MA, et al 
2006 194 
Hospital based study; MCI = 
15, 
controls = 15 
age ≥ 70 years; 
 
Caucasians 






- MCI patients display significantly less GM volume in medial 
temporal lobe and posterior cingulate gyrus compared to controls 
(p=<0.01) 
- Discriminative accuracy for distinguishing MCI from controls was 
87% 
Karas G et al. 
2008 96 
Hospital based study; MCI = 
24; 
age ≥ 70 years; 
Caucasians 
Gray matter volume Voxel based 
morphometry 
MCI - Converters had more left parietal atrophy and left lateral temporal 
lobe atrophy than stable MCI patients (p=<0.001) 
Frisoni et al. 2002 
93 
Hospital based study; AD = 29 
controls = 26; 
age ≥ 65 years;   Caucasians 
Gray matter density Voxel based 
morphometry 
AD and controls  AD subjects had more localised atrophic regions in the temporal 
and cingulate gyri, precuneus, insular cortex, caudate nucleus, and 
frontal cortex compared to controls (p=<0.0001) 
Singh V et al. 
2006 94 
Hospital based study; controls= 
34, MCI = 62 and AD = 42; 
age ≥ 70 years; 
  
Caucasians 
Cortical thickness Automatic 
segmentation MNI 
AD, MCI and 
controls 
- Cortical thickness decreased significantly when controls were 
compared to MCI, mainly in the medial temporal lobe region and in 
some regions of the frontal and the parietal cortices (p<0.05).  
- With the progression of disease from MCI to AD, a general 
thinning of the entire cortex was observed  
Lerch JP et al. 
2005 91 
Hospital based study; AD = 19, 
controls=17; 
age ≥ 60 years; 
Caucasians 
 
Cortical thickness Automatic 
segmentation 
AD and controls - Cortical thickness decline in AD in temporal, orbitofrontal and 
parietal regions, with the most in medial 
temporal lobes with a loss of >1.25 millimeters of cortical thickness. 
- Focal cortical areas decline with progression of the disease as 
measured by time from baseline scan (p= <0.006) as well as the 
Mini-Mental State Exam (p=0.06) 




Table 2 – 4 (b): Studies showing association between cortical thickness and cognition in cognitive impairment and Alzheimer’s dementia 
Authors and 
Study 




Methodology Diagnosis/Evaluation Findings with effect measure and 95% confidence 
interval or p value 






controls = 222 
age 55-90 years; 
 
Caucasians 
Cortical thickness FREE SURFER MCI and controls 
Cognitive tests include; MMSE,  
Auditory Verbal Learning Test,  Long 
delay free recall and a recognition trial,  
logical memory  subtest, Trail making 
test (A & B), Digit span (backward), 
Animal fluency and ADAS- Cog 
- Compared to MCI high executive function (EF) group, 
MCI low EF demonstrated cortical thinning in frontal 
lobe (p=<0.0025) 
- Compared to MCI high EF, MCI low EF performed 
worse in verbal memory (p=<0.005) 




study; AD = 27, 
MCI = 30,  
controls = 16 
age ≥ 70 years; 
 
Caucasians 
Cortical thickness FREE SURFER AD, MCI and controls 
 
Cognitive tests include; CERAD battery 
(Verbal Fluency, 15-item Boston 
Naming Test, MMSE, 10-item Word 
List Learning, Recall and Recognition 
Test, Constructional Praxis, 
Constructional Praxis Recall) 
- CERAD total scores correlated with mean cortical 
thickness, (r: 0.34–0.38, p= < 0.001) and MMSE (r: 
0.19, p = 0.01).  
- Of the vertex clusters that showed thinning in 
progressive MCI, 60–75% related to the CERAD total 
scores and 3% to the MMSE 
Seo SW, et al. 
2007 100 
Hospital based study; 
MCI = 31, 
controls = 61 
age ≥ 65 years; 
 
Asian (Korean) 




Single and multiple domain a MCI and 
controls 
 
Cognitive tests include; Digit Span, 
Boston Naming Test,  Rey–Osterrieth 
Complex Figure Test,  Seoul Verbal 
Learning Test,  Controlled Oral Word 
Association Test, Stroop Test 
- Relative to controls, Single domain –aMCI patients 
showed cortical thinning in the left medial temporal lobe 
(p=<0.05) 
- Multi domain - aMCI patients showed cortical thinning 
in the left medial temporal lobe, precuneus, and anterior 
and inferior basal temporal, insular, and temporal 
association cortices (p=<0.01) 
 
Seo SW, et al. 
2011 101 
Hospital based study; 
AD = 196, 
controls = 142, 








AD and controls 
 
Cognitive tests include; Digit Span, 
Boston Naming Test,  Rey–Osterrieth 
Complex Figure Test,  Seoul Verbal 
Learning Test,  Controlled Oral Word 
Association Test, Stroop Test 
High levels of education in the AD group correlated 
with cortical thinning in the frontal and temporo-parietal 
association cortices (p=<0.001) 
 
ADNI= Alzheimer Disease Neuroimaging Initiative; AD= Alzheimer’s disease; MCI= mild cognitive impairment; MMSE= mini mental status examination; CERAD= Consortium to 














Findings with effect measure and 95% confidence interval or p value 




age 18-82 years; 
Caucasians 
Gyral curvature, 






Healthy volunteers - Sulcal (more flattened and less curve) and gyral (sharp and steeply curved) 
changes over time (p=<0.001).  
- Cortical thickness decreases over time (p=<0.001) 
Preul C, et al 2006 
87 
Community based 
study; n= 525; 
age 17-68 years; 
 
Caucasians 





using voxels  
Healthy volunteers - Cortical thickness decreases with age (r: –0.49, 
p =0.01; r: –0.502, p= <0.01 in males and r: –0.461, p= <0.01 in females). 
- Ventricles enlarge with age (r: 0.67, p= 0.01; r: 0.71, p=  0.01 for males, and 
r: 0.63, p= 0.01 for female subjects 
Lemaitre H, et al. 
2012 85  
Community based 
study; n= 216; 




volume and surface 
area 
FREE SURFER Healthy volunteers - Age related volume reductions in middle frontal 
gyrus, the superior frontal gyrus and the frontal pole (p=<0.001) 
- Age-related changes in cortical thickness reductions in superior frontal gyrus, 
the paracentral gyrus,  
pars opercularis and triangularis of the inferior frontal gyrus (p= <0.001) 
- Age-related reduction in surface area in  middle frontal gyrus and the superior 
frontal gyrus 
Long X, et al. 2012 
88 
Community 
subjects; n= 314; 
age 18-94 years; 
Caucasians 
Cortical surface area, 
cortical thickness, 
curvature index, white 
matter volume  
FREE SURFER Healthy subjects -  Significant cortical thinning observed in parietal (r: 0.553, p= < 0.001) and 
insula regions (r: 0.405, p= < 0.001) with aging  
-  Surface area and mean curvature less affected by aging relative to cortical 
thickness and white matter volume 
Salat DH, et al. 
2004 89 
Community based 
study; n= 106;  
age 18-93 years;  
Caucasians 
Cortical thickness FREE SURFER Healthy subjects - Aging associated with prefrontal lobe atrophy (r2: 0.25) 
- Additional atrophy in in frontal cortex near motor cortex (r2: 0.34) and 
calcarine cortex (r2: 0.38) 






study; n= 1092 
age ≥ 55 years; 
 
Caucasians 
Cortical thickness FREE SURFER Healthy subjects - Women had thicker cortex than men (p=< 0.01) 
- With increasing age, cortical thickness decreased (approximately 0.2% per 
year), with the largest age effects for the occipital and temporal lobes 
- Higher education, higher diastolic blood pressure and larger intra-cranial 
volume were related to a larger cortical thickness 
- Diabetes mellitus and higher HDL cholesterol levels were related to a thinner 
cortex 




Table 2 – 5: Studies showing association of subcortical volumes/density in Alzheimer’s dementia, cognitive impairment and cognitively normal subjects 
Authors and 
Study 




Methodology Diagnosis/ Evaluation Findings with effect measure and 95% confidence 
interval or p value 
Frisoni, et al. 
2002 93 
Hospital based study; 
AD = 29 
controls = 26; 
age ≥ 65 years 
Gray matter density Voxel based 
morphometry 
AD and controls - AD patients had more atrophy in right and left 
hippocampal/amygdalar complex (p=<0.0001). All parts 
of the hippocampus (head, body, and tail) were affected.  
- More localised atrophic regions observed in the 
temporal and cingulate gyri, precuneus, insular cortex, 
caudate nucleus, and frontal cortex p=<0.0001) 
de Jong LW, et 
al. 2008 108 
Hospital based study; 
AD = 69, 
memory complainers= 
70; 








AD and subjective memory complaints 
 
Cognitive tests used were; Cambridge 
Cognitive Examination-Revised and MMSE 
- Significant reduction in hippocampus (p=<0.05), 
thalamus (p=<0.01) and putamen (p=<0.01) in AD 
patients compared to memory complainers  
- Decreased volumes of left putamen and thalamus 
correlate independently to poorer cognitive test results 
(p=<0.001) 
Mrzilková J, et 
al. 2012 111 
Hospital based study; 
AD = 26 
controls = 29; 




AD with MMSE ≥ 18 and < 18 scores 
 
Cognitive tests include: MMSE, Mattis 
Dementia Rating Scale, Trail Making Test 
version A and B, Disability Assessment in 
Dementia, 7-Minute Screen, verbal fluency 
tests and Edinburgh Handedness 
Inventory 
- Hippocampus volume reduction in both AD groups ≥18 
MMSE score (p=0.006) and <18 MMSE score (p=0.02) 
compared to controls 
- No reduction in pons and cerebellar volumes 
Roh JH, et al. 
2011 109 
Hospital based study; 
AD= 179, 
controls = 57; 








AD and controls. Severity of disease 
defined by clinical dementia rating scale 
(CDR) 
 
Cognitive tests include; Digit Span, Boston 
Naming Test,  Rey–Osterrieth Complex 
Figure Test,  Seoul Verbal Learning Test,  
Controlled Oral Word Association Test, 
Stroop Test 
- Volume loss in amygdala and hippocampus in very 
mild stage of AD (CDR=0.5) 
- Volume reduction in thalamus and putamen in mild to 
moderate stages of AD (CDR= 1and 2) 
- Globus pallidus and caudate reduction in moderate 
stages (CDR= 2, p = <0.01) 
- All these structures correlated with cognitive 
performance (p=<0.01) 
Ryan N, et al. 
2013 195 
Hospital based; 
AD = 20, controls =20; 
age 30-50 years 
Gray matter density Voxel based 
morphometry 
Presymptomatic, symptomatic AD and 
controls 
Atrophy in caudate (p=<0.001) and thalamus 
(p=<0.0025) in presymptomatic mutation carriers 
compared to controls  













Findings with effect measure and 95% confidence interval or p value 
Fjell AM, et al. 
2009 113 
Case control study; 
AD = 96, 
controls = 1143; 
age 18-87 years 
Subcortical structure 
volume 
FREE SURFER AD and controls - Pallidum corrected for intracranial volume showed slightly 
higher age correlations for men (p=<0.05) 
- No age effects on men and women cortex 
- Analysis in AD subjects showed no age and sex interactions 
Cho H, et al. 
2013 110 
Case control study; 
AD = 36, 
controls = 14 
age 50-80 years 
Subcortical structure 
volumes 
FREE SURFER Early onset (EO) and 
late onset (LO) ADs 
and controls  
- No differences in the volumes of subcortical structures between patients 
with EOAD and LOAD.  
- Patients with EOAD showed more rapid volumetric decline in the caudate 
(p=<0.001), putamen (p=0.003), and thalamus (p=0.001) than patients with 
LOAD on 3 years of longitudinal follow-up, 
Thong JY, et al. 
2014 116 
Case control study; 
VCI = 55, 
controls = 25 






severe and mild) and 
controls 
- Cortex in moderate/severe VCI was thinner in the parietal and lateral 
temporal cortices than that in VCI mild. 
- Compared to controls, mild VCI and moderate/severe VCI 
showed smaller shapes in the thalamus, putamen and globus pallidus 
Walhovd KB, et 
al. 2005 114 
Community study; 
n= 73;  
age 20-88 years 
Cortical thickness, 
subcortical structures 
FREE SURFER Healthy volunteers - Age effects all cortical and subcortical structures (p= <0.0001) except 
pallidum and the 4th ventricle 
- Age relationships for cortex, amygdala, thalamus, accumbens and caudate 
were linear (p=<0.003) 
- Age relationship for cerebral white matter, hippocampus, brainstem, 
cerebellar white, and gray matter, lateral, inferior lateral and 3rd ventricles 
volume were curvilinear (p=<0.05) 
Long X, et al. 
2012 88 
Community 
subjects; n= 314; 
age 18-94 years 




FREE SURFER Healthy subjects Moderate atrophy observed in subcortical gray matter structures, including 
the thalamus (r2: 0.476, p= < 0.001), nucleus accumbens (r2: 0.525, p= < 
0.001), pallidum (r2: 0.461, p= < 0.001) and putamen (r2: 0.533, p= < 
0.001) with age 
Goodro M, et al. 
2012 115 
Community 
subjects; n= 226; 






Healthy volunteers Older subjects (60–85 years of age) showed a stronger correlation with 
structural volume for the ventricles (p=<0.001), hippocampus (p=<0.07), 
amygdala (p=<0.01) than middle aged (35–60 years of age) subjects 
Li W, et al. 2014 
112 
Community study;  
n= 76; 
age 19-69 ye  ars 
Subcortical structure 
volumes 
FREE SURFER Healthy subjects - Age-related absolute atrophy found in the basal ganglia and thalamus in 
males, females showed disproportionate degeneration 
- Hippocampus decline only observed in males (p=0.004) 
- Subcortical structures showed significantly smaller absolute volumes in 
females than in males (p= < 0.05) 
 
Table 2 – 5 (continued): Studies showing association of subcortical volumes in Alzheimer’s dementia, cognitive impairment & cognitively normal subjects 








Study type and population Retinopathy  Outcome Findings with effect measure and 95% confidence interval 
or pvalue 
Wong TY, et al. 
2001144 (ARIC) 
Prospective population based 
study; n= 10358; 
age 51-72 years 
Microaneurysms, soft exudates, blot 
and flame-hemorrhages, 
arteriovenous nicking 
Incident stroke Any retinopathy associated with incident stroke,   
- HR: 2.58 (1.59, 4.20)  
Arteriovenous nicking associated with incident stroke, 
- HR: 1.60 (1.03, 2.47) 
Wong TY, et al. 
2002145 (ARIC) 
Prospective population based 
study; n=1684;  
age 51-72 years 
Microaneurysms, soft exudates, blot 
and flame-hemorrhages, 
arteriovenous nicking 
Incident clinical stroke - Persons with WMH had higher incidence of stroke, 
HR: 3.4 (1.5, 7.7) 
- Persons with both WMH and retinopathy had higher incidence 
of stroke,  HR: 18.1 (5.9, 55.4) 
Wong TY, et al. 
2003 146 (ARIC) 
Prospective population based 
study; n=1684;  age 51-72 years 
Microaneurysms, soft exudates, blot 
flame-hemorrhages, AV nicking 
Sulcal widening and 
ventricular enlargement 
- Sulcal widening, OR: 1.9 (1.2, 3.0) 
- Ventricular enlargement, OR: 1.5 (1.0, 2.3) 
Mitchell P, et al. 
2005 147 (BMES) 
Prospective population based 





Combined (stroke, TIA and death), RR: 1.7 (1.0, 2.8) 
Incident stroke,  RR: 3.5 (1.5, 8.2) 
Cooper LS, et al. 
2006 148 (ARIC) 
Cross-sectional population-based 
study; n=1684;  
age 55-74 years 
Arteriovenous nicking, focal 
arteriolar narrowing, retinal 
hemorrhages, soft exudates and 
microaneurysms, arterio-venous 
ratio 
MRI defined infarcts Cerebral infarcts associated with retinal microvascular 
abnormalities,  
-  Arteriovenous nicking, OR: 1.90 (1.25, 2.88)   
-  Focal arteriolar narrowing, OR: 1.89 (1.22, 2.92)  
-  Blot hemorrhages, OR: 2.95 (1.30 , 6.71) 
-  Soft exudates, OR: 2.08 (0.69, 6.31)  
-  Microaneurysms, OR: 3.17 (1.05, 9.64)  
-  Arteriovenous ratio, OR: 1.74 (0.95, 3.21)  
Longstreth W, et 
al. 2007 149 (CHS) 
Prospective population based 
study; n=1285; age>65 years 
Retinopathy, focal arteriolar 
narrowing, arteriovenous nicking, 
and arteriovenous ratio 
Prevalent infarcts and 
WMH,  
incident infarcts and 
worsening of WMH 
Arteriovenous ratio associated with, 
- Prevalent infarcts, OR: 1.18 (1.05, 1.34),  
- White matter grade, ß: 0.093; (p =0.011),  
- Incident infarct, OR: 1.26 (1.09, 1.46)  
- Worsening white matter grade, OR: 1.12 (0.98, 1.29) 
Arteriovenous nicking associated with,  
- Prevalent infarcts, OR: 1.84 (1.23, 2.76)  
- Incident infarcts, OR: 1.84 (1.15, 2.94) 
ARIC= Atheroscelorsis Risk in Communities Study; BMES= Blue Mountain Eye Study; CHS= Cardiovascular Health Study; TIA= Transient Ischemic Attack; Magnetic Resonance Imaging; 




Table 2 - 6 (a) continued: Studies showing association of retinopathy signs with MRI markers of cerebrovascular diseases  
Authors and Study Study type and population Retinopathy  Outcome Findings with effect measure and 95% confidence interval or 
p value 
Qiu C, et al. 2009150 
(AGES- Reykjavik 
study) 
Cross-sectional study; n=4176; 
mean age=76 years 
Retinal focal arteriolar signs 
(arteriolar narrowing arterio-venous 
nicking), Retinopathy lesions 
(retinal blot hemorrhages, 
microaneurysms) 
Cerebral infarcts and WMHs - Retinal focal arteriolar signs associated with increasing load of 
subcortical, OR: 1.40 (1.09, 1.79) and periventricular WMHs, OR: 1.64 
(1.36, 1.97) 
- Arteriovenous nicking was significantly associated with subcortical 
infarcts,  OR: 1.33 (1.09, 1.62) 
Yatsuya H, et al. 
2010 151 (ARIC) 
Prospective population based 
study; n=10496;  
age 45-64 years 
Microaneurysms, retinal 
hemorrhages, arteriovenous 




Retinopathy signs (aneurysm, hemorrhage),  
- Non-lacunar thrombotic, HR: 2.41 (1.47, 3.95) 
- Cardioembolic, HR: 2.25 (1.09, 4.65) 
- Retinal narrowing associated with incident infarct, HR: 2.22 
(1.11, 4.48) 
- Arteriovenous nicking associated with incident infarct,  HR: 
2.38 (1.20, 4.71) 
Cheung N, et al. 2010 
196 (ARIC) 
Prospective population based 
study; n=810;  
age≥ 55 years 
Microaneurysms, soft exudates, 
blot and flame-hemorrhages, 
arteriovenous nicking 
Incident infarct, incident 
WMH, WMH progression 
Retinopathy (microaneurysms, retinal hemorrhages) with; 
- Incident cerebral infarct, OR: 2.82 (1.42, 5.60)  
- Incident lacunar infarct, OR: 3.19 (1.56, 6.50) 
Retinal arteriovenous nicking with; 
- Incident cerebral infarct, OR: 2.82 (1.66, 4.76)  
- Lacunar infarct, OR: 2.48 (1.39, 4.40) 
- WMH incidence, OR: 2.12 (1.18, 3.81) 
- Progression of WMH, OR: 2.22 (1.00, 5.88) 
Kawasaki, et al. 2010 
152 (ARIC) 
Prospective population based 
study; n=810;  
age≥ 55 years 
Microaneurysms, soft exudates, 
blot and flame-hemorrhages, 
arteriovenous nicking 
10-year sulcal widening 
and ventricular 
enlargement 
- Retinopathy, OR: 2.03 (1.20, 4.42)  
- Arteriovenous nicking, OR: 2.19 (1.23, 3.90) 
de Silva DA, et al. 
2011197 (MCRS) 




Recurrent vascular events 
(cerebrovascular, 
coronary, vascular death, 
and composite vascular 
events) 
- Arteriovenous, HR: 2.28 (1.20, 4.33) 
- Focal arteriolar narrowing, HR: 2.75 (1.14, 6.63)  
Qiu C, et al. 2008153  
(AGES- Reykjavik 
study) 
Cross-sectional study; n=4218, 
mean age=76 years 





- AV nicking, OR: 1.44 (1.06, 1.95) 
- Focal arteriolar narrowing, OR: 1.45 (1.01, 2.09) 
- Microaneurysms/ hemorrhages, OR: 1.75 (1.25, 2.45) 









Study type and population Retinal vascular 
parameters 
Outcome Findings with effect measure and 95% confidence interval or 
p value 
Wong TY, et al. 
2006 134 (CHS) 
Prospective cohort study; n=1992; 
age 69-97 years 
Retinal vascular calibers Incident stroke Venular widening, HR: 2.2 (1.1, 4.3) 
Ikram MK, et al. 
2006 135  (RSS) 
Prospective cohort study; n=5540; 
age ≥ 55 years 
Retinal vascular calibers Incident stroke Large venular diameters associated with increased risk for 
- Stroke, HR: 1.12 (1.02, 1.24)  
- cerebral infarction, HR: 1.15 (1.02, 1.29) 
Ikram MK, et al. 
2006 155 (RSS) 
Prospective cohort study; n=490; 
age 60-90 years 
Retinal vascular calibers Changes in WMH and 
incident lacunar infarcts 
Large venular diameters associated with increased risk for, 
- Periventricular WMH progression, HR: 1.71 (1.11, 2.61)  
- Subcortical WMH progression, HR: 1.72 (1.09, 2.71)  
- Incident lacunar infarcts, HR: 1.59 (1.06, 2.39) 
Yatsuya H, et al. 
2010 151 (ARIC) 
Prospective population based study; 
n=10496; age 45-64 years 
Retinal vascular calibers Incident lacunar stroke  - Arteriolar narrowing, OR: 1.67 (1.23, 2.26) 
- Venular widening, OR: 1.44 (1.09, 1.91) 
Wieberdink RG, 
et al. 2010 154 
(RSS) 
Prospective cohort study; n=5518; 
age≥ 55 years 
Retinal vascular calibers Incident stroke Large venular caliber associated with an increased risk for  
- Stroke, HR: 1.20 (1.09, 1.33),  
- Cerebral infarction, HR: 1.28 (1.13, 1.46)  
- Intracerebral hemorrhage, HR: 1.53 (1.09, 2.15) 
Kawasaki R, et 
al. 2011157 
(BMES) 
Nested case-control study; stroke 
=10, controls=184, age ≥ 70 years 
Fractal dimension Incident stroke or 
mortality 
OR: 1.39 (1.06, 1.83) 
Bettermann K et 
al. 2012 156 
Case-control study; chronic 
ischemic white matter disease =12, 
controls = 14; 
age 43-85 years 
Retinal vasoreactivity Chronic WMH Increased WMH (p=0.006) 
ARIC= Atheroscelorsis Risk in Communities Study; BMES= Blue Mountain Eye Study; CHS= Cardiovascular Health Study; RSS= Rotterdam Scan Study; WMH= white matter 




Table 2 - 6 (c): Studies showing association of retinopathy signs with cognition 
Authors and Study Study type and population Retinopathy signs Outcome/ Evaluation Findings with effect measure and 95% 
confidence interval or p value 
Baker et al. 2007 160 
(CHS) 
Cross-sectional population based 
study, n=2211, age 69-97 years 
Microaneurysms, soft 





Cognitive test: Digit-Symbol Substitution 
Test, MMSE 
Retinopathy associated with; 
- Dementia, OR: 2.10 (1.04, 4.24) 
- Lower mean Digit-Symbol Substitution Test 
scores (p=0.002) 
Focal arteriolar narrowing associated with  
- Dementia, OR: 3.02 (1.51, 6.02)  
Qiu C, et al. 2010 50 
(AGES-Reykjavik 
Study) 
Cross-sectional study; n=3906, age 
66-96 years 
Microaneurysms, soft 




Cognitive test: California Verbal Learning 
Test, Digit Symbol Substitution Test, Salt 
house Figure Comparison Test, Stroop Test, 
Digit backwards 
OR: 1.95 (1.04 to 3.62) 
 
Persons with multiple microbleeds and 
retinopathy had lower Z scores on tests of  
- Processing speed, ß: -0.25 (-0.37, -0.12)   
- Executive function, ß: -0.19 (-0.31, -0.07) 
Schrijvers EM, et al. 
2012 161 (RSS)  
Cross-sectional population based 
study, n=6273, age≥55 years 
Microaneurysms, soft 
exudates, blot and flame-
hemorrhages, 
Dementia, AD and Vascular dementia - Dementia, OR: 1.92 (1.24, 2.98) 
- AD, OR: 1.89 (1.15, 3.10) 
- Vascular dementia, OR: 2.00 (0.71, 5.63) 
Wong TY, et al. 2002 
198 (ARIC) 
Cross-sectional population based 
study; n=8734, age 51-70 years 
Microaneurysms, soft 
exudates, blot and flame-
hemorrhages 
Cognitive function tested on; Delayed word 
recall test, Digit Symbol subtest, Word 
Fluency test 
- Delayed Word Recall Test, OR: 2.60 (1.70, 
3.99) 
- Digit Symbol subtest, OR: 1.91 (1.04, 3.49) 
- Word Fluency Test, OR: 2.03 (1.07, 3.86) 
Liew G, et al. 2009 163 Cross-sectional population based 
study; n=1988, age 49-97 years 
Microaneurysms, hemo-
rrhages, hard/soft exudates 
Cognitive impairment defined on MMSE  
(≤23) 
OR: 1.7 (1.0, 3.2) in hypertensives 
Lesage SR, et al. 2009 
164 (ARIC)  
Prospective population based study; 
n=803, age 55-72 years 
Microaneurysms, soft 
exudates, blot and flame-
hemorrhages 
Cognitive function tested on; Delayed word 
recall test, Digit Symbol subtest, Word 
Fluency test 
- Decline in Word Fluency, score difference: -
1.70 (-3.3,  -0.02) 
- Decline in Digit Symbol, OR: 2.18 (1.02, 4.64) 
Ding J, et al. 2010 199 
(The Edinburgh Type 2 
Diabetes Study) 
Cross-sectional population based 
study; n=1044; age 60-75 years 
Retinopathy  Faces and Family Pictures Sub-test, Matrix 
Reasoning, Letter-Number Sequencing, 
Digit Symbol Test, Borkowski Verbal 
Fluency Test, Trail Making Test 
- General cognitive ability (Ƞ2= 0.020, p=<0.001) 
- Verbal Fluency Test, (Ƞ2= 0.020, p=0.001)  
- Trail Making Test, (Ƞ2=0.012, p=0.009)  
- Digit Span Test, (Ƞ2=0.032, p=0.001) 
Haan M, et al. 2012 200  
(WHIMS & WHISE) 
Prospective population based study; 
n=505 women; age 64-79 years 
Retinopathy Cognitive dysfunction defined on 10 year 
follow up change in Modified MMSEscores 
Lower MMSE score, mean difference: 1.01, (p = 
0.019) 
Ong SY, et al. 2012 201 
(SIMES) 
Cross-sectional population based 
study, n=1179, age 60-80 years 
Retinopathy  Cognitive dysfunction defined on 
Abbreviated Mental Test 
OR: 5.57 (1.56, 19.91) in diabetics 
ARIC= Atheroscelorsis Risk in Communities Study; CHS= Cardiovascular Health Study; RSS=Rotterdam Scan Study; WHIMS= Women’s Health Initiative Memory Study; WHISE=Women’s Health Initiative Sight; 




Authors and Study Study type and population Retinal structural 
changes 
Outcome/ Evaluation Findings with effect measure and 95% confidence 
interval or p value 
Berisha F, et al. 2007 
166 
Case-control study;  
AD =9, controls = 8 
mean age= 74.3 years (AD),  
mean age= 74.3 years (controls) 
Retinal vascular calibers AD - Significant narrowing of the retinal venous blood column 
diameter in AD (131.7 +/- 10.8 μm) compared with control 
(148.3 +/- 12.7 μm), (p= 0.01) 
de Jong FJ, et al. 
2011165 (RSS) 
Prospective cohort study;  
n=5553, age≥50 years, 
Retinal vascular calibers Incident dementia, 
Incident vascular dementia 
Large venular caliber associated with; 
- Incident dementia, HR: 1.11 (1.00, 1.22) 
- Incident Vascular dementia, HR: 1.44 (1.10, 1.89) 
Smaller arteriolar caliber associated with; 
- Incident dementia, HR: 1.05 (0.96, 1.16) 
- Incident Vascular dementia, HR: 1.33 (0.99, 1.78) 
Liew G, et al. 2009 
163 
Cross-sectional population based 
study; n=1988, age 49-97 years 
Retinal vascular calibers Cognitive impairment defined 
on MMSE 
(≤ 23) 
Retinal venular dilation, OR: 1.8 (1.0, 3.2)  
Retinal venular dilation, OR: 2.7 (1.2, 6.1) in hypertensives 
Ding J, et al. 2011 202  
(The Edinburgh Type 
2 Diabetes Study) 
Cross-sectional population based 
study; n=954; age 60-75 years 
Retinal vascular calibers Faces and Family Pictures 
Sub-test, Matrix Reasoning, 
Letter-Number Sequencing, 
Digit Symbol Test, 
Borkowski Verbal Fluency 
Test, Trail Making Test 
- Increasing venular caliber associated with lower logical 
memory score, β: -0.069, (p=<0.05) 
- Increasing arteriolar caliber associated with lower 
Logical memory scores, β: -0.080, (p=<0.01)  
Kim DH, et al. 
2011203 (CHS) 
Cross-sectional population based 
study; n=1744, age≥ 65 years 
Retinal vascular calibers Digit Symbol Substitution 
Test score 
- Large venular caliber, mean difference: −4.81 
(−8.81,−0.81), p = 0.018 
- Smaller arteriolar caliber, mean difference: −4.51 (−6.38, 
−2.64), p = <0.001 
 
Gatto NM, et al. 
2012 162  (Los 
Angeles Latino Eye 
Study) 
Cross-sectional population based 
study; n= 809; mean age=70.3 
years 
Retinal vascular calibers Low Cognitive Abilities 
Screening Instrument-Short 
(CASI-S) score 
OR: 2.04 (1.14, 3.66) 
Cheung CY, et al. 
2010 167 (SIMES) 
Cross-sectional population based 
study, n=1202, age≥ 60 years 
Fractal dimension Abbreviated Mental Test OR: 1.71 (1.03, 2.82) 
Table 2 - 6 (d): Studies showing association of retinal vascular parameters with cognition  
 
RSS= Rotterdam Scan Study; CHS= Cardiovascular Health Study; SIMES= Singapore Malay Eye Study; AD= Alzheimer’s disease; MMSE= mini mental status examination; OR= odds 





  Table 2 – 7: Studies showing retinal neuronal changes with cognitive impairment and Alzheimer’s dementia   
Authors and 
Study 
Study type and population Retinal 
structural 
changes 
Methodology Outcome Findings with effect measure and 95% confidence interval or p 
value 
Kergoat H, et al. 
2001 203 
Case-control study;  
AD = 30, controls = 30,  
mean age= 72.0 years (AD),  
mean age= 72.1 years (controls) 
RNFL thickness Scanning laser 
polarimetry 
AD RNFL thickness was not significantly different in AD compared to 
controls (p=>0.05) 
Kergoat H, et al. 
2001 174 
Case-control study;  
AD =27, controls = 27,  
mean age=70.1 years (AD),  
mean age=71.7 years (controls) 
RNFL thickness Scanning laser 
polarimetry 
Early AD RNFL thickness was not significantly different in AD compared to 
controls (p=>0.05) 
Parisi V, et al. 
2001 180 
Case-control study,  
AD =17, controls= 14 
mean age=70.4 years (AD),  
mean age=71 years (controls) 
RNFL thickness  Time-domain 
OCT 
AD - Significant reduction in RNFL thickness in AD (99.9±8.95μm) 
compared to controls (59.5±16.7μm) (p=<0.01), - Significant 
reduction in RNFL thickness in all quadrants (p=<0.01) 
Iseri P, et al. 
2001 181 
Case-control study,  
AD =14, controls= 15, 
mean age= 70.1 years (AD),  
mean age= 65.1 years (controls) 
RNFL thickness Time-domain 
OCT 
AD  - Significant reduction in mean RNFL thickness in AD 
(59.5±16.70μm) compared to controls (99.9±8.95μm) (p=<0.01) – 
Significant reduction in RNFL thickness in all quadrants (p=<0.05) 
Berisha F, et al. 
2007 166 
Case-control study;  
AD =9, controls = 8 
mean age= 74.3 years (AD),  
mean age= 74.3 years (controls) 
RNFL thickness Time-domain 
OCT 
AD - Significant reduction in RNFL thickness in superior quadrant of AD 
patients (92.2 ± 21.6 μm) compared to controls (113.6 ± 10.7 μm)  
(p=0.02) 
Paquet C, et al. 
2007 204 
Case-control study;  
AD= 26, MCI= 23, controls= 15  
mean age=78.3 years (AD),  
mean age=78.7 years (MCI),  
mean age=75.5 years (controls) 







- Significant reduction in mean RNFL thickness in MCI (89.3 ± 
2.7μm, p<0.001), mild AD (89.2 ± 2.9μm, p=<0.01) and moderate-
severe AD (76.6 ± 3.8μm, p=<0.001) compared to controls (102.2 ± 
1.8μm) 
- Significant reduction in RNFL thickness in moderate-severe AD 
compared to MCI patients (p=<0.01) 





     Table 2 – 7 (continued): Studies showing retinal neuronal changes with cognitive impairment and Alzheimer’s dementia  
Authors and 
Study 
Study type and population Retinal structural 
changes 
Methodology Outcome Findings with effect measure and 95% confidence interval 
or p value 
Kesler A, et al. 
2011 205 
Case-control study;  
AD= 30, MCI= 24, controls= 24, 
mean age=72.1 years 




- Reduced average RNFL thickness in AD and MCI (p<0.05) 
compared to controls  
- Reduced RNFL thickness in superior and inferior quadrants 
in AD (p<0.05) compared to controls  
- Reduced RNFL thickness in inferior quadrant in MCI 
compared to controls (p<0.05)  
- No significant difference between AD and MCI 
Moschos MM, 
et al 2012 177 
Case-control study;  
AD= 30, controls = 30;  
age 42-84 years 
RNFL thickness Time-domain 
OCT 
AD Reduced RNFL thickness in inferior (p=<0.0001), superior 
(p<0.0001) and temporal quadrants (p=0.024) in AD compared 
to controls 
Kirbas S, et al. 
2013 178 
Case-control study;  
AD= 40, controls= 40;  
mean age=69.3 years (AD),  
mean age=68.9 years (controls) 
RNFL thickness Spectral domain 
OCT 
AD - Reduced average RNFL thickness in AD compared to 
controls (p=0.001)  
- Reduced RNFL thickness in superior quadrant in AD 
compared to controls (p=0.001) 
Larossa JM, et 
al. 2014 179 
Case-control study;  
AD=151, controls= 61   
age 55-90 years 
RNFL thickness Spectral domain 
OCT and 
Spectralis OCT 
AD - Reduced superior (p=0.010), inferior (p<0.001), temporal 
(p=0.023) RNFL thickness in AD by Spectral domain OCT  
- Reduced average (p=0.049), nasal (p=0.005), nasal inferior 
(p=0.020), temporal inferior (p<0.001), temporal superior 
(p<0.001) RNFL thickness by Spectralis OCT 
Garcia-Martin 
ES, et al. 2014 
182  
Case-control study;  
AD=20, controls = 28,  
mean age=79.3 years (AD),  




OCT and 3D 
OCT 
AD - Reduced RNFL thickness in macular region (p=<0.01) 
Marziani E, et 
al. 2013185 
Case-control study;  
AD=21, controls=21;  
mean age=79.3 years (AD),  
mean age=77.0 years (controls) 
Macular RNFL and 




AD - Reduced macular RNFL thickness in all sectors, mean diff -
8.5 to-4.2μm (p<0.02) in AD compared to controls 
- Reduced macular RNFL+GCL thickness in all sectors, mean 
diff -15.7 to 7.3μm (p<0.005) in AD compared to controls 
 
              
 









CHAPTER 3:  







1.  STUDY POPULATION 
To achieve the specific aims mentioned in chapter 1, the following studies were 
used; 
a. Epidemiology of Dementia In Singapore study (EDIS) 
b. Case Control study from memory clinic  
a. Epidemiology of Dementia In Singapore study (EDIS) 
The EDIS study drew subjects from the on-going population-based community-
dwelling study of Chinese, Malays and Indians cohorts aged 40-80 years who 
participated in the Singapore Epidemiology of Eye Disease (SEED; n=7,454), which 
comprises the Singapore Chinese Eye Study (SCES; n=3,353), Singapore Malay Eye 
Study -2 (SiMES-2; n=1,901) and Singapore Indian Eye Study -2 (SINDI-2; 
n=2,200).  
As part of the SEED study, participants were randomly selected from the community, 
and were invited to Singapore Eye Research Institute (SERI) for interview and 
clinical assessments.1, 2 Briefly, SiMES, SINDI and SCES were designed to study the 
prevalence and risk factors for major eye diseases including age-related macular 
degeneration,3 diabetic retinopathy,4 glaucoma,5 cataract 6 and myopia.7 Information 
on participants was collected by means of a questionnaire, physical examination and 
laboratory based tests. The questionnaire included data on demographics, lifestyle 
factors, personal and family health history and medication use. Physical examination 
included anthropometry, blood pressure, pulse rate measurement and extensive eye 
examination including digital fundal photography. Laboratory examinations included 
serum creatinine, serum lipids, plasma glucose, glycosylated hemoglobin (HbA1c) 
and urine for albumin and creatinine. Blood samples were stored for future 
biomarkers and genetic analysis. 
As part of the first phase of the EDIS study, SEED participants who were 60 years 
and above (n=3,800) (44% of the total population) also underwent cognitive 




forgetfulness (PF), both of which have been previously validated in Singapore.8-10 
Screen positives were defined  as AMT  ≤ 6, among those with up to 6 years of 
formal education, or ≤ 8 among those with more than 6 years of formal education; or 
if the caregiver confirmed progressive forgetfulness. Subsequently, these screen-
positive subjects (n=1,598) were invited to participate in the second phase of the 
EDIS study, which was conducted at the Centre for Life Sciences, National 
University of Singapore (NUS). Participants who declined the initial invitation were 
contacted again at a later time to increase the participation rate. Those who declined 
at the first attempt were mailed study brochures, and offered free transportation and 
pick up services. A person was termed ‘uncontactable’ if he/she failed to respond 
after 6 attempts.11 The total number of subjects who agreed to participate in phase II 
were 957. Brief study assesment flow chart is provided in (Figure 3 – 1).  
b.    Case Control Study 
For the case control study, the cases (CIND and dementia) with subjective complaints 
of memory loss and cognitive impairment on neuropsychological assessment were 
recruited from two study sites in Singapore (i.e. memory clinics from National 
University Hospital and Saint Luke’s Hospital). Controls were recruited from both 
memory clinics and the community (Epidemiology of Dementia In Singapore study, 
with a similar catchment area as cases). Controls (from memory clinic and 
community) were defined as those with subjective cognitive complaints but were 
cognitively normal on objective neuropsychological assessment (Figure 3 – 2). 
Patients with other diagnoses, or significant neurological comorbidities (e.g. 
Parkinson’s disease), or loss of functional independence (modified Rankin Scale 4), 




2.  EXAMINATION PROCEDURES 
Participants in the EDIS study (during the second phase) and of case control study, 
underwent standardized extensive clinical, neuropsychological evaluation, laboratory 
tests, neuroimaging, and retinal photography. 
Questionnaire 
A detailed questionnaire was administered by the interviewer to collect relevant 
demographic and medical information. Data collected included age, gender, 
education, marital status, occupation, ability to live independently, handedness, 
previous head trauma, smoking, alcohol consumption and family history of dementia. 
Previous medical history including stroke, cardiovascular diseases, hypertension, 
hyperlipidemia, diabetes mellitus, vitamin B 12 deficiency, thyroid disease, urinary 
and bowel incontinence, Parkinson’s disease and psychiatric illnesses were noted, and 
subsequently verified by medical records. The Instrumental activities of daily living 
and Barthel activities of daily living indices were assessed for functional status.12, 13 
Physical Examination and Clinical Assessment 
Clinical assessment included height, weight, blood pressure, pulse rate, ankle and 
brachial blood pressures and indices (e.g. ankle brachial index), modified versions of 
National Institutes of Health Stroke Scale, Hachinski Ischemic Scale and frontal 
release signs. Clinical history and Clinical Dementia Rating Scale (CDR) evaluations 
were performed by clinicians, in accordance with established clinical guidelines for 
the evaluation of cognitive impairment and dementia. 
Vascular risk factors 
Systolic and diastolic blood pressures were measured using a digital automatic blood 
pressure monitor (OMRON-HEM 7203, Japan) after the subject rested for five 




two readings was considered as the relevant blood pressure. Hypertension was 
defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥ 90 
mmHg, or use of antihypertensive medication. Mean arterial blood pressure was 
calculated as two-thirds of the diastolic blood pressure plus one-third of the systolic 
blood pressure. Diabetes mellitus was defined as glycated hemoglobin ≥ 6·5 %, or 
use of anti-diabetic medication. Hyperlipidemia was defined as total cholesterol 
levels ≥ 4·14 mmol/l, or use of lipid lowering medication. 
Blood Tests 
A total of 20 cc of blood was drawn in the fasting state. All blood samples were sent 
to National University Hospital Laboratory for measurements on the same day. Blood 
tests included the following: full blood count, glucose, lipids, creatinine, alanine 
transaminase, aspartate transaminase, calcium, albumin, thyroid function, vitamin 
B12, folate, syphilis screen, homocysteine, high sensitivity C-reactive protein. 
Additionally the blood samples from case control study were collected and stored at 
the Neuroscience Research Laboratory for future genetic and biomarker analysis. 
Neuroimaging 
Sequences 
MRI scans were performed on a 3T Siemens Magnetom Trio Tim scanner, using a 
32-channel head coil, at the Clinical Imaging Research Centre of the NUS. A number 
of standardized and advanced MRI brain sequences were performed to allow 
morphologic, microstructure and functional assessments. These included; 
- High-resolution T1-weighted Magnetization Prepared Rapid Gradient Recalled 
Echo (MPRAGE) sequence (repetition time, TR = 7.2 ms, time to echo, TE =3.3 ms, 
matrix = 256×256×180 mm3) was used to obtain high resolution anatomical 




- Fluid attenuated inversion recovery (FLAIR) (TR = 9.3 ms, TE = 140 ms, matrix = 
256×192 mm3) and T2 sequences (TR = 3,000 ms, time to echo, TE = 10.1 ms, matrix 
= 256×247 mm3) for assessment of signal alterations in brain tissues and to detect 
infarcts, white matter hyperintensities and confirm microinfarcts (previously detected 
on T1).  
- Susceptibility Weighted Imaging (SWI) sequence (TR = 27 ms, TE = 20 ms, matrix 
= 240× 240 mm3) was used to detect microbleeds.  
- Finally, a three dimensional Time of Flight (ToF) Magnetic Resonance 
Angiography (MRA) (TR = 24 ms, TE = 4.1 ms, spatial resolution = 0.6×0.6×0.6 
mm3, flip angle of 20°, 192mm field of view, 218 × 256 acquisition matrix, slice 
thickness of 0·80mm, distance factor -22.73% and an acquisition time of 6 minutes 
and 28 seconds) was conducted to assess the intracranial vessels.  
Scanning time was approximately 60 minutes. Subjects with claustrophobia, 
contraindications for MRI, or those who were unable to tolerate the procedure, 
underwent a non-contrast enhanced Computed Tomography (CT) scan, which was 
performed in axial slices at 5mm intervals rostrally from the orbitomeatal line. 
Scanning time was approximately 3 minutes. 
Visual grading of MRI scans 
All MRI scans were visually graded for infarcts, white matter hyperintensities, 
cerebral microbleeds, atrophy, intracranial stenosis and cerebral cortical microinfarcts 
(Figure 3 – 3). The details of each marker is described below; 
Infarcts: 
- Lacunar infarcts were defined on focal lesions measuring ≥ 3mm to < 15mm, 
hyperintense rim on T2 FLAIR with center following CSF intensity and 
hyperintensity on T2 weighted images. Differentiation of lacunes from 
perivascular spaces was based on morphology of typical vascular shape and 




- Cortical infarcts were defined as focal lesions involving cortical gray matter, 
signal following cerebrospinal fluid intensity, hyperintense rim on FLAIR 
images, and tissue loss of variable magnitude, with prominent adjacent sulci 
and ipsilateral ventricular enlargement.14  
The anotomical location together with arterial territory of these infarcts were 
noted and collected. The inter- and intrarater reliability as expressed by kappa 
statistic ranged from 0.59 to 0.80. 
Cerebral microbleeds (CMBs): 
CMBs were defined as focal, rounded areas of hypointensity (T1 and T2 weighted 
images), 2-10 mm in diameter with blooming on Susceptibility Weighted Imaging 
(SWI) sequences using Brain Observer Micro Bleed Scale (BOMBS).15 Symmetrical 
hypointensities in the basal ganglia, choroid plexus and pineal gland caused by 
calcification, hypointense lesions within the subarachnoid space, or those possibly 
associated with traumatic brain injury, hemorrhagic infarcts or vascular malformation 
were carefully excluded. CMBs were categorized according to their location into 
cortical [cortical gray matter and gray-white matter junction], subcortical white 
matter [subcortical or periventricular white matter], subcortical gray matter [basal 
ganglia and the thalamus] and infratentorial [brain stem and cerebellum] (Figure 3 - 
4). Furthermore, lobar location was defined as cortical, subcortical or periventricular 
white matter, whereas deep as subcortical gray matter, and the white matter of the 
corpus callosum, internal and external capsule. 
Cortical cerebral microinfarcts (CMIs): 
CMIs were defined as hypointense on T1, <5 mm in diameter, restricted to the cortex, 
perpendicular to the cortical surface, and distinct from perivascular spaces. The 
location of a hypointense cortical lesion found on T1 was explored on FLAIR and 
T2-weighted images. The lesion was rated as a definite cortical CMI if the location 
was hyperintense or isointense on FLAIR and T2. The lesion was discarded as a CMI 




T1 hypointense lesion was either due to a hemorrhagic lesion, a vessel, or an artifact 
(Figure 3 – 5).  Possible cortical CMIs in tissue affected by larger cortical infarcts 
were discarded. 
Intracranial stenosis (ICS): 
ICS was defined as narrowing exceeding 50% of the luminal diameter in any of the 
intracranial vessels assessed on 3D TOF MRA. The images were first visually 
assessed on the coronal sequences and then on reconstruction. The final decision on 
stenosis (>50%) was based on the reconstruction sections. The arteries that were 
assessed were vertebral, basilar, internal carotids, posterior cerebral, middle cerebral 
and anterior cerebral arteries. Radiologists and clinicians, who were blinded to 
clinical data, graded each participant’s MRA independently. The inter-rater reliability 
expressed as kappa statistic ranged from 0.51 to 0.79. 
Quantitative MRI grading 
Intracranial volume and white matter hyperintensities volume 
Total intracranial volume and white matter hyperintensities were quantified by 
automatic segmentation using the proton density-weighted T1 sequence, T2 weighted 
images and FLAIR sequences. Briefly, cerebrospinal fluid, gray matter and white 
matter were segmented by an atlas-based k-nearest neighbour classifier on multi-
modal MRI data. This classifier was trained by registering brain atlases to the subject. 
The resulting gray matter segmentation was used to automatically find a white matter 
hyperintensities threshold in a FLAIR image. False positive lesions were removed by 
ensuring that the lesions are within the white matter. This method has been previously 
validated on the manual segmentations.16, 17 Total brain volume and white matter 
hyperintensities were calculated for the five regions (frontal, parietal, occipital, 






Cortical thickness was calculated using a model-based automated procedure 
(FreeSurfer, v.5.1.0) on T1-weighted images (TR = 7.2 ms, TE = 3.3 ms, matrix = 
256 × 256 × 180 mm3). Cortical thickness was measured at each vertex by taking the 
shortest distance between white matter/gray matter boundary and pial surface.18 
Whole brain (global) and regional (lobar) averages of cortical thickness were 
expressed in micrometers (μm). Lobar average was calculated from right and left 
thicknesses using the parcellation guide on gyral and sulcal structures of cerebral 
cortex.18 Lobar averages were calculated for the frontal, parietal, occipital, temporal, 
insular and limbic regions. 
Subcortical structure volume 
Volumes of subcortical structures (accumbens, amygdala, caudate, pallidum, 
putamen, thalamus, hippocampus and brainstem) were segmented using a model 
based automated procedure (FreeSurfer, v.5.1.0) on T1 weighted images (TR= 7.2 
ms, TE= 3.3 ms, matrix = 256×256×180 mm3). Segmentation was performed by 
rigid-body registration and nonlinear normalization of images to a probabilistic brain 
atlas. In the segmentation process, each voxel of the MRI volumes was labeled 
automatically as a corresponding brain region based on a parcellation guide. Finally 
the volumes of accumbens, amygdala, caudate, pallidum, putamen thalamus and 
hippocampus were calculated separately for left and right hemispheres.19 
The segmentation technique of both cortical thicknesses and subcortical structures is 
shown in Figure 3 – 7.  
Retinal assessment 
Assessment of Retinal Vasculature 
Retinal microvascular changes were assessed using non-mydriatic retinal fundus 
photography. Retinal photographs centered on the optic disc and the macula was 




Vessel Assessment (SIVA) system is a semi-automated computer-based program 
designed to assess quantitative structural retinal vascular parameters from optic-disc. 
Retinal fundus images were centered at the optic disc and were taken 0.5 to 2.0 disc 
diameter away from the optic disc margin. The major parameters extracted from this 
system include retinal vascular diameter, fractal dimension, and tortuosity (Figure 3 
– 5).   
Retinal Vascular Caliber 
The program calculates retinal arteriolar and venular calibers as central retinal artery 
equivalent (CRAE) and central retinal vein equivalent (CRVE), based on the revised 
Knudtson-Parr-Hubbard formula.20, 21 
Retinal Vascular Fractal Dimension 
Retinal vascular dimension was evaluated from the skeletonized vascular network 
using the box-counting method, and represents a “global” measure that summarizes 
the whole branching pattern of the retinal vascular tree.20, 21 Larger values indicate a 
more complex branching pattern.  
Retinal Vascular Tortuosity 
Retinal vascular tortuosity was computed as the integral of the curvature square along 
the path of the vessel, normalized by the total path length; this measure is 
dimensionless as it represents a ratio measure.20, 21 The estimates were summarized as 
retinal arteriolar and venular tortuosity separately, representing the average tortuosity 
of arterioles and venules, respectively. Retinal vascular tortuosity reflects the extent 
of curvature in the vessels; a smaller tortuosity value indicates a straighter retinal 
vessel. 
Assessment of Retinal Neuronal Layers 
Besides the retinal microvascular changes, spectral domain optical coherence 
tomography (SD-OCT) was used to assess the retinal neuronal changes. SD-OCT can 




plexiform layer. After pupil dilatation, SD-OCT (Cirrus HD-OCT; Carl Zeiss 
Meditec) was used to acquire macular and optic disc scans using the macular cube 
200x200 and optic nerve head cube 200x200 scan protocols respectively in each eye. 
Scans were repeated if motion artifacts (as indicated by blood vessels discontinuity) 
or saccades were detected. Details of the Cirrus HD-OCT macular and optic disc scan 
protocols have been described in detail elsewhere.22, 23 Peripapillary RNFL thickness 
parameters (average, superior quadrant, nasal quadrant, inferior quadrant and 
temporal quadrant) were derived automatically from optic nerve head cube scan. The 
built-in algorithm automatically detects the optic disc center and positions a 
calculation circle of diameter 3.46mm around the optic disc on the RNFL thickness 
map.  
Using the same software, a series of GC-IPL parameters (average, superior, 
superonasal, inferonasal, inferior, inferotemporal, superotemporal sectors) from 
macular cube scan were derived automatically. The software detects and measures the 
GC-IPL thicknesses automatically within a 14.13mm2 elliptical annulus area centered 
on the fovea from 3-dimensions. The ganglion cell analysis algorithm detects and 
yields the combined thickness of the GCL and the IPL (Figure 3 – 8). Additional 
details are available in chapter 13. 
Neuropsychological Test Battery 
Trained research psychologists administered brief cognitive screening tests, the Mini-
Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), 
the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) and a 
formal neuropsychological battery locally validated for Singaporean elderly.11 This 
battery assessed seven domains, five of which were non-memory domains (executive 




memory domains (visual and verbal memory). The list of the neuropsychological 
tests used for respective domains are described below; 
- Executive Function (Frontal Assessment Battery,24 Maze Task25),  
- Attention (Digit Span, Visual Memory Span26 and Auditory Detection27),  
- Language (Boston Naming Test28 and Verbal Fluency29),  
- Visuomotor speed (Symbol Digit Modality Test30, Digit Cancellation31),  
- Visuoconstruction (Weschler Memory Scale – Revised (WMS-R) Visual 
Reproduction Copy Task,24 Clock Drawing,32AIS-R subtest of Block Design),33 
- Verbal Memory (Word List Recall34 and Story Recall),  
- Visual Memory (Picture Recall, WMS-R Visual Reproduction). 26  
For each participant, raw scores from each individual test within a domain were first 
transformed to standardized Z-scores using the mean and standard deviation [SD] of 
that test in this cohort. A higher Z-score reflected a better performance on that test. 
Subsequently, for each participant a mean Z-score for each domain was calculated by 
averaging the Z-scores of all the individual tests within that domain. These mean Z-
scores of each domain were then standardized using the mean and SD of that domain-
specific mean Z-score. Finally, composite Z-score reflecting global cognitive 
functioning was calculated by averaging the seven domain-specific mean Z-scores, 
which were also standardized using the corresponding mean and SD.  The modified 
15-item Geriatric Depression Scale (GDS) was also administered to all subjects.35 
Diagnosis of Cognitive Impairment and Dementia 
Diagnoses of cognitive impairment and dementia were made at weekly consensus 
meetings attended by study clinicians, neuropsychologists, clinical research fellows, 
research coordinators and research assistants. The clinical features, blood 
investigations, psychometrics and neuroimages were reviewed. Subjects with no 
objective evidence of impairment in cognitive domains were classified as no 




defined as impairment in at least one domain of the neuropsychological test battery 
without functional impairment.  
- CIND-mild was diagnosed when less than or two domains were impaired,  
- CIND-moderate was diagnosed when more than two domains were impaired. 
Dementia was diagnosed according to the DSM-IV criteria. Details on the CIND 
severity, vascular CIND and etiological diagnosis of dementia are described in details 
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Cases, from memory clinic diagnosed as either  
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Figure 3 – 3: Markers of cerebrovascular diseases visually graded on MRI scans.  
(A) Lacunes, visible on Fluid Attenuated Inversion Recovery (FLAIR) as round or ovoid 
hypointense lesions with hyperintense rim. (B) White matter hyperintensities, identified as 
signal abnormality of variable size in white matter without cavitation on FLAIR. (C) Cerebral 
microbleeds, visible as focal, rounded areas of hypointensity on Susceptibility Weighted 
Images (SWI). (D) Cortical cerebral microinfarcts, appear as hypointense, perpendicular 
lesions in cortical ribbon on T1. (E) Intracranial stenosis, identified as flow void in internal 
carotid artery on Magnetic Resonance Angiography (MRA). (F) Atrophy, visible as widening 
of sulcus, enlargement of ventricles and shrinkage of medial temporal lobe (enlargement of 







Figure  3 – 4: Cerebral microbleeds on Susceptibility Weighted Images (SWI) 
Microbleeds visible as focal, rounded areas of  hypointensity, 2-10 mm in diameter with 
blooming on SWI. Mircobleeds were categorized according to their location into infratentorial 













Figure 3 – 5: Cortical cerebral microinfarct (CMI) on 3T MRI 
CMI in an 87-year old woman, visible as a hypointense lesion on T1 in sagittal (A), coronal 
(B), and axial sections (C). This CMI was confirmed as a hyperintense lesion on fluid-
attenuated inversion recovery (D) and T2 weighted images (E) and not hypointense on 















Figure 3 – 6: Quantitative segmentations of the brain parenchyma. 
(A) Segmentations of the white and gray matter and cerebrospinal fluid (in colours). (B) 
Segmentations of the white matter hyperintensities together with the brain parenchyma. (C) 
Cerebral cortex parcellated into sulci and gyri cortices (displayed by colours) based on 









Figure 3 – 7: Measurement of retinal microvascular parameters using Singapore I Vessel 
Assessment (SIVA) 
All retinal microvascular parameters are measured within the grid drawn over a region 0.5 to 2 
disc diameter away from the optic disc. SIVA programme automatically traces the vessels (A) 
Calibers are calculated separately for arterioles (red) and venules (blue). (B) Fractal dimension 
calculated from the skeletonized line using box counting method. (C) Tortuosity is derived 
















Figure 3 – 8: Measurement of retinal neuronal layers using spectral domain optical 
coherence tomography (SD-OCT) 
Retinal nerve fiber layer (RNFL) is measured at the purple circle (A) around the optic disc 
using optic nerve head cube scans where RNFL is automatically delineated as seen in a cross 
section (between two red lines) (B). Ganglion cell inner plexiform layer (GC-IPL) is measured 
at red circle on the fovea (C) using macular cube scans where GC-IPL is automatically 
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CHAPTER 4:  
Cerebral Microbleeds and Cognition- The Epidemiology of 





1.  INTRODUCTION 
Cerebral microbleeds (CMB) are radiologically defined lesions on magnetic 
resonance imaging (MRI) sequences, most commonly on gradient-echo (GE) T2* or 
susceptibility weighted images (SWI), which correspond pathologically to 
hemosiderin deposits surrounding small vessels.1, 2 In healthy populations the 
reported prevalence of CMBs ranges from 3.8% to 38.3%, whereas in patients with 
stroke the corresponding figures may be as high as 50-70%.3-6  
Histo-pathological studies have shown that CMBs are associated with surrounding 
tissue damage.7, 8 Although a direct impact of CMBs on cognitive function has been 
hypothesized, results from studies have varied.9-12  CMBs are associated with both a 
higher amyloid burden and are also known to occur in patients with Alzheimer’s 
disease. Furthermore, previous studies showed that CMBs occur concomitantly with 
white matter hyperintensities (WMH) and lacunar stroke.12-14 Thus, an independent 
effect of CMBs on cognition may be implicated only if other associated pathologies 
are accounted for.15  
With respect to Asian populations, studies from Japan reported that presence of 
CMBs is related to a poorer cognitive function.16, 17 However, in these studies 
cognitive function was assessed solely by the mini mental status examination 
(MMSE), and 1.5T MRI was utilized for assessment of CMBs. As yet, there are no 
data from Chinese populations on the association with cognitive impairment as 
assessed by an extensive neuropsychological test battery. Therefore, in the present 
study, we investigated the association of CMBs with cognition, as assessed by a 
comprehensive neuropsychological evaluation among Chinese subjects from the 
population-based Singapore Chinese Eye Study (SCES), who failed an initial 
cognitive screening and were recruited into the on-going Epidemiology of Dementia 
in Singapore (EDIS) Study. Furthermore, when examining this association we took 
into account the presence of other MRI features, as reflected by markers of cerebral 




2.  METHODS 
2.1  Study Population 
The ongoing Epidemiology of Dementia in Singapore (EDIS) study drew subjects 
from the population-based study among Chinese aged 40-85 years, who participated 
in the Singapore Chinese Eye Study (SCES). In order to use the limited resources in 
an efficient way, it was decided to focus on those subjects who were most likely to 
have some cognitive problems. Hence, in the first phase of the EDIS Study, Chinese 
participants from SCES aged ≥ 60 years (n=1,538) were screened using the 
Abbreviated Mental Test (AMT) and a self-report of progressive forgetfulness. 
Screen-positives were defined as AMT score ≤ 6, among those with ≤ 6 years of 
formal education, or ≤ 8 among those with > 6 years of formal education; or if the 
subject or caregiver reported progressive forgetfulness. Screen-positive subjects 
(n=612) were invited to take part in the second phase of this study, which included an 
extensive neuropsychological test battery and brain magnetic resonance imaging 
(MRI). Of these 612 participants, 300 agreed to participate in phase II and hence were 
included in the present study. Ethics approval for EDIS was obtained from the 
Singapore Eye Research Institute (SERI) and National Healthcare group (NHG) 
Institutional Review Boards. Informed consent was obtained for all participants prior 
to recruitment. The details of the study methodology have been described 
elsewhere.18 
2.2  Neuroimaging 
MRI Acquisition  
MRI scans were performed on a 3T Siemens Magnetom Trio Tim scanner using a 32-
channel head coil at the Clinical Imaging Research Centre, National University of 
Singapore, Singapore. A number of standardized and advanced MRI Brain sequences 
were performed including Susceptibility Weighted Imaging (SWI) sequences to 




contraindications for MRI, or those who were unable to tolerate the procedure were 
excluded. 
Grading of Cerebral Microbleeds (CMB)  
The presence, location and number of CMBs were graded on SWI images according 
to the Brain Observer Micro Bleed Scale (BOMBS)19 (Chapter 3).  
Other markers on MRI 
Other MRI markers of cerebrovascular diseases (lacunes and WMH volume) and 
involutional changes (total brain volume) have been described in detail in Chapter 3. 
2.3  Cognitive Assessment 
A formal neuropsychological battery, previously validated for the Singaporean 
elderly, was administered to all participants.20 The details of cognitive domains, 
utilizing respective neuropsychological tests have been described in Chapter 3.  
2.4  Assessment of Other Risk Factors  
Demographic and vascular risk factors including age, sex, education, smoking, 
hypertension, diabetes, hyperlipidemia, height, weight and history of stroke were 
collected and verified by medical records.18 Data on medication use included use of 
antiplatelets or anticoagulants. Education was categorized into < Primary 6 and ≥ 
Primary 6. Smoking was categorized into ever smokers (past and current smokers) vs. 
never smokers. Body mass index (BMI) was calculated as the weight in kg divided by 
the square of height in meters. 
2.5  Statistical Analysis 
Baseline characteristics are presented as means ± standard deviation [SD] or number 
(percentage), and were compared between subjects with and without CMB. Chi-
square test was used for categorical variables, student’s t-test for normally distributed 
continuous variables and Mann-Whitney U test for skewed distributed continuous 
variable (WMH).  
Regarding quantitative MRI markers, WMH volume was logarithmically 




CMBs and other MRI markers: logistic regression models were constructed for 
lacunes, and linear regression models for WMH and total brain volume. These 
models were adjusted initially for age and sex; subsequently for smoking, mean 
arterial blood pressure, cholesterol, random blood glucose and, finally, for the other 
MRI markers.  
For the associations of CMBs with cognition, linear regression models were 
constructed for composite and domain-specific Z-scores. These regression models 
with cognition were adjusted initially for age, sex and education; subsequently for 
mean arterial blood pressure, cholesterol, random blood glucose, smoking, BMI, 
antiplatelet/ anticoagulant, GDS and, finally, for the other MRI markers.  
For all the models, measures of association were expressed with the corresponding 
95% confidence intervals (CI). In order to examine the robustness of the associations, 
CMBs were included in these models as (1) per CMB increase and (2) multiple (≥2) 
versus none/single (<2) CMB. P-values < 0.05 were considered statistically 
significant. In view of the multiple tests performed on the specific cognitive domains 
(7 domains), we also used the Bonferroni correction to obtain an adjusted significance 
level for each domain-specific test: 0.05/7=0.007. These analyses were performed 
using standard statistical software (Statistical Package for Social Science, SPSS V20, 
SPSS Inc., USA). 
3.  RESULTS 
A total of 1,538 Chinese subjects participated in phase I of the EDIS Study, of whom 
612 were screen positive and thus were invited for the second phase. Out of 612 
screened positive participants, 300 subjects agreed to participate in phase II. 
Compared to those who did not participate in phase II (n=312), those who 
participated were younger (mean age 69.9), more often women, had a higher 
education and higher socio-economic status, less often hypertensive, whereas the 




subjects had MRI scans that could not be graded.  Of the remaining 282 subjects, 
91(32.3%) subjects had any CMBs. Among subjects with CMBs, 55 (60.4%) had a 
single CMB, 19 (20.8%) had 2 CMB and 17 (18.7%) > 2 CMBs. Lobar CMBs were 
present in 75 (82.4%), of which 36 (39.6%) were cortical CMBs. The range of CMB 
counts was 0 to 43. Baseline characteristics of the participants with and without CMB 
are shown in Table 4–2. Subjects with CMB more often used antiplatelets and 
anticoagulants and had more lacunes and a higher WMH volume compared to those 
without CMBs.  
Increasing age was associated with higher prevalence of CMBs: among persons aged 
60-64 years the prevalence was 28.6% increasing to 35.7% in those older than 75 
years. With respect to other MRI markers, the most consistent associations were 
found between CMBs and lacunes, which were independent even after adjusting for 
WMH and total brain volumes. For WMH, only the model, which included CMBs as 
“a one lesion increase”, suggested an association with WMH volume: 0.05 (95% CI 
0.01; 0.09) (Table 4-3). However, this was not supported by the categorized analysis. 
Finally, CMBs were not associated with total brain volume.  
With respect to cognition, Table 4-4 shows that there was an association between 
CMB and global composite Z–score (difference in mean Z-score per CMB increase: -
0.06 [-0.11; -0.01]). Furthermore, these associations were independent of other 
cardiovascular risk factors and other markers of cerebral small vessel disease. The 
findings were further supported when CMBs were categorized as multiple versus 
none/single.  
As we found a significant association with the global composite Z-score, further 
analyses were conducted with domain-specific Z-scores (Table 4-5). In the fully 
adjusted models CMBs were associated with executive function, attention and 
visuoconstruction. Similar associations were observed when CMBs were categorized 




0.007 to the domain specific analyses, only the association with visuoconstruction 
reached this revised level of significance.  
4.  DISCUSSION 
 
In this study of an elderly Chinese population, we showed that the presence and 
number of CMBs were - independent of other markers of cerebral small vessel 
disease – associated with poorer cognitive function.  
There is considerable debate about the exact role of CMBs in the pathophysiology of 
cognitive impairment and dementia. A recent systemic review and meta-analysis 
reported an association between CMBs and cognitive impairment.21 Furthermore, the 
RUN DMC study examining non-demented subjects (50-85 years) with cerebral 
small vessel disease also reported significant associations of presence and number of 
CMBs with global cognitive function, as measured by the Cognitive Index, 
psychomotor speed and attention, though no association was found with the MMSE.9  
On the other hand, data from the Rotterdam Study (n=3,979) has suggested that the 
number of CMBs is associated with MMSE scores after additional adjustment for 
brain atrophy, WMH volume and lacunar infarcts, suggesting that concomitant 
occurrence of traditional markers of cerebral small vessel disease explained their 
findings.10 In contrast, several other studies in Caucasians have failed to find an 
independent association between CMB and cognitive decline.22,23 Finally, a clinic-
based study among subjects with Alzheimer’s disease (mean age 68 ± 9 years) 
showed that the presence and number of CMB was neither associated with baseline 
MMSE, nor with change in MMSE over a period of 3 years.24  
With respect to Asian populations, thus far two Asian studies have shown an 
association of CMB with lower scores on MMSE.16, 17 However, these studies lacked 
detailed neuropsychological assessment, utilized low resolution MRI scans and other 
cerebrovascular diseases (strokes and WMH) were not taken into consideration. With 




associated with cognitive function independent of other markers of cerebral small 
vessel disease. In order to examine the robustness of our findings, we also examined 
these associations using a different categorization (≥2 versus <2), apart from the “per 
CMB increase” analyses. This categorization further supported our original findings.  
In relation to MRI markers of cerebrovascular disease, previous studies have reported 
an association of CMBs with silent brain infarcts, lacunar infarcts and WMH.14,25,26 
Our observations confirm the association of cerebral CMBs with other markers of 
cerebral small vessel disease, including lacunes and – less clearly – WMH.  
Some methodological issues need to be discussed. First, only half of the screen 
positive subjects took part in phase II of the study, as described previously.18 This 
might have led to an underestimation of the prevalence of CMBs on MRI and 
subjects with poorer cognitive function and subsequently attenuation of the effect 
sizes. Despite this underestimation, we still found an association with the composite 
and several domain-specific Z-scores. Second, we did not have sufficient number of 
CMBs to specifically examine the association between location of CMBs (such as 
lobar region) and cognition. Third, due to the cross-sectional design of our study the 
temporal relationship between the presence of CMBs and the development of 
cognitive decline cannot be assessed. Fourth, due to the small number of dementia 
cases (n=5) in this sample, we were unable to determine the effect of CMBs on 
clinically defined dementia. Fifth, even after adjusting for MRI markers such as 
WMH, lacunes and total brain volume, we cannot exclude the possibility of residual 
confounding by other effects of small vessel disease not fully captured by the current 
MRI markers. Finally, for the domain specific analyses, although we found several 
significant associations at a nominal significance level of 0.05, after applying 
Bonferroni correction only the association with visuoconstruction reached the revised 
significance level of 0.007. Probably due to low power of our study we were not able 




The strengths of this study include: utilization of a validated comprehensive 
neuropsychological test battery for the evaluation of cognitive function and a multi-
modal MRI (3T) to visualize CMBs and other markers of cerebral small vessel 
disease. Furthermore, quantitative MRI markers, such as WMH and total brain 
volume were utilized and adjusted for in our analysis.   
5.  CONCLUSION 
In this study among Chinese subjects, CMBs were, independent of other concomitant 
markers of cerebral small vessel disease, associated with poorer cognitive function. 
Future studies with a prospective design are required to further elucidate the exact 
role of this novel marker of cerebral small vessel disease in the pathophysiology of 
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CHAPTER 4 – TABLES 
 
Table 4 – 1: Baseline characteristics of screen positive participants in phase II compared 






Participated in phase II 











Women, no. (%) 146 (51.8) 172 (55.1) 0.408 
No formal education, no. (%) 124 (43.9) 171 (55) 0.007 
Low Socioeconomic status, no. (%)  184 (65.2) 242 (77.5) <0.001 
Hypertension, no. (%) 208 (73.5) 258 (83) 0.005 
Diabetes mellitus, no. (%) 78 (27.6) 77 (24.8) 0.698 
Hyperlipidemia, no. (%) 245 (74.8) 147 (47.3) <0.001 
Mean arterial blood pressure, mmHg, (SD)  97.1 (9.7) 99.1 (11.9) 0.026 
Random blood glucose, mmol/l (SD) 6.6 (2.7) 6.7 (2.9) 0.603 
Total cholesterol, mmol/l (SD) 5.8 (1.7) 5.2 (1.1) 0.010 
Ever smokers, no.  (%) 86 (30.5) 93 (29.9) 0.271 
Alcohol drinking, no. (%) 







Abbreviation: SD, standard deviation; kg/m2, kilogram per meter square; mmHg, millimeters 
of mercury; mmol/l, millimoles per liter 







Table 4 – 2: Baseline characteristics of the participants with and without cerebral 
microbleeds on MRI (n= 282) 
 
Baseline characteristics CMB absence   
(n=191) 





























































































































Abbreviations: CMB, cerebral microbleed; MRI, magnetic resonance imaging; WMH, white 
matter hyperintensities; SD, standard deviation; kg/m2, kilogram per meter square; mmHg, 
millimeters of mercury; mmol/l, millimoles per liter; ml, milliliters; IQR, interquartile range 
* p < 0.05; significant 






Table 4 – 3: Association between the presence of cerebral microbleeds and MRI markers 
of cerebrovascular disease and involutional changes (n = 282) 
 
Abbreviations: OR, odds ratios; CI, confidence interval; CMB, cerebral microbleed; MRI, 
magnetic resonance imaging; WMH, white matter hyperintensities. 
*Adjusted for age and sex. 
†Adjusted for age, sex, smoking, mean arterial blood pressure, cholesterol, and random blood 
glucose. 
‡Adjusted for age, sex, smoking, mean arterial blood pressure, cholesterol, random blood 
glucose, and other MRI markers. 
§Other MRI markers include WMH and total brain volume. 
║Other MRI markers include lacunes and total brain volume. 
¶Other MRI markers include lacunes and WMH volume. 
Bold values represent statistically significant associations at P<0.05. 
 
 











Per CMB increase 
Model I* 
 
1.34 (1.09; 1.63) 
 
0.04 (0.01; 0.07) 
 
0.63 (-2.12; 3.37) 
Model II† 1.33 (1.05; 1.69) 0.07 (0.03; 0.12) -1.31 (-6.27; 3.66) 
Model III‡  1.25 (0.95; 1.63)§  0.05 (0.01; 0.09)║  -2.47 (-7.53; 2.59)¶ 
CMB, ≥ 2 versus <2 
Model I* 
 
3.42 (1.55; 7.54) 
 
0.25 (-0.01; 0.49) 
 
13.94 (-11.92; 39.82) 
Model II† 3.23 (1.38; 7.56) 0.17 (-0.08; 0.42) 4.05 (-22.52; 30.61) 
Model III‡ 2.94 (1.16; 7.45)§ 0.07 (-0.17; 0.31)║ 2.51 (-24.15; 29.17)¶ 
CMB 0, 1, or ≥ 2    
Model I*    
0 Reference Reference Reference 
1 1.83 (0.82; 4.06) 0.11 (-0.10; 0.32) 5.71 (-16.18; 27.60) 
≥ 2 4.00 (1.74; 9.23) 0.26 (0.02; 0.51) 16.06 (-10.47; 42.58) 
Model II†    
0 Reference Reference Reference 
1 1.69 (0.71; 4.08) 0.14 (-0.07; 0.35) 0.48 (-22.25; 23.22) 
≥ 2 3.77 (1.53; 9.33) 0.20 (-0.05; 0.46) 4.87 (-22.21; 31.95) 
Model II†    
0 Reference Reference Reference 
1 1.63 (0.61; 4.38)§ 0.09 (-0.10; 0.28)║ -1.31 (-23.83; 21.22)¶ 




Table 4 – 4: Association between cerebral microbleeds and cognitive-impairment 
expressed as odd ratios and mean difference with 95% confidence intervals 
 Composite Z-score 
 
Mean difference (95% CI) 













-0.06 (-0.11; -0.01) 













-0.18 (-0.43; 0.08) 







































-0.18 (-0.45; 0.09) 
Abbreviation: CI, confidence interval; CMB, cerebral microbleed; MRI, magnetic resonance 
imaging; WMH, white matter hyperintensities 
* Adjusted for age, sex and education 
† Adjusted for age, sex, education, mean arterial blood pressure, cholesterol, random blood 
glucose, smoking, body mass index, antiplatelets/anticoagulants and Geriatric Depression 
Scale 
‡ Adjusted for age, sex, education, mean arterial blood pressure, cholesterol, random blood 
glucose, smoking, body mass index, antiplatelets/anticoagulants, Geriatric Depression Scale 
and other MRI markers (lacunes, WMH and total brain volumes) 






Table  4 – 5: Association between the number of cerebral microbleeds (per lesion increase) and specific cognitive domains expressed as mean differences 
with 95% confidence intervals 
 
  Executive function Attention Language Visuomotor speed Visuoconstruction Verbal memory Visual memory 
 B (95%CI) B (95%CI) B (95%CI) B (95%CI)  B (95%CI) B (95%CI) B (95%CI) 
Model I* -0.05 (-0.08; -0.02) -0.02 (-0.05; 0.01) -0.03 (-0.06; 0.00) -0.02 (-0.05; 0.00) -0.05 (-0.07; -0.02)# -0.02 (-0.05; 0.01) -0.04 (-0.06; -0.01) 
Model II† -0.10 (-0.16; -0.04) -0.09 (-0.15; -0.04) -0.08 (-0.14; -0.02) -0.05 (-0.09; -0.00) -0.09 (-0.15; -0.04)# -0.06 (-0.11; -0.00) -0.06 (-0.12; -0.01) 
Model III‡ -0.07 (-0.13; -0.02) -0.06 (-0.12; -0.01) -0.06 (-0.12; 0.01) -0.02 (-0.07; 0.03) -0.08 (-0.13; -0.02)# -0.03 (-0.08; 0.03) -0.03 (-0.08; 0.02) 
Abbreviations: B= mean difference; CI= confidence interval 
* Adjusted for age, sex and education 
† Adjusted for age, sex, education, mean arterial blood pressure, cholesterol, random blood glucose, smoking, body mass index, antiplatelets/anticoagulants and 
Geriatric Depression Scale 
‡ Adjusted for age, sex, education, mean arterial blood pressure, cholesterol, random blood glucose, smoking, body mass index, antiplatelets/anticoagulants, 
Geriatric Depression Scale and other MRI markers (lacunes, WMH and total brain volumes) 
# Significant after accounting for multiple testing with Bonferroni correction 










CHAPTER 5:  






1.  INTRODUCTION 
Cerebrovascular disease is an important contributor to cognitive decline and dementia in 
the aging population.1 On autopsy, vascular pathology is found in the majority of patients 
with clinically diagnosed dementia.2 This vascular pathology frequently involves the 
cerebral small vessels. In vivo, signs of cerebral small vessel disease (SVD) on 
conventional magnetic resonance imaging (MRI) include white matter hyperintensities 
(WMHs), lacunes, and microbleeds.3,4 However, these conventional MRI markers do not 
fully capture the burden of SVD in cognitive decline and dementia. In this context, 
cerebral microinfarcts (CMIs) have attracted increasing attention.5 CMIs are regarded as 
the most widespread form of brain infarction and hence could play an important role in 
cognitive decline and dementia.5,6 A systematic review with a pooled analysis of autopsy 
studies showed that CMIs are observed in 24% of non-demented older subjects, in 43% of 
patients with Alzheimer’s disease (AD), and in 62% of patients with vascular dementia 
(VaD).6  Moreover, autopsy studies link CMIs to ante-mortem cognitive decline, also 
independent of Alzheimer pathology.7,8  Recently, it has been shown that cortical CMIs 
can be visualized in vivo using high-field 7 tesla (7T) MRI,9 and that these CMIs can also 
be detected on 3T MRI scans.9,10 
In this study, we examined the frequency of cortical CMIs on 3T MRI in a multi-ethnic 
Asian memory clinic population with a high vascular burden from Singapore. 
Furthermore, we investigated their association with vascular risk factors, cognition, and 
conventional SVD markers. 
2.  METHODS 
2.1  Study Population 
This study involves patients from the National University Health System Memory Ageing 




University Hospital and St. Luke’s Hospital in Singapore. Patients received a referral 
diagnosis prior to enrolment into the study. Five diagnostic categories were eligible for 
inclusion in this study, which were based on the referral diagnosis. 1) ‘No cognitive 
impairment’ (NCI): this diagnosis was given to patients visiting the memory clinic who 
had no objective cognitive impairment on formal neuropsychological tests, or functional 
loss. 2) ’Cognitive impairment no dementia’ (CIND), with (2a) or without (2b) a history 
of stroke was diagnosed in patients who were impaired in at least one cognitive domain of 
a formal neuropsychological test battery, but did not meet DSM-IV (Diagnostic and 
Statistical Manual of Mental Disorders - Fourth Edition) criteria for dementia. Subjects 
were considered to have failed a test it they scored lower than age and education-adjusted 
1.5 SDs below established normal means on individual tests. Failure in at least half of the 
tests in a domain was considered as impairment in that domain. Ischemic stroke was 
assessed based on medical history, and confirmed by neuroimaging. Patients with a 
history of hemorrhagic stroke were excluded. 3) AD was diagnosed in accordance with 
the NINCDS—ADRDA criteria.11 4) VaD was diagnosed in accordance with the NINDS-
AIREN criteria.12 Patients with other diagnoses, or significant neurological co-morbidities 
(e.g. Parkinson’s disease), or loss of functional independence (modified Rankin Scale 
>4), were not included in the cohort. 
As part of the cohort study these diagnoses were confirmed in a multidisciplinary 
consensus meeting, attended by neurologists, psychologists, and a neuroradiologist. All 
study patients underwent a standardized extensive physical, clinical, and 
neuropsychological assessment as well as 3T MRI, all on the same day, at the National 
University of Singapore. For the present study, we selected all consecutive patients 
(N=251), meeting the abovementioned criteria, included between December 2010 and 
September 2013. Of these 251 subjects, 13 were excluded due to missing T1-, FLAIR, or 




Ethical approval for this study was obtained from the National Healthcare Group 
Domain-Specific Review Board (DSRB). The study was conducted in accordance with 
the Declaration of Helsinki. Written informed consent was obtained, in the preferred 
language of the patients, by bilingual study coordinators prior to recruitment into the 
study. Consent for patients lacking capacity was provided by their legal representative, as 
allowed by the DSRB. 
The vascular risk profile was recorded for each patient, which included: a) Diabetes 
mellitus: defined as a history or previous diagnosis of diabetes mellitus, or use of glucose-
lowering medication; b) Hypertension: defined as a history or previous diagnosis of 
hypertension, or use of antihypertensive medication; c) Hyperlipidemia: defined as a 
history or  previous diagnosis of hyperlipidemia, or use of lipid-lowering medication; d) 
Cardiovascular disease: defined as a previous diagnosis of myocardial infarction, 
congestive heart failure, atrial fibrillation, or intervention procedures such as angioplasty, 
or stenting. 
2.2  Cognitive Assessment 
The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment 
(MoCA) as well as a formal neuropsychological battery, previously validated for elderly 
Singaporeans,13 were administered. The subtests to assess the seven cognitive domains 
have been described previously in Chapter 3. 
The assessment was administered according to the patient’s preferred language (i.e. 
English, Mandarin, or Malay). All individual raw test scores were transformed to 
standardized z-scores using the means and SDs of the whole group (N=238). Further 
information on calculation of Z scores have been described in Chapter 3. 
2.3  MRI Protocol 
All scans were acquired on a 3T Siemens Magnetom Trio Tim system, with a 32-channel 




Singapore. The standardized protocol for 3D T1-weighted, a 2D multislice T2-weighted, 
fluid-attenuated inversion recovery (FLAIR) and susceptibility weighted imaging (SWI), 
for the assessment of markers of SVD and intracranial stenosis has been described 
previously in Chapter 3.  
2.4  MRI Rating 
Rating criteria for cortical CMIs were based on a previous study that included 
histological validation (Figure 5-1).9 In that study 15 CMIs were found on 7T in 6/22 
subjects. A proportion (4/15 = 27%) of those CMIs in 2 subjects could also be visualized 
on 3T MRI, especially on the 3D T1-weighted image (Figure 5-2).9 Based on those 
results, the rating criteria for cortical CMIs on 3T for the present study were defined in 
the similar fashion as decribed in Chapter 3 (Figure 5-3).  
The reliability of these 3T rating criteria were tested, using scans from the database of a 
previous study.14 From this dataset, 3T scans were selected based on the earlier 7T 
evaluation by a single rater [SvV]. The validation set included 12 subjects with CMIs on 
the 7T MR images with appropriate 3T MR images, and 11 subjects without CMIs on 7T. 
Cortical CMIs were identified by one visual rater [SvV] on the 3T FLAIR, T1, and T2 
images of these 23 subjects, using the 3T rating criteria as described above, blinded to the 
7T results and clinical information. Identified cortical CMI locations on 3T were then 
compared to the 7T FLAIR, T1, and T2 of the same subject to verify the presence of a 
CMI. It was found that 7/8 (88%) of the identified cortical CMI locations on 3T in these 
subjects, matched with CMIs on the 7T MRI. One of the 8 CMI locations proved to be a 
sulcus on the higher resolution 7T images. The 7 CMIs identified on 3T represented 27% 
of the total number of CMIs (N=26) identified by the same rater on the 7T MRI scans in 
this dataset.  
Cortical CMIs were assessed by one experienced rater [SvV]. The intra-rater agreement 




representative subset of 3T MRI scans, was excellent (ICC=0.97) and good, as assessed 
with Dice’s similarity coefficient (DSC) (DSC=0.65).15 CMI size was estimated on T1 
along the longest axis of the lesion. 
Microbleeds were assessed by one rater [SH] on T2*-weighted images using the Brain 
Observer MicroBleeds Scale (BOMBS) criteria. The intra-rater agreement was excellent 
(ICC=0.89). 
The presence of any large cortical infarct (>5 mm), any cerebellar infarct, or any 
subcortical infarct (i.e. a large subcortical infarct and/or a lacunar infarct) was assessed 
on FLAIR and T1, by two independent raters [SH, NW]. Subsequently, both infarct and 
WMH volume were segmented manually [NW] on FLAIR and T1-weighted images 
using an in-house developed tool based on MeVisLab (MeVis Medical Solutions AG, 
Bremen, Germany).16,17 
Total brain volume and intracranial volume were quantified using a unified segmentation 
approach as implemented in Statistical Parametric Mapping 12b.18 WMH and infarct 
volumes were censored in the segmentation using a mask based on the manual 
delineation of WMHs and infarcts, but were considered as part of total brain volume. 
Intracranial volume was calculated using total brain volume, intraventricular, and 
extracortical cerebrospinal fluid volume. 
The presence of intracranial stenosis, assessed by one rater [SH] on time of flight, was 
defined as a narrowing exceeding 50% of the luminal diameter of either the vertebral, 
basilar, internal carotid, posterior cerebral, middle cerebral, or anterior cerebral artery.  
All MRI ratings were performed blinded to clinical information and without knowledge 
of cortical CMI ratings. 
2.5  Statistical Analyses 
Differences between patients without and with ≥1 or ≥3 (upper tertile) cortical CMIs on 




dichotomous variables, and Mann-Whitney U tests for non-parametric data. Linear 
regression was used for the association of cortical CMIs (determinant) with MMSE, 
MoCA, cognitive domains, the composite z-score, and diagnosis (outcomes), adjusted for 
age, gender, and level of education. Linear regression was used for the association of 
cortical CMIs (determinant) with total brain volume and WMH volume (log transformed) 
(outcomes), adjusted for age, gender, and intracranial volume. The B from the linear 
regression models reflects a ‘mean difference’ between patients with cortical CMIs and 
those without cortical CMIs on MRI. Binary logistic regression was used for the 
association of cortical CMIs with vascular risk factors (except BMI, which was assessed 
using linear regression), the presence of intracranial stenosis, (subcortical and cortical) 
infarcts, (deep and lobar) microbleeds, and the presence of confluent WMHs, adjusted for 
age and gender. Dummy variables were constructed for the analysis, using chi-square 
tests, of diagnosis in relation to cortical CMIs. P-values <0.05 were regarded as 
statistically significant. All analyses were performed using IBM SPSS Statistics, version 
20.0. 
3.  RESULTS 
3.1  Demographics and Vascular Risk Factor Profile 
The mean age of the 238 patients in this study was 72.5 ± 9.1 years (range 50 - 95), 
including 117 (49%) men. Demographic and vascular risk factor profile characteristics of 
patients with and without cortical CMIs on MRI are presented in Table 5-1. Seventy-five 
patients (32%) had cortical CMIs (Figure 3), ranging between 1 - 43 CMIs, with a 
median of 1. Of the patients with cortical CMIs, 39 (52%) had one, 11 (15%) had two, 
and 25 (33%) had three or more cortical CMIs (median 1in those with ≥3 CMIs: median 
5, range 31 - 43). Median size of CMIs was 3 mm, only 8% was larger than 3 mm. 




cortical areas (Supplementary Figure 5-1). Presence of cortical CMIs was not related to 
age, gender, race, or level of education. Presence of CMIs was associated with 
hyperlipidemia, a history of stroke, and cardiovascular disease, but not with other 
vascular risk factors. 
3.2  Cognitive Profile 
The association of cortical CMIs with cognition is presented in Table 5-2. The presence 
of cortical CMIs was associated with lower MMSE score and a lower overall composite 
z-score, and worse performance on the specific domains, including language and 
visuoconstruction. The presence of ≥3 cortical CMIs was also associated with impaired 
executive function.  
3.3  MRI Findings 
The association of cortical CMIs with other MRI findings is presented in Table 5-3.  
The presence of cortical CMIs was associated with the presence of both large cortical and 
subcortical infarcts, and both deep and lobar microbleeds. In patients with a large cortical 
infarct, cortical CMIs were often not always restricted to the same hemisphere as the 
infarct. The relation between cortical CMIs with hyperlipidemia and cardiovascular 
disease did not alter when we adjusted for presence of large cortical infarcts. 
The presence of cortical CMIs was associated with smaller brain volume, and larger 
WMH volume. The association of the presence of cortical CMIs with brain volume did 
not alter when we subsequently adjusted for WMH volume, presence of infarcts, or 
presence of microbleeds. 
The presence of cortical CMIs was associated with the presence of any intracranial 
stenosis. Of note, location of the CMI and the stenosis appeared to be interrelated. 
Cortical CMIs in the right middle cerebral artery (MCA) territory were more common in 
patients with a right MCA stenosis (patients with a right MCA stenosis N=16; 50% CMIs 




MCA territory; p=0.001). The same was true for left MCA stenosis (patients with a left 
MCA stenosis N=14; 36% CMIs in left MCA territory; patients without a left MCA 
stenosis N=215; 12% CMIs in left MCA territory; p=0.010). 
The association of the presence of cortical CMIs with MMSE was independent of the 
presence of infarcts, attenuated after adjusting for WMH volume, the presence of 
microbleeds, and after adjustment for brain volume (as percentage of intracranial 
volume), a marker for brain atrophy. The association of the presence of cortical CMIs 
with the domain language was independent of the presence of infarcts and microbleeds, 
and attenuated after adjusting for WMH volume, and after adjustment for brain volume. 
The association of the presence of cortical CMIs with the domain visuoconstruction was 
independent of the presence of infarcts, microbleeds, and WMH, and attenuated after 
adjustment for brain volume (Table 5-4). 
3.4  Clinical Diagnosis 
The presence of cortical CMIs was linked to the assigned referral diagnoses (Table 4). 
Patients with cortical CMIs on MRI were less often diagnosed with NCI (0.27 [0.09 ; 
0.85] p=0.025) or CIND without stroke (0.34 [0.12 ; 0.92] p=0.033), whereas patients 
with cortical CMIs were more often diagnosed with VaD (2.86 [1.17 ; 6.99] p=0.021), 
compared to patients without cortical CMIs (Supplementary Table 5-1). 
4.  DISCUSSION 
This study showed that cortical CMIs are a common finding on 3T MRI in a memory 
clinic population. Presence of CMIs was associated with several distinct clinical features, 
including reduced performance in the domains of language and visuoconstruction, 
domains that are not typically related to other MRI markers of vascular disease. On MRI, 




Until recently, cortical CMIs could not be visualized on MRI, giving rise to the term ‘the 
invisible lesion’.5 Recently, it was shown that cortical CMIs can be visualized with 7T 
MRI, but also with 3T MRI.9 In the present study we show that CMIs are a common 
finding on 3T MRI scans from a memory clinic population. This is important because 3T 
is more widely available than 7T, allowing a more widespread evaluation of the clinical 
relevance of CMIs in the context of aging, cerebrovascular disease, and dementia in 
future clinical studies. In the present cohort, cortical CMIs were more common in 
patients with dementia (36%) compared to patients without dementia (27%), which is in 
line with neuropathological findings6 and a previous 7T MRI study.19 It should be 
acknowledged, however, that 3T MRI only detects the larger CMIs. Neuropathological 
studies report that sizes of CMIs vary between 50 µm and 5 mm.6 The vast majority of 
CMIs that are captured on 3T MRI are 2-3 mm. Hence, these CMIs on MRI are likely to 
represent only a small fraction of the largest lesions from a much larger underlying total 
CMI burden. The same applies, albeit to a lesser extent, for 7T, as again only the larger 
CMIs are detected. Indeed, estimates from neuropathological studies indicate that CMI 
counts are much higher than observed in the present study.20 Nevertheless, as shown here, 
the CMIs that are detected by MRI do have important clinical correlates.  
Of the demographic and vascular risk factors examined in this study, only 
hyperlipidemia, a history of stroke, and a history of cardiovascular disease were 
associated with the presence of cortical CMIs. Relatively few autopsy studies have 
systematically examined the relation between CMIs and demographic or vascular risk 
factors. Some autopsy studies found an association of CMIs with advanced age at 
death,21,22 but other studies did not.8 No relation with gender has been found,8, 21,23 which 
is in line with our findings. Severe hypertension was identified as a risk factor for 
microscopic infarcts upon autopsy in one population-based study.23 Another population-




and CMIs in individuals younger than 80 years of age at entry.24As far as we know, the 
relation between CMIs and dyslipidemia has not been explored in post-mortem studies. 
The strong association of hyperlipidemia, rather than hypertension, with cortical CMIs in 
our study is remarkable, as hypertension is the most important risk factor for the 
conventional markers of SVD (i.e. lacunar infarcts, microbleeds, WMHs). This implies 
that CMIs may also occur in the context of other etiological processes. 
We found that cortical CMIs were associated with worse cognitive performance, in 
particular tasks assessing cortical function (i.e. language and visuoconstruction). 
Interestingly, tasks that are known to be related to vascular damage in subcortical regions 
(e.g. attention, visuomotor speed) were relatively less affected. The significant 
association with MMSE score in contrast to MoCA score further underlines this finding, 
as the MoCA incorporates more tests of executive function. Few autopsy studies have 
looked into the relation of CMIs and specific cognitive domains. A relation between 
cortical CMIs and worse performance on semantic memory, perceptual speed, and 
visuospatial abilities was found in one study, whereas subcortical CMIs were not 
associated with any of the cognitive domains.8 
Cortical CMIs were strongly associated with larger cortical infarcts. They were not solely 
found in cortical areas surrounding the infarct, but also in other cortical areas and the 
other hemisphere. This suggests global underlying vessel pathology instead of a more 
local manifestation of cerebrovascular disease. Cortical CMIs are generally considered as 
manifestations of cerebral SVD.5 Our results suggest that CMIs are likely to be 
attributable to different aetiologies. The strong associations of cortical CMIs with larger 
cortical infarcts and the spatial relation with presence of intracranial stenosis suggest that 
they are also related to large vessel disease. Possibly CMIs downstream from a large 
vessel stenosis are due to hypoperfusion, but microemboli might also be a causative 




particular cerebral amyloid angiopathy,22,23, 25-28 but can also be attributed to large vessel 
disease.29 The present study cohort was enriched for patients with ischemic stroke, but 
patients with hemorrhagic stroke were excluded. In future studies it would be interesting 
to assess CMI burden also in patients with hemorrhagic stroke, for example in the context 
of cerebral amyloid angiopathy, because CMIs appear to be common in such patients.26-28, 
30 
This study further showed that cortical CMIs are related to brain atrophy. 
Neuropathological studies have suggested that a single CMI on routine pathological 
examination indicates the presence of hundreds up to a thousand CMIs in a single brain.20 
It could be argued that this lesion burden by itself contributes to volume loss. With our 
current scan protocol, only the largest of the whole CMI spectrum can be captured. 
Extending the neuropathological findings, several CMIs on MRI could therefore indicate 
the presence of many more smaller CMIs. Nevertheless, whether many CMIs in a single 
brain by themselves explain global brain atrophy remains to be determined. Even 
hundreds of CMIs still only account for a total lesion volume of less than one ml, which 
is still only a fraction of total cortical volume. The relation of cortical CMIs with worse 
cognitive performance in this study lost statistical significance when we adjusted for 
atrophy measured by brain volume as part of intracranial volume. Apparently, cortical 
atrophy and CMIs may be linked through shared aetiologies or risk factors. The 
interrelation between atrophy, CMIs, and cognition should be a topic of future studies.  
There are some limitations to this study that need to be considered. Cortical CMI rating 
criteria have been developed and validated with histology on 7T MRI. The current 3T 
rating criteria proved to be very consistent with 7T MRI, in the sense that 88% of 3T 
MRI CMIs proved to be CMIs on 7T in our validation study. However, it needs to be 
acknowledged that the sensitivity of 3T to detect cortical CMIs is much lower than 7T 




that was developed on 7T MRI to conventional MRI is of importance, as it allows the 
assessment of this novel marker of cerebrovascular disease in much larger groups of 
patients and in the general population. Longitudinal studies are needed to further unravel 
the clinical importance of cortical CMIs. To further improve cortical CMI rating, we 
suggest scan protocol improvements, including the use of 3T 3D FLAIR images. Finally, 
it remains to be investigated if the current findings are generalizable to non-Asian 
populations and patients from other memory clinics, or comparable in those with a 
different vascular risk factor profile. 
5.  CONCLUSION 
Our 3T MRI study showed that cortical CMIs are a common finding in an Asian memory 
clinic population. Cortical CMIs are associated with cerebral SVD, but most strongly 
with cortical infarcts. In contrast with subcortical SVD, cortical CMIs are particularly 
related with worse language and visuoconstructive abilities, domains considered cortical 
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Abbreviations: CMI, cerebral microinfarcts; OR, odds ratio; CI, confidence interval; n/a, not available; SD, standard deviation; CVD, cardiovascular diseases 
 
Bold text indicates P<0.05. *Chinese (N = 185), Malay (N = 33), Indian (N = 15), mixed (N = 2), others (N = 3) 
 
†Nil (N = 52), primary (N = 88), secondary (N = 69), tertiary (N = 28). ‡Based on self-reported stroke. Odds ratio in binary logistic regression, adjusted for age 
and gender, compared with patients without CMIs. §Mean difference in BMI between groups, adjusted for age and gender 




OR (95%CI) P-value Multiple (≥3) CMIs 
(N=25) 
OR (95%CI) P-value 
Demographics        
Age (years), mean (SD) 72.5 ± 9.2 72.4 ± 9.0 - 0.976 73.4 ± 9.5 - 0.643 
Male, no. (%) 76 (47) 41 (55) - 0.249 17 (68) - 0.047 
Race (Chinese)*, no (%) 130 (78) 55 (73) - 0.298 21 (84) - 0.639 
Education†, median (min-max) 1 [0-3] 1 [0-3] - 0.960 1 [0-3] - 0.792 
Vascular risk factor profile        
Current smoking, no (%) 14 (9) 10 (13) 1.58 [0.65 ; 3.86] 0.312 3 (12) 1.11 [0.28 ; 4.41] 0.884 
Alcohol use, no (%) 5 (3) 2 (3) 0.81 [0.15 ; 4.36] 0.804 0 (0) n/a n/a 
Body-mass index, mean (SD) 23.7 ± 3.7 24.6 ± 4.6 0.88 [-0.22 ; 1.98]§ 0.118 24.4 ± 4.5 0.69 [-0.95 ; 2.33]§ 0.407 
Hypertension, no (%) 120 (74) 60 (80) 1.42 [0.73 ; 2.76] 0.304 19 (76) 1.10 [0.41 ; 2.98] 0.852 
Diabetes mellitus, no (%) 56 (34) 34 (45) 1.59 [0.91 ; 2.78] 0.104 10 (40) 1.26 [0.52 ; 3.03] 0.609 
Hyperlipidemia, no (%) 103 (63) 65 (87) 3.79 [1.81 ; 7.95] 0.000 24 (96) 14.06 [1.84 ; 107.35] 0.011 
History of stroke‡, no (%) 53 (33) 39 (52) 2.40 [1.30 ; 4.41] 0.005 15 (60) 3.35 [1.29 ; 8.68] 0.013 
History of CVD, no (%) 25 (15) 28 (37) 3.28 [1.72 ; 6.24] 0.000 13 (52) 5.76 [2.29 ; 14.51] 0.000 
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Table 5 – 2: Cognitive profile 
 
 
Abbreviations: CMI, cerebral microinfarcts; CI, confidence interval 
 
 
NOTE. Data are presented as mean ± standard deviation (SD). B: Mean difference between patients with cortical CMIs and patients without, from linear 
regression analyses, adjusted for age, gender, and level of education. Z-scores were based on the mean and SDs of the whole patient group (N = 238) 
 




B [95% CI] P-value Multiple (≥3) 
CMIs (N=25) 
B [95% CI] P-value 
Cognitive profile        
Mini-mental state examination 21.0 ± 6.2 19.5 ± 5.9 -1.49 [-2.89; -0.08] 0.038 18.8 ± 6.2 -2.17 [-4.37; 0.04] 0.054 
Montreal Cognitive Assessment  16.5 ± 7.2 15.2 ± 6.9 -1.38 [-2.96; 0.20] 0.086 14.2 ± 6.2 -2.19 [-4.63; 0.25] 0.078 
Composite z-score 0.08 ± 1.05 -0.17 ± 0.10 -0.20 [-0.42; 0.01] 0.067 -0.37 ± 0.79 -0.38 [-0.74; -0.03] 0.036 
Executive function 0.06 ± 1.00 -0.13 ± 1.00 -0.18 [-0.41; 0.05] 0.133 -0.36 ± 1.05 -0.39 [-0.76; -0.01] 0.042 
Attention  0.03 ± 1.00 -0.07 ± 1.02 -0.11 [-0.34; 0.13] 0.375 -0.19 ± 1.06 -0.21 [-0.59; 0.17] 0.282 
Language  0.09 ± 1.04 -0.21 ± 0.89 -0.28 [-0.53; -0.04] 0.023 -0.44 ± 0.62 -0.48 [-0.87; -0.09] 0.017 
Verbal memory  0.05 ± 1.05 -0.11 ± 0.88 -0.13 [-0.37; 0.10] 0.268 -0.24 ± 0.78 -0.21 [-0.59; 0.17] 0.273 
Visual memory  0.07 ± 1.06 -0.15 ± 0.84 -0.21 [-0.45; 0.03] 0.086 -0.34 ± 0.55 -0.37 [-0.77; 0.02] 0.063 
Visuoconstruction  0.10 ± 1.03 -0.21 ± 0.89 -0.30 [-0.52; -0.08] 0.008 -0.44 ± 0.77 -0.51 [-0.87; -0.15] 0.005 








CMI, cerebral microinfarcts; WMH, white matter hyperintensities; OR, odds ratio; MRI, magnetic resonance imaging; CI, confidence interval. 
 
NOTE. Data are presented as mean ± standard deviation, or number (percentage). B: mean difference between patients with cortical CMIs and patients 
without, from linear regression analyses, adjusted for age, gender, and intracranial volume. Odds ratio in binary logistic regression, adjusted for age and gender, 
compared with patients without CMIs.  
 
*Presence of WMHs is defined as beginning confluence or large confluent area, on Fazekas scale 




B [95% CI] P-value Multiple (≥3) CMIs 
(N=25) 
B [95% CI] P-value 
Intracranial volume (ml)  1434 ± 137 1459 ± 152 10 [-19 ; 39] 0.506 1497 ± 166 24 [-21 ; 68] 0.298 
Brain volume (ml)  918 ± 114 897 ± 109 -32 [-50 ; -13] 0.001 905 ± 117 -35 [-64 ; -7] 0.017 
WMH volume (ml), log  15.4 ± 16.7 21.6 ± 21.1 0.4 [0.1 ; 0.7] 0.008 27.8 ± 26.9 0.5 [0.0 ; 1.0]  0.035 
   OR [95% CI]   OR [95% CI]  
Intracranial stenosis  31 (20) 24 (34) 2.04 [1.08 ; 3.84] 0.027 11 (46) 3.39 [1.37 ; 8.43] 0.009 
Presence of infarcts 56 (34) 48 (65) 3.35 [1.87 ; 6.02] 0.000 21 (84) 8.90 [2.86 ; 27.65] 0.000 
- cortical infarcts 12 (7) 27 (36) 6.91 [3.24 ; 14.77] 0.000 18 (72) 29.64 [10.26 ; 85.64] 0.000 
- subcortical infarcts 42 (26) 33 (44) 2.19 [1.22 ; 3.94] 0.009 11 (44) 1.88 [0.77 ; 4.58] 0.163 
Presence of microbleeds  83 (51) 52 (72) 2.42 [1.33 ; 4.43] 0.004 21 (84) 5.04 [1.64 ; 15.48] 0.005 
- deep microbleeds 28 (17) 25 (35) 2.46 [1.30 ; 4.65] 0.006 10 (40) 3.04 [1.22 ; 7.57] 0.017 
- lobar microbleeds 70 (43) 45 (63) 2.15 [1.21 ; 3.80] 0.009 19 (76) 4.36 [1.63 ; 11.65] 0.003 
Presence of WMH*  101 (62) 56 (75) 1.93 [1.02 ; 3.67] 0.044 21 (84) 3.53 [1.08 ; 11.55] 0.037 





Table 5 – 4: Association of cortical CMIs with cognition, adjusted for other MRI markers 
MRI markers included in the model B [95% CI] P-value 
MMSE (in points)   
CMIs alone -1.49 [-2.89 ; -0.08] 0.038 
CMIs + presence of infarcts -1.61 [-3.07 ; -0.15] 0.031 
CMIs + WMH volume -1.22 [-2.63 ; 0.18] 0.087 
CMIs + presence of microbleeds -1.34 [-2.79 ; 0.11] 0.070 
CMIs + brain volume (% ICV) -0.68 [-2.00 ; 0.65] 0.315 
   
Language (z-score)   
CMIs alone -0.28 [-0.53 ; -0.04] 0.023 
CMIs + presence of infarcts -0.28 [-0.53 ; -0.02] 0.034 
CMIs + WMH volume -0.24 [-0.49 ; 0.01] 0.057 
CMIs + presence of microbleeds -0.27 [-0.52 ; -0.02] 0.038 
CMIs + brain volume (% ICV) -0.15 [-0.38 ; 0.08] 0.196 
   
Visuoconstruction (z-score)   
CMIs alone -0.30 [-0.52 ; -0.08] 0.008 
CMIs + presence of infarcts -0.26 [-0.49 ; -0.03] 0.027 
CMIs + WMH volume -0.26 [-0.48 ; -0.04] 0.019 
CMIs + presence of microbleeds -0.28 [-0.51 ; -0.05] 0.015 
CMIs + brain volume (% ICV) -0.18 [-0.38 ; 0.03] 0.086 
Abbreviations: CMI, cerebral microinfarcts; MRI, magnetic resonance imaging; CI, confidence 
interval; MMSE, Mini-Mental State Examination; WMH, white matter hyperintensities; ICV, 
intracranial volume. 
 
NOTE. B: mean difference between patients with cortical CMIs and patients without, from linear 
regression analyses, adjusted for age, gender, level of education, and for each of the individual 





   Supplementary Table  5 – 1: Clinical diagnosis 




OR [95%CI] P-value Multiple (≥3) CMIs 
(N=25) 
OR [95% CI] P-value 
Referral diagnosis        
No cognitive impairment 26 (16) 4 (5) 0.27 [0.09 ; 0.85] 0.025 1 (4) 0.20 [0.02 ; 1.79] 0.151 
CIND, without stroke 29 (18) 5 (7) 0.34 [0.12 ; 0.92] 0.033 1 (4) 0.20 [0.03 ; 1.55] 0.124 
CIND with stroke 32 (20) 23 (31) 1.80 [0.94 ; 3.47] 0.078 7 (28) 1.39 [0.51 ; 3.82] 0.523 
Alzheimer’s disease 66 (40) 31 (41) 1.13 [0.60 ; 2.12] 0.708 8 (32) 0.61 [0.22 ; 1.67] 0.333 
Vascular dementia 10 (6) 12 (16) 2.86 [1.17 ; 6.99] 0.021 8 (32) 7.10 [2.37 ; 21.21] 0.000 
   
Abbreviations: CMI, cerebral microinfarcts; CIND, cognitive impairment no dementia;  
NOTE: Data are presented as number (percentage). OR: odds ratio in binary logistic regression, adjusted for age, gender, and level of education, compared to 






CHAPTER 5 – FIGURES 
 
Figure 5 – 1: Cortical microinfarct on 7T postmortem MRI and histology 
A cortical microinfarct on 7 tesla post-mortem MRI and histology, in the brain of an 83 year-old 
male with pathologically confirmed vascular dementia. A presumed cortical microinfarct (arrow) 
was identified on post-mortem 7 tesla 3D T1 (A; 0.4 mm isotropic voxels), which was less 
conspicuous on post-mortem 7 tesla 3D FLAIR (B; 0.4 mm isotropic voxels). After sampling and 
histological verification of the area indicated with the white square, this cortical lesion was 
verified as a microinfarct (C; Hematoxylin & Eosin stain). The adjacent section, immunostained 






Figure 5 - 2: Same cortical microinfarct on 7T visible on 3T MRI 
The same cortical microinfarct on 7 tesla MRI (top row) and 3 tesla MRI (bottom row) in a 66 
year-old non-demented Dutch female. A cortical microinfarct (arrow) was found on 7 tesla 3D 
FLAIR (A; 0.8 mm isotropic voxels), and 7 tesla 3D T1 (B; 1.0 mm isotropic voxels). The same 
cortical microinfarct could not be retrieved on the 3 tesla FLAIR (C; 1.0x1.3x3.0 mm3 voxels), but 
could be identified on the 3 tesla 3D T1 (D; 1.0 mm isotropic voxels), made on the same day as 






















Figure 5 – 3: Cortical microinfarcts on 3T visible on different sequences 
Three cortical microinfarcts on the 3 tesla MR images of a 63-year old Singaporean male with 
vascular cognitive impairment no dementia. Depicted are a 3D T1 (A), FLAIR (B), and T2 (C) 







Supplementary figure 5 – 1:  3D representation of the cortical microinfarcts 
A 3D representation of total cortical microinfarct distribution. Cortical microinfarcts are 
represented by red dots in a transversal (A), sagittal (B), and coronal (C) view of the brain. There 















CHAPTER 6:  
Cortical Cerebral Microinfarcts on 3 Tesla Magnetic Resonance 
Imaging - A Marker of Cerebrovascular Diseases 
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1.  INTRODUCTION 
 
Cerebrovascular disease (CeVD) is a common pathological finding in older individuals 
and a major cause and contributor to cognitive decline and dementia.1, 2 Brain 
parenchymal damage in cognitive decline secondary to CeVD or vascular cognitive 
impairment, is conventionally visualised on magnetic resonance imaging (MRI) as 
infarcts, white matter hyperintensities (WMH), cerebral microbleeds and atrophy. 
However, autopsy studies have shown that cerebral microinfarcts (CMIs) are highly 
prevalent in dementia (43% in Alzheimer’s Disease and 62% in Vascular dementia), as 
well as in non-demented elderly subjects (up to 33%) and are strongly associated with 
cognitive impairment and dementia.3, 4 CMIs have reported sizes ranging from 50μm to 
~5mm,4 although small and previously held to be “invisible” lesions during life, they may 
be present in sufficient numbers to impair cognition and predict poor outcome in elderly 
with CeVD.5, 6  
Recently, it has been shown that CMIs can be detected in-vivo using 7 Tesla (T) 
Magnetic Resonance Imaging (MRI).7 However, due to the limited accessibility of 7T 
scanners in the clinical setting, there has been a successful effort to extend the detection 
of CMIs using 3T MRI in order to understand their clinical relevance in larger 
populations.8, 9  A recent study from a memory clinic population in Singapore, has shown 
the feasibility of detection of cortical CMIs on 3T MRI scans and an association with 
cognitive dysfunction and dementia.10 However, limited data are available on the risk 
factors of CMIs and no data exist on the effects of CMI on cognition in the general 
elderly population. We, therefore, examined the risk factors of CMIs and their association 
with cognition in a subsample from a population-based study in Singapore.  
2.  METHODS 
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2.1  Study Population 
The Epidemiology of Dementia In Singapore (EDIS) study drew participants from 
ongoing Singapore Epidemiology of Eye Disease (SEED) study, a population-based 
study of three ethnic cohorts : Chinese (Singapore Chinese Eye Study [SCES]),11 Malay 
(Singapore Malay Eye Study [SiMES-2]),12 and Indians (Singapore Indian Eye Study 
[SINDI-2]). The details of the study methodology have been described in Chapter 3.11 
Ethics approval for the EDIS study was obtained from the Singapore Eye Research 
Institute, and National Healthcare Group Domain-Specific Review Board. The study was 
conducted in accordance with the Declaration of Helsinki. Written informed consent was 
obtained prior to their recruitment into the study. 
2.2  Demographic and Cardiovascular Risk Factor Assessment  
The demographic and cardiovascular risk factors were collected for all the subjects in a 
similar fashion11 as described in Chapter 3. Hypertension, diabetes and hyperlipidemia 
were taken as presence and absence. Education was categorized into ≤ 6 years or > 6 
years. Smoking was categorized into ever (past and current smokers) and never smokers. 
Body mass index (BMI) was calculated as the weight (kg) divided by the square of the 
height (meters). Stroke was defined as the presence of focal neurological deficits whereas 
cardiovascular diseases were defined based on the presence of ischemic heart disease, 
congestive heart failure, atrial fibrillation and cardiac bypass.  
2.3  Neuroimaging 
MRI was performed on a 3T Siemens Magnetom Trio Tim scanner, using a 32-channel 
head coil, at the Clinical Imaging Research Centre of the National University of 
Singapore. Subjects with claustrophobia, contraindications for MRI, or those who were 
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unable to tolerate the procedure were excluded. For each participant, the following MRI 
markers were determined: 
Cortical CMIs 
Cortical CMIs were graded on T1, T2 weighted and Fluid-Attenuated Inversion Recovery 
(FLAIR) sequences, according to a validated protocol 10 described in Chapter 3.  
MRI rating for CMIs in EDIS study was independently performed by two trained graders 
(SH, ES). A set of 20 alternate scans were graded for CMIs by the two graders, blinded to 
subject’s characteristics. All the identified cortical CMIs were then discussed in the 
weekly consensus meetings. Any disagreement was further discussed with a third 
experienced grader (SvV) to make a final decision. A subset of 60 scans was randomly 
selected to assess inter-rater reliability, which showed good to excellent agreement 
(kappa=0.83).   
Other MRI Markers 
Quantitative MRI analyses (WMH volume) and visual gradings (cortical infarcts, lacunar 
infarcts, cerebral microbleeds and intracranial stenosis) were collected using the protocol 
and definitions as mentioned in Chapter 3.   
2.4  Cognitive Assessment 
The Mini-Mental Status Examination (MMSE), Montreal Cognitive Assessment 
(MoCA), and an extensive neuropsychological battery, which has been previously 
validated in Singaporean elderly, was administered to assess cognitive function. The 
criteria for defining CIND and calculation of z scores have been described in detail in 
Chapter 3.  
  Chapter 6 
163 
 
2.5.  Statistical Analysis 
In order to examine the differences in demographic, vascular risk factors and MRI 
markers, the chi square test was used for categorical variables, student t test for 
continuous variables and Mann Whitney U test for skewed distributed continuous 
variables (WML). WMH volume was logarithmically transformed, to ensure a normal 
distribution for regression analysis. With respect to the associations between risk factors 
and CMIs, Poisson regression models were used to compute relative risk (RR) and 95% 
confidence intervals (CI), initially adjusting for age, gender and each risk factor 
separately. The fully adjusted model consisted of risk factors significant from first model 
with each MRI marker added one at a time.  
For clinical outcomes (CIND-mild, CIND-moderate and dementia), multiple logistic 
regression analysis was used to compute odds ratios (OR) and 95%confidence interval 
(CI). These regression models with cognition were initially adjusted for age, gender, 
education and subsequently for ethnicity and vascular risk factors. In order to examine 
whether the association between CMI and cognition was independent of other MRI 
markers of CeVD, we additionally adjusted the models for each MRI marker separately. 
With regards to the association between CMIs and cognitive profile, linear regression 
models were constructed for MMSE, MoCA, composite, and domain-specific Z-scores. 
The models were adjusted in the similar fashion as described above.  P-value < 0·05 was 
considered statistically significant. In view of the multiple tests performed on the specific 
cognitive domains (7 domains), we also used the Bonferroni correction to obtain an 
adjusted significance level for each domain specific test: 0.05/7~0.007. Statistical 
analysis was performed using standard statistical software (Statistical Package for Social 
Science, SPSS V23, SPSS Inc., USA). 
  Chapter 6 
164 
 
3.  RESULTS 
 
Assessments of subjects were performed from August 12, 2010 to July 24, 2015. Out of 
957 subjects who participated in EDIS study in phase II, 88 had no MRI scans and 8 had 
ungradable scans. Supplementary table 6-1 presents baseline data of included and 
excluded subjects (screened positive- non-participants and without/ungradable MRI 
scans). Those who were excluded were likely to be older, more often Chinese, had lower 
education and had higher frequency of hypertension, and lower frequency of 
hyperlipidemia. Of the 861 subjects with gradable MRIs, 54 (6·3%) subjects had ≥1 
cortical CMIs. Among subjects with cortical CMIs, 33 (61·1%) had a single cortical 
CMI, 15 (27·8%) with 2-4 and six (11.1%) had ≥ 5, with a range of 0 to 13. Cortical 
CMIs were present throughout the brain with a strong predilection for parietal lobes 
(41·9%) followed by frontal (20·9%), occipital (11·6%) and temporal (4·7%) lobes. Out 
of 861 subjects, 275 (31.9%) subjects were diagnosed with CIND-mild, 290 (33.6%) with 
CIND-moderate and 40 (4.6%) with dementia. Baseline characteristics of subjects with 
and without cortical CMIs are shown in table 6-1. Subjects with cortical CMIs were 
likely to be older, of Malay ethnicity. had higher frequency of hypertension, smoking and 
history of stroke. Moreover, compared to subjects without cortical CMIs, the prevalence 
of cerebral small (lacunar infarcts, WMH, and microbleeds) and large vessel (cortical 
infarcts and intracranial stenosis) diseases on MRI was higher in persons with cortical 
CMIs.  
Table 6-2 shows the association of risk factors with cortical CMIs. In fully adjusted 
models, the most important demographic and cardiovascular risk factors were increasing 
age (per year increase, OR: 1·09; 1·06-1·12), Malay ethnicity (Malay vs. Chinese, OR: 
2·29; 95%CI: 1·42-3·69 and Malay vs. Indians, OR: 1·79; 95%CI: 1·14-2·81), 
hypertension (yes vs. no, OR: 4·33; 95%CI: 1·58-11·83), diabetes (yes vs. no, OR: 1·59; 
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95%CI: 1·10-2·31) and history of stroke (yes vs. no, OR: 4·85; 95%CI: 3·17-7·43). MRI 
markers of both large (cortical infarcts and intracranial stenosis) and small (lacunar 
infarcts, WMH and microbleeds) vessel diseases were associated with increasing number 
of cortical CMIs. When the analysis was restricted to strictly lobar microbleeds, the 
association remains unaltered.  
The presence of cortical CMIs was significantly associated with both CIND moderate 
(OR: 3·28; 95%CI: 1·26-8·58) and dementia (OR: 11.88; 95%CI: 2.18-64.78) after 
adjusting for age, gender and education. On further adjustment with cardiovascular risk 
factors and MRI markers, the association remained unaltered. However, after including 
lacunar infarcts in the model, the association became attenuated but still showed a trend 
towards significance (Table 6-3). When the analysis was performed with cortical CMI 
numbers as risk factor, an independent association was observed between increasing 
numbers of cortical CMIs and CIND moderate and dementia. 
Cortical CMIs was significantly associated with worse performance on MMSE (mean 
difference in MMSE scores: -1·85; 95%CI: -2·84; 0·86), MOCA (mean difference in 
MOCA scores: -2·55; 95% CI: -3·79; -1·29), and composite Z-scores (mean difference in 
composite Z-score: -0·42; 95% CI: -0·62; -0·21) in age, gender and education adjusted 
models. Following further adjustments for ethnicity, cardiovascular risk factors, and MRI 
markers, the associations of CMIs with cognitive profiles remained statistically 
significant (Table 6-4). Finally, in the domain-specific analyses, CMIs were 
independently associated with executive function, visual memory, and verbal memory 
after adjustments for age, gender, education, ethnicity, cardiovascular risk factors, and 
MRI markers. After applying Bonferroni correction, most of the associations remained 
statistically significant (Table 6-5). Lastly, all the associations with cognitive profiles 
remain unaltered after excluding subjects with dementia.  
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4.  DISCUSSION 
 
In this study, we found that cortical CMIs are a novel MRI marker of cerebrovascular 
disease in a general elderly population and are associated with worse cognitive 
functioning, in particular executive function, verbal, and visual memory. In terms of the 
clinical outcomes, persons with cortical CMIs were more likely to have significant 
cognitive impairment. These associations remained independent of cardiovascular risk 
factors and other MRI markers suggesting that these lesions do play an important role in 
cognitive impairment and dementia.  
To our knowledge, this is the first study to report the detection of cortical CMIs on 3T 
MRI from a population based study. We have found a cortical CMI prevalence of 6·3%-  
comparable with the previous prevalence of 6% in hypertensive subjects9 but less than the 
32% from a memory clinic based  study10. The observed lower prevalence of cortical 
CMIs in the present study might be due to fact that our subjects were drawn from a 
population-based study. Moreover, it has been shown that only about 25% of cortical 
CMIs identified on 7T are detectable on 3T.7 However, it should be acknowledged that 
cortical CMIs identified on either 3T or 7T are usually larger and hence only reflects a 
small fraction of the total CMI burden. Indeed, autopsy studies have shown that the actual 
CMI prevalence is much higher (24%-62%) then what is observed in the present study,4 
thus indicating that the CMIs observed on MRI are an underestimate.  
So far, relatively few autopsy and MRI studies have examined the association between 
demographic and cardiovascular risk factors with CMIs. The reported effects of age on 
CMIs have been variable with some studies reporting an association with advanced age13, 
14 whereas others report no association.7, 15 The association of cortical CMIs with 
increasing age in our study is further supported by a recent study where persons with 
cortical CMIs were older compared to those without CMI.9 Moreover, we also reported 
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that the men were more likely to have CMIs compared to women which differ from the 
findings reported previously where no relation with gender was found. 9, 10, 16 This gender 
difference might due to the increased vulnerability of males to cardiovascular risk factors 
and stroke. In terms of ethnic differences, Malays have a higher prevalence of ApoE4 
carriers17 compared to Chinese and Indians which increases their susceptibility to develop 
cerebral amyloid angiopathy (CAA) – a possible mechanism behind CMIs.18 Besides 
genetic factors, environmental factors such as lifestyle, cardiovascular risk factors and 
their complex interactions may also explain the underlying differences in CMI prevalence 
among the three ethnicities.17 
Among the cardiovascular risk factors, hypertension, systolic blood pressure and diabetes 
were identified as the major risk factors for CMIs in a few neuropathological studies.14, 19, 
20 Similar to these findings, our study has also shown an independent association of 
hypertension and diabetes with increasing numbers of cortical CMIs. The possible 
mechanism behind high systolic blood pressure and diabetes leading to microinfarcts has 
been attributed to decreased luminal diameter (atherosclerosis and lipohyalinosis) in the 
small penetrating arteries in the cerebrum.20, 21 Besides, hypertension and diabetes, history 
of stroke was also recognized as an important risk factor for CMIs in our study. This 
highlights the importance of CMIs occurring in parallel with strokes and the vascular 
pathology underlying development of CMIs. 
With respect to MRI markers, we found - in accordance with a previous study10 - that 
both cerebral large (cortical infarcts and intracranial stenosis) and small vessel (lacunar 
infarcts, white matter lesions, and microbleeds) disease markers are associated with the 
presence of cortical CMIs, thus suggesting that these lesions have a heterogeneous 
etiology. It has previously been suggested that CMIs may represent proxies for both small 
and large infarcts or even diffuse injury.16 On the basis of these findings, we could 
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hypothesize that mechanisms such as arteriosclerosis, microembolisms and 
hypoperfusion might contribute to the development of CMIs.18, 22 Moreover, we have also 
reported an association with lobar cerebral microbleeds which indicate that CMIs might 
also be CAA related- attributed to reduced blood flow in small cortical arteries due to the 
deposition of amyloid in the vessel wall. 23 
With regards to cognition, the present study shows that the persons with cortical CMIs 
are more likely to have worse cognitive function in terms of clinical outcomes (CIND / 
dementia), brief tests (MMSE and MoCA) and global cognitive performance. Moreover, 
persons with cortical CMIs performed worse in tasks of executive function, verbal and 
visual memory independent of cardiovascular risk factors and other MRI markers of 
cerebrovascular disease pathology. However, the association of cortical CMIs with 
language and visuomotor speed were attenuated only in the presence of infarcts leading 
to the possibility this association is partly mediated by cerebral ischemic damage. So far, 
only one autopsy study has shown the association of CMIs with specific cognitive 
domains such as semantic memory, perceptual speed and visuospatial function.16 The role 
of cortical CMIs in causing cognitive dysfunction has also been shown in a study on 
memory clinic patients where those with cortical CMI had worse language and 
visuoconstructive abilities.10 Possibly this association with executive function and 
memory domains can be attributed by the abundance of cortical CMIs in the frontal and 
parietal cortex.  Moreover, executive function, visuomotor speed and language are also 
commonly affected in cognitive impairment secondary to both small vessel and 
macroscopic ischemic damage. 24 Impairment of these cognitive domains in persons with 
cortical CMIs might be meditated or modified by processes such as hypoperfusion with 
hypoxia, oxidative stress, and inflammation.16 Finally, patients with single or multiple 
CMIs may also have an unrecognized burden of hundreds of thousands more CMIs in the 
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rest of the brain.16, 25 This may explain why neuropathological studies have shown that 
CMIs disrupt important cognitive networks underlying the cognitive dysfunction 
observed in these subjects.5 
Limitations of this study include: first, 46·1% of the screened positive subjects were 
excluded from these analyses. Compared to the included participants, these excluded 
subjects were relatively older, less educated, and more likely to have hypertension. 
However, despite this non-participation of subjects more likely to have cortical CMIs, we 
still found significant associations with CMIs and in turn with cognition. Second, due to 
the cross-sectional design of our study the temporal relationship between risk factors and 
cortical CMIs and its effect on cognitive impairment could not be assessed. Third, due to 
the lower resolution of 3T MRI compared to 7T, smaller cortical CMIs <2mm might have 
gone undetected. Despite this under detection on 3T, we nevertheless found significant 
associations of risk factors with CMIs and its link with cognitive functioning. 
Furthermore, as the grading of the 3T MRI scans was independent of clinical 
characteristics of the subjects, it is likely that the true effects with risk factors and 
cognition may have been even larger. Strengths of the study include: subjects were 
selected from a population-based study, extensive neuropsychological tests were used to 
diagnose cognitive impairment and dementia. The final models with cognition were 
adjusted for all possible risk factors of cortical CMIs to show an independent effect of 
cortical CMIs with cognition.  
5.  CONCLUSION 
 
In conclusion, in this study in the general elderly population, we found that cortical CMIs 
are indeed a distinct MRI marker of cerebrovascular disease and are associated with 
worse cognitive functioning, in particular executive function, verbal, and visual memory.  
Future longitudinal studies focusing on the clinical relevance of cortical CMIs may 
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provide novel insights into the pathophysiological link between cortical CMIs and 
cognition. It would be interesting to investigate the effects of this novel, emerging MRI 
marker on vascular cognitive impairment in addition to the traditional small vessel 
disease markers and its additional value in predicting cognitive decline. Finally, it would 
be of importance to determine if interventions can effectively reduce the incidence of 
CMIs and hence cognitive decline in clinical trials or observational studies. 
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Characteristics With CMIs 
(n= 54) 
Without CMIs  
(n= 807) 
P valuea 
Demographics,    
Age, years, mean (SD) 74.3 (6.6) 70.0 (6.6) <0.001 
Men, no. (%) 30 (55.6) 373 (46.2) 0.183 
Ethnicity,    
Chinese, no. (%) 13 (24.1) 268 (33.2) 0.004 
Malays, no. (%) 30 (55.6) 270 (33.5)  
Indians, no. (%) 11 (20.4) 269 (33.3)  
Cardiovascular risk factors,    
Hypertension, no. (%) 51 (94.4) 643 (79.7) 0.008 
Hyperlipidemia, no. (%) 40 (74.1) 609 (75.5) 0.818 
Diabetes, no. (%) 26 (48.1) 297 (36.8) 0.096 
Mean arterial blood pressure, mmHg, mean (SD) 100.7 (12.5) 98.1 (10) 0.071 
Total Cholesterol, mmol/l, mean (SD) 4.7 (1.2) 5.0 (1.1) 0.054 
Random blood glucose, mean (SD) 7.3 (3.0) 7.1 (3.1) 0.593 
Smoking, no. (%) 21 (38.9) 207 (25.7) 0.033 
Body mass index, kg/m2, mean (SD) 19.6 (2.8) 20.1 (3.6) 0.329 
History of stroke, no. (%) 12 (22.2) 35 (4.3) <0.001 
History of cardiovascular diseases, no. (%) 6 (11.1) 59 (7.3) 0.306 
MRI markers,    
Presence of any infarcts, no. (%) 35 (64.8) 140 (17.3) <0.001 
Lacunes, no. (%) 29 (53.7) 127 (15.7) <0.001 
Cortical infarcts, no. (%) 13 (24.1) 15 (1.9) <0.001 
White matter hyperintensity volume, median (IQR) 5.79 (18.7) 1.47 (3.9) <0.001 
Presence of cerebral microbleeds, no. (%) 27 (50.9) 267 (33.9) 0.012 
Presence of intracranial stenosis, no. (%) 17 (32.1) 98 (12.5) <0.001 
Table 6 – 1: Baseline demographic and clinical characteristics of subjects (n=861) 
Abbreviation: SD, Standard deviation; no, number; mmHg, millimeter of mercury; mmol/l, 
millimoles per liters; kg/m2, kilogram per meter square; MRI, magnetic resonance imaging; IQR, 
interquartile range; ml, milliliters; CMI, cerebral microinfarct 
a p-value < 0.05 was considered statistically significant 
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Table 6 – 2: Association of risk factors (as determinants) with cortical CMIs (as outcome) 
 
Abbreviation: CMI, cerebral microinfarct; RR, rate ratios; CI, confidence interval; BMI, body mass index; 
MRI, magnetic resonance imaging; ml, milliliters; WMH, white matter hyperintensity 
Model I included age, gender, and each associated factor separately 




Per CMI increase 
Model I 
RR (95% CI) 
Model II 
RR (95%CI) 
Demographics,   
Age, (per year increase)  1.10 (1.07-1.13) 1.09 (1.06-1.12) 
Gender (men vs. women) 1.82 (1.26-2.63) 1.77 (1.22-2.56) 
Ethnicity, 
Malay vs. Chinese 
Malay vs. Indian 










Cardiovascular risk factors,   
Hypertension, (yes vs. no) 5.69 (2.09-15.48) 4.33 (1.58-11.83) 
Hyperlipidemia, (yes vs. no) 1.42 (0.89-2.24) 0.91 (0.56-1.45) 
Diabetes, (yes vs. no) 1.82 (1.27-2.62) 1.59 (1.10-2.31) 
Smoking (ever vs. never) 1.38 (0.90-2.15) 1.36 (0.85-2.17) 
BMI (kg/m2) 1.01 (0.96-1.07) 0.98 (0.93-1.04) 
History of stroke, (yes vs. no) 4.95 (3.27-7.49) 4.85 (3.17-7.43) 
History of cardiovascular disease, (yes vs. no) 1.19 (0.69-2.07) 0.90 (0.52-1.58) 
MRI markers,   
Cortical infarct, (yes vs. no) 16.74 (11.56-24.23) 13.64 (9.40-19.78) 
Lacunar infarct, (yes vs. no) 7.03 (4.73-10.44) 4.94 (3.25-7.50) 
WMH volume, ml, log transformed 3.22 (2.24-4.61) 2.28 (1.55-3.33) 
Presence of cerebral microbleed (yes vs. no) 2.16 (1.46-3.20) 1.72 (1.15-2.57) 
Presence of intracranial stenosis (yes vs. no) 5.19 (3.54-7.62) 3.57 (2.40-5.31) 




Table 6 – 3: Association between cortical cerebral microinfarcts (presence vs. absence) and cognition (clinical outcomes) 
 
Abbreviations: CIND, cognitive impairment no dementia; OR, odds ratios; CI, confidence interval 
Model I included age, gender, and education 
Model II included age, gender, race, education, hypertension, diabetes 
Model I + II + each individual MRI marker added separately  
 
 
 CIND mild (n=275) 
OR (95%CI) 




CIND moderate/dementia (n=330) 
OR (95%CI) 
Model I 1.26 (0.46-3.40) 3.28 (1.26-8.58) 11.88 (2.18-64.78) 3.66 (1.43-9.39) 
Model II 1.23 (0.44-3.44) 3.57 (1.31-9.68) 13.95 (2.45-79.30) 3.91 (1.47-10.39) 
Model III     
Intracranial stenosis 1.25 (0.45-3.49) 3.49 (1.26-9.68) 13.51 (2.27-80.48) 3.82 (1.41-10.36) 
Cerebral microbleeds 1.24 (0.44-3.44) 3.63 (1.33-9.93) 12.61 (2.14-74.21) 3.96 (1.48-10.62) 
White matter hyperintensity volume 1.19 (0.43-3.35) 2.94 (1.05-8.22) 11.52 (1.73-76.98) 3.23 (1.18-8.84) 
Lacunar infarcts 1.04 (0.37-2.93) 2.38 (0.86-6.64) 4.47 (0.58-34.46) 2.44 (0.89-6.73) 
Cortical infarcts 1.17 (0.41-3.31) 2.85 (1.01-8.05) 10.39 (1.65-65.25) 3.02 (1.08-8.38) 








Abbreviations: CMI, cerebral microinfarct; MMSE, Mini Mental Status Examination; MOCA, 
Montreal Cognitive Assessment; CI, confidence interval; WMH, white matter hyperintensity 
Model I included age, gender, and education 
Model II included age, gender, education, ethnicity, hypertension, diabetes, smoking 
Model I + II + each individual MRI marker added separately 
CMI,  







Composite Z scores 
Mean difference 
(95%CI) 
Model I -1.85 (-2.84; -0.86) -2.55 (-3.79; -1.29) -0.42 (-0.62; -0.21) 
 p=<0.001 p=<0.001 p=<0.001 
Model II -1.83 (-2.81; -0.84) -2.47 (-3.69; -1.24) -0.39 (-0.59; -0.19) 
 p=<0.001 p=<0.001 p=<0.001 
Model III    
Intracranial stenosis -1.93 (-2.90; -0.96) -2.34 (-3.57; -1.12) -0.38 (-0.58; -0.18) 
 p=<0.001 p=<0.001 p=<0.001 
Cerebral microbleeds -1.95 (-2.92; -0.99) -2.51 (-3.74; -1.28) -0.41 (-0.61; -0.21) 
 p=<0.001 p=<0.001 p=<0.001 
WMH volume -1.49 (-2.48; -0.52) -2.04 (-3.26; -0.81) -0.31 (-0.50; -0.11) 
 p=0.003 p=0.001 p=0.002 
Lacunar infarcts -1.53 (-2.53; -0.53) -2.01 (-3.25; -0.76) -0.29 (-0.49; -0.09) 
 p=0.003 p=0.002 p=0.004 
Cortical infarcts -1.11 (-2.13; -0.09) -1.95 (-3.23; -0.67) -0.31 (-0.52; -0.10) 
 p=0.032 p=0.003 p=0.003 






























Model I -0.42 (-0.65; -0.19) -0.30 (-0.53; -0.07) -0.37 (-0.61; -0.13) -0.29 (-0.49; -0.09) -0.22 (-0.44; -0.00) -0.46 (-0.67; -0.24) -0.41 (-0.64; -0.19) 
 p=<0.001 p=0.010 p=0.002 p=0.004 p=0.045 p=<0.001 p=<0.001 
Model II -0.40 (-0.63; -0.17) -0.28 (-0.50; -0.06) -0.36 (-0.60; -0.12) -0.26 (-0.46; -0.07) -0.19 (-0.41; 0.02) -0.44 (-0.66; -0.22) -0.39 (-0.62; -0.17) 
 p=0.001 p=0.011 p=0.003 p=0.008 p=0.070 p=<0.001 p=0.001 
Model III        
ICS -0.41 (-0.64; -0.17) -0.27 (-0.49; -0.05) -0.36 (-0.61; -0.12) -0.26 (-0.45; -0.06) -0.19 (-0.41; 0.02) -0.44 (-0.66; -0.22) -0.36 (-0.58; -0.14) 
 p=0.001* p=0.015 p=0.003* p=0.009 p=0.069 p=<0.001* p=0.002* 
CMB -0.43 (-0.66; -0.19) -0.29 (-0.51; -0.07) -0.36 (-0.61; -0.12) -0.29 (-0.49; -0.10) -0.21 (-0.42; 0.00) -0.46 (-0.68; -0.24) -0.39 (-0.62; -0.17) 
 p=<0.001* p=0.009 p=0.003* p=0.003* p=0.054 p=<0.001* p=0.001* 
WMH volume -0.33 (-0.56; -0.09) -0.22 (-0.44; -0.00) -0.27 (-0.51; -0.03) -0.21 (-0.40; -0.01) -0.11 (-0.33; 0.09) -0.35 (-0.57; -0.13) -0.33 (-0.56; -0.11) 
 p=0.005* p=0.047 p=0.028 p=0.039 p=0.295 p=0.002* p=0.003* 
Lacunar infarcts -0.30 (-0.54; -0.07) -0.21 (-0.43; 0.01) -0.29 (-0.53; -0.04) -0.18 (-0.38; 0.01) -0.12 (-0.34; 0.09) -0.34 (-0.57; -0.12) -0.32 (-0.54; -0.09) 
 p=0.011 p=0.065 p=0.021 p=0.069 p=0.275 p=0.002* p=0.005* 
Cortical infarcts -0.34 (-0.58; -0.09) -0.21 (-0.44; 0.01) -0.25 (-0.49; 0.00) -0.22 (-0.43; -0.02) -0.16 (-0.38; 0.06) -0.33 (-0.56; -0.11) -0.34 (-0.57; -0.11) 
 p=0.006* p=0.066 p=0.054 p=0.033 p=0.164 p=0.004* p=0.004* 
Abbreviations: CMI, cerebral microinfarct; CI, confidence interval; ICS, intracranial stenosis; CMB, cerebral microbleed; WMH, white matter hyperintensity 
Model I included age, gender, and education 
Model II included age, gender, education, ethnicity, hypertension, diabetes, smoking 
Model I + II + each individual MRI marker added separately  





Supplementary table 6 – 1: Comparison of baseline characteristics of included and excluded 
subjects  
Characteristics Included (n=861) Excluded (n=737) P valuea 
Age (years) 70.2 (6.7) 71.9 (6.9) <0.001 
Women, no. (%) 457 (53.1) 419 (56.9) 0.131 
Race, no. (%)    
Chinese 281 (32.6) 332 (45) <0.001b 
Malays 300 (34.8) 184 (25)  
Indians  280 (32.5) 221 (30)  
Primary education > 6 years, no. (%) 316 (36.7) 200 (27.1) <0.001 
Hypertension, no. (%) 679 (78.9) 618 (83.9) 0.011 
Diabetes, no. (%) 322 (37.4) 250 (33.9) 0.148 
Hyperlipidemia, no. (%) 633 (73.5) 486 (65.9) 0.001 
Mean arterial blood pressure, mmHg, (SD) 97.4 (10.5) 97.8 (11.3) 0.486 
Random blood glucose, mmol/l, (SD) 7.09 (3.12) 7.07 (3.08) 0.890 
Total cholesterol, mmol/l, (SD) 5.11 (1.2) 5.14 (1.16) 0.562 
Smoking, no. (%) 209 (24.3) 180 (24.4) 0.945 
Body mass index, kg/m2, (SD) 23.5 (4.6) 23.6 (4.6) 0.648 
 
Abbreviation: SD, Standard deviation; no, number; mmHg, millimeter of mercury; mmol/l, 
millimoles per liters; kg/m2, kilogram per meter square 
a p-value < 0.05 was considered statistically significant 














CHAPTER 7:  
Intracranial Stenosis, Cerebrovascular Diseases and Cognitive 




1.  INTRODUCTION 
Intracranial stenosis (ICS) in stroke patients has been suggested to vary among different 
ethnicities with higher prevalence (40-50%) reported in Chinese, Africans, and Hispanics 
as compared to Caucasians (8-10%).1-3 This difference in the prevalence figures may, 
next to differences in study populations, be influenced by the imaging modalities 
[transcranial Doppler ultrasound (TCD) vs. Magnetic Resonance Angiography (MRA)] 
and criteria used to define ICS. Furthermore, data on ICS from asymptomatic and 
community-based subjects – especially Asian populations - are largely lacking. One study 
using TCD among asymptomatic subjects from rural China (mean age: 53.5 years) 
reported a prevalence of ICS of 6.9%. Another study in asymptomatic predominantly 
white US subjects, ICS was identified in 12.9% using TCD. However, this was a 
relatively older population with a mean age of 71.4 years.4 The use of TCD may limit the 
ability to diagnose ICS, as this is not feasible in patients with poor bone windows and is 
also rater dependent with high inter- and intra-observer variability.5 More recently, with 
the application of higher resolution imaging with flow enhancement, investigators have 
started to employ MRA in population-based research settings, thereby creating 
opportunities to examine the determinants and consequences of ICS.6  
With respect to cognitive impairment, studies have suggested that extra carotid artery 
disease is associated with impaired neuropsychological test performance, probably as a 
consequence of cerebral ischemic damage.7 However, the majority of these studies have 
focused on extracranial carotid artery stenosis, rather than ICS.8-12 Specifically, the 
association between ICS and cognitive impairment has not been investigated previously. 
We, therefore, examined the association of ICS with cognitive impairment in a Chinese 
population from Singapore, and whether this association is mediated by the presence of 





2.  METHODS 
2.1  Study population 
The ongoing Epidemiology of Dementia in Singapore (EDIS) study drew subjects from 
the population-based study among Chinese aged 40-85 years, who participated in the 
Singapore Chinese Eye Study (SCES).13 The details of study population in Chinese 
subjects have been described in Chapter 4.  
2.2  Neuroimaging 
MRI Acquisition 
Magnetic Resonance Imaging (MRI) and intracranial MRA were performed on a 3T 
Siemens Magnetom Trio Tim scanner, using a 32-channel head coil, at the Clinical 
Imaging Research Centre of the National University of Singapore. The study details on 
MRA were provided previously in Chapter 3.  
Intracranial Stenosis on MRA 
ICS was defined as narrowing exceeding 50% of the luminal diameter in any of the 
intracranial vessels assessed on 3D TOF MRA  as mentioned in Chapter 3.The images 
were first visually assessed on the coronal sequences and then on reconstruction. The 
final decision on stenosis (>50%) was based on the reconstruction sections (Figure 7-1).   
Other Markers on MRI 
Other markers of cerebrovascular diseases (infarcts, white matter hyperintensities and 
cerebral microbleeds) and involutional changes (total brain volume) were also graded on 
MRI using the same methods described in Chapter 3.  
2.3  Cognitive Assessment 
An extensive neuropsychological battery, which has been previously validated in 
Singaporean elderly, was administered to assess cognitive function.14 Details on subtests 




in Chapter 3. The modified 15-item Geriatric Depression Scale (GDS) was also 
administered to all subjects.15  
Cognitive impairment without dementia (CIND) was defined as impairment in at least 
one domain of the neuropsychological test battery using education-adjusted cutoffs of 1.5 
standard deviations below established normal means on individual tests. CIND was 
classified into mild (when ≤ 2 domains were impaired) and moderate (when > 2 domains 
were impaired).16 The diagnosis of dementia was made according to DSM-IV criteria. 
2.4  Assessment of Other Risk Factors 
Demographic and vascular risk factors including age, gender, education, smoking, 
hypertension, diabetes, hyperlipidemia, height, weight and history of stroke were 
collected and verified by medical records (details in Chapter 3). Education was 
categorized into < Primary 6 and ≥ Primary 6. Smoking was categorized into non-
smokers and smokers (past and current smokers). Body mass index (BMI) was calculated 
as the weight in kg divided by the square of height in meters.  
2.5  Statistical Analysis 
To assess the differences between included and excluded subjects, Chi-square tests were 
utilized for categorical variables and Student t-tests were used for continuous variables. 
We analyzed the associations between presence of ICS and Z-scores for cognition using 
multiple linear regression models expressing the effect sizes as mean differences in Z-
score between those with ICS and those without ICS together with 95% confidence 
intervals (CI). Models were initially adjusted for age, gender and education and 
additionally for mean arterial blood pressure, cholesterol, random blood glucose, 
smoking, BMI and GDS. For clinical outcomes (CIND-mild, CIND-moderate, dementia), 
multiple logistic regression models were used to compute odds ratios (OR) and 95% CI. 
To examine whether the association between ICS and cognitive impairment are mediated 




additionally for each MRI marker. Standardized total brain volume and WMH volume, 
presence of microbleeds and lacunar infarcts were entered into the model one at a time. In 
order to calculate standardized volumes, the mean total brain volume of the study 
population was subtracted from individual volumes; the results were then divided by the 
standard deviation (of our population) to obtain standardized brain volume. The total 
brain volume was then standardized with total intracranial volume in order to have a true 
measure of atrophy. The same procedure was also applied to standardize WMH volumes 
first with the study population and then with total white matter volume. P-value < 0.05 
was considered statistically significant. In view of the multiple tests performed on the 
specific cognitive domains (7 domains), we also used the Bonferroni correction to obtain 
an adjusted significance level for each domain specific test: 0.05/7=0.007. Statistical 
analysis was performed using standard statistical software (Statistical Package for Social 
Science, SPSS V20, SPSS Inc., USA). 
3.  RESULTS 
Table 7-1 shows the comparison between included (n=278) and excluded (n=1260) 
subjects. Compared to excluded subjects, those that were included were more likely to be 
older and diabetic and less likely to be hypertensive with low mean arterial blood 
pressure. The baseline characteristics of the participants with and without ICS are shown 
in Table 7-2. Those who had ICS were more likely to have hypertension, diabetes and 
presence of infarcts on their MRI scans. Out of 278 included subjects, 77 (27.7%) were 
diagnosed with CIND-mild, 74 (26.6%) with CIND-moderate and 4 (1.4%) with 
dementia. Due to the small numbers of dementia cases, these subjects were combined 
together with CIND-moderate as “significant cognitive impairment” for further analysis.  
Twenty-nine subjects (10.4%) were diagnosed with ICS of which 10 were symptomatic 
(history of stroke) and 19 asymptomatic. Among persons aged 60-64 years, the 




in 5 (4.1%) subjects with normal cognition, 9 (11.7%) with CIND-mild and 15 (19.2%) 
with CIND-moderate/dementia. The presence of ICS was significantly associated with 
both CIND-moderate/dementia as well as composite Z-scores (Table 7-3). Following 
further adjustments with MRI markers including standardized total brain volume, WMH 
volume and presence of cerebral microbleeds, the associations of ICS with both the 
clinical outcomes and the composite Z-scores remained statistically significant. After 
adjustment for the presence of lacunar infarcts, however, these associations attenuated 
and partly became non-significant, suggesting that these associations are partially 
mediated through infarcts.  
With respect to specific domains, ICS was related to executive function, language, 
visuomotor speed, verbal and visual memory after adjusting for age, gender, education, 
and vascular risk factors (Table 7-4). In terms of additional adjustment for MRI markers, 
similar trends were also seen for the domain specific analyses: additional adjustment for 
standardized total brain volume, WMH volume and presence of cerebral microbleeds did 
not alter these associations. However, these associations did become non-significant after 
including presence of infarcts in the model, except for executive function. Finally, when 
applying Bonferroni corrected significance level of 0.007 (~0.05/7 domains) to the 
domain specific analyses, none of these associations in these models reached this revised 
level of significance. 
4.  DISCUSSION 
In this study we found that persons with ICS were more likely to have poorer overall 
cognitive performance. In particular, these persons performed worse on tasks of 
executive function, language, visuomotor speed, verbal and visual memory. In terms of 




impairment. Additional adjustment for MRI markers revealed that these associations may 
be partially mediated by the presence of lacunar infarcts on MRI. 
Several studies have shown that cognitive deficits were present in both symptomatic 
(with history of stroke) and asymptomatic subjects with extracranial carotid artery 
occlusion.17,18,11,12 Additionally, a few studies on extracranial carotid stenosis and 
cognition have shown that stroke-free subjects with moderate carotid stenosis (stenosis of 
50-69%) have poorer performance on several cognitive tests than persons without carotid 
stenosis.9,19 In the Tromso study, tests of attention, particularly sustained attention, and 
psychomotor speed were strongly associated with carotid stenosis, while a weaker 
association was observed between tests of memory and carotid stenosis independent of 
clinical ischemic episodes or structural vascular MRI changes.10 Several studies have also 
shown that patients with asymptomatic carotid stenosis improved significantly with 
respect to their neuropsychological assessments after prophylactic carotid surgery, 
including improvement in attention, visual memory and psychomotor speed.8,20 However, 
it was unclear whether these associations were mediated through the presence of infarcts 
(or other lesions on MRI), as these studies lacked such data.21-23   
The present study extends these previous findings by showing that persons with ICS were 
also more likely to have poorer cognitive function.8 However, the association between 
ICS and cognitive impairment attenuated when adjusting for the presence of lacunar 
infarcts on MRI leading to the possibility that this association is partially mediated by 
cerebral ischemia. It has been hypothesized that cognitive deficits in patients with carotid 
stenosis may occur as a result of diffuse ischemic damage.24,25 It has also been suggested 
that patients with carotid stenosis have cerebral hypoperfusion which is associated with 
white matter lesions and cerebral atrophy. However, hypoperfusion was not directly 
measured in this or earlier studies.10 The specific role of carotid disease in producing 




observed in patients with TIA and internal carotid occlusion irrespective of the presence 
of cerebrovascular disease (WMH) or the localization (retinal versus cerebral) of 
symptoms.26 However, in this study the presence of WMH was graded visually and other 
markers such as brain volume and microbleeds were not taken into consideration. 
Some methodological issues need to be discussed. First, almost half of the screened 
positive subjects refused to participate in phase II. These subjects were relatively older, 
less educated, and had higher mean arterial blood pressure compared to those who 
participated, which may have led to the underestimation of prevalence of ICS in our 
sample. Furthermore, those excluded subjects might also be more cognitively impaired 
suggesting that the effect sizes described in this study may be underestimated. Second, 
due to the cross-sectional design of our study the temporal relationship between the 
presence of ICS and the development of cognitive decline cannot be assessed. Third, due 
to the small number of dementia cases, we were unable to determine the effect of ICS on 
clinically defined dementia. However, the dose-response relationship with significant 
cognitive impairment, suggests that these findings may be extendable to dementia. Also 
with relatively small numbers of ICS, we were not able to examine asymptomatic ICS 
separately. Finally, for the domain specific analyses, although we found several 
significant associations at a nominal significance level of 0.05, after applying Bonferroni 
correction none of these associations reached the revised significance level of 0.007, 
probably due to low power of our study to examine a large number of specific cognitive 
domains separately. Finally, conventional cerebral angiograms are considered to be the 
gold standard to diagnose occlusive disease of the intracerebral arteries; however, it 
would not have been feasible or ethical to conduct such tests in these subjects, who were 
drawn from a community-dwelling population.  
The strengths of the study are: an extensive neuropsychological battery was used to 




cerebrovascular diseases. Furthermore, quantitative MRI measures such as the total brain 
volume and WMH volume were adjusted for in this study, which are more reliable 
compared to visual scales. 
5.  CONCLUSION 
In conclusion, in this study we showed that ICS was - independent of vascular risk factor 
- related to overall poorer cognitive performance. Although the effect of ICS on cognitive 
impairment may be partly mediated through infarcts, other mechanisms may also be 
involved. Future studies focusing on perfusion and cerebrovascular reserve may provide 
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CHAPTER 7 – TABLES 
 
Table 7 - 1: Baseline characteristics of subjects who were screen positive at phase I and 
participated in phase II (n = 278) compared with those who were excluded from this analyses 
(n = 1260) 
Abbreviations: SD, standard deviation; kg/m2, kilogram per meter square; mmol/l, millimoles per 
liter; mmHg, millimeters of mercury 
*Excluded were those subjects who were either screen negative (n=926) at phase I and hence were 
not invited for phase II of the EDIS study or those subjects who were screen positive at phase I, 
but refused participation at phase II or had missing data (n=334) 
† Participants at phase II 





   Excluded*             Included† 











Women, no. (%) 582 (46.2) 143 (51.4) 0.11 
No formal education, no. (%) 480 (38.1) 120 (43.2) 0.11 
Low Socioeconomic status, no. (%)  812 (66) 180 (66.4) 0.89 
Hypertension, no. (%) 991 (78.7) 204 (73.4) 0.05 
Diabetes mellitus, no. (%) 261 (20.7) 72 (25.9) 0.05 
Hyperlipidemia, no. (%) 661 (52.5) 146 (52.5) 0.98 
Mean arterial blood pressure, mmHg, (SD)  99.9 (11.2) 97.1 (9.7) <0.001 
Random blood glucose, mmol/l (SD) 6.7 (2.8) 6.6 (2.7) 0.61 
Total cholesterol, mmol/l (SD) 5.3 (1.1) 5.2 (1.0) 0.13 
Ever smokers, no.  (%) 377 (29.9) 71 (25.5) 0.15 












Table 7 - 2: Baseline demographic and clinical characteristics of the subjects with and 
without ICS (n= 278)  
 
Baseline characteristics ICS absence 
(n=249) 




























































































































Abbreviations: ICS, intracranial stenosis; SD, standard deviation; kg/m2, kilogram per meter 
square;  MABP, mean arterial blood pressure; mmol/l, millimoles per liter; IQR, interquartile 
range; ml, milliliters; WMH, white matter hyperintensities volume 
 





Table 7 – 3: Association between intracranial stenosis (presence vs. absence) and cognitive 
function 
 
Abbreviations: CIND, cognitive impairment no dementia; WMH, white matter hyperintensities; 
MRI, magnetic resonance imaging; OR, odds ratios 
*Model I: adjusted for age, sex, and education 
†Model II: model I+ mean arterial blood pressure, cholesterol, random blood glucose, smoking, 
body mass index, and Geriatric Depression Scale 
‡Model III: model II+ individual MRI markers 
Values in bold indicates P<0.05 
  
 CIND-mild  
(n=77) 
OR (95% CI) 
CIND-moderate/dementia 
(n=78) 
OR (95% CI) 
Composite Z scores 
(n=278) 
Mean differences (95%CI) 
Model I* 3.47 (1.00–12.03) 6.42 (1.61–25.65) -0.54 (-0.80; -0.27) 
Model II† 2.89 (0.75–11.17) 5.54 (1.23–24.98) -0.48 (-0.77; -0.18) 
Model III‡    
Total brain volume 2.89 (0.75–11.16) 5.12 (1.12–23.40) 
 
-0.47 (-0.77; -0.17) 
WMH volume 3.01 (0.78–11.60) 5.99 (1.31–27.33) -0.48 (-0.78; -0.19) 
Presence of microbleeds 2.88 (0.75–11.08) 5.35 (1.19–24.04) -0.47 (-0.76; -0.17) 
Presence of infarcts 2.54 (0.64–10.14) 3.14 (0.50–19.82) -0.32 (-0.62; -0.03) 
 





Abbreviations: TBV, total brain volume; WMH, white matter hyperintensities; MRI, magnetic resonance imaging, CI, confidence interval 
* Model I: Adjusted for age, gender and education 
† Model II: Model I + mean arterial blood pressure, cholesterol, random blood glucose, smoking, body mass index and Geriatric Depression Scale 
‡ Model III: Model II + individual MRI markers 
Values in bold indicates P<0.05   





















        
Model I* -0.60 (-0.93; -0.28) -0.29 (-0.60; 0.01) -0.44 (-0.78; -0.11) -0.42 (-0.67; -0.16) -0.41 (-0.71; -0.12) -0.51 (-0.81; -0.20) -0.51 (-0.79; -0.23) 






All MRI markers 
 
-0.56 (-0.93; -0.20) 
-0.58 (-0.93; -0.22) 
-0.56 (-0.92; -0.20) 
-0.42 (-0.78; -0.06) 
-0.46 (-0.82; -0.09) 
 
-0.31 (-0.64; 0.02) 
-0.31 (-0.64; 0.02) 
-0.30 (-0.64; 0.03) 
-0.20 (-0.53; 0.14) 
-0.22 (-0.55; 0.12) 
 
-0.38 (-0.76; -0.01) 
-0.39 (-0.77; -0.03) 
-0.38 (-0.75; -0.01) 
-0.27 (-0.64; 0.11) 
-0.29 (-0.67; 0.08) 
 
-0.38 (-0.67; -0.09) 
-0.39 (-0.68; -0.11) 
-0.39 (-0.67; -0.10) 
-0.26 (-0.55; 0.02) 
-0.27 (-0.55; 0.02) 
 
-0.31 (-0.64; 0.02) 
-0.31 (-0.64; 0.01) 
-0.30 (-0.63; 0.03) 
-0.23 (-0.56; 0.11) 
-0.26 (-0.59; 0.08) 
 
-0.44 (-0.77; -0.11) 
-0.46 (-0.79; -0.13) 
-0.46 (-0.72; -0.06) 
-0.29 (-0.61; 0.05) 
-0.30 (-0.64; 0.03) 
 
-0.42 (-0.73; -0.10) 
-0.44 (-0.75; -0.12) 
-0.43 (-0.75; -0.12) 
-0.27 (-0.59; 0.04) 
-0.27 (-0.59; 0.04) 
Table 7 - 4: Association between intracranial stenosis (presence versus absence) and specific cognitive domains expressed as mean differences with 





CHAPTER 7 – FIGURE 
 
Figure 7 – 1: Intracranial stenosis on Magnetic Resonance Angiography (MRA) 
 
Intracranial stenosis is defined as the narrowing exceeding 50% of the luminal diameter in any of 
the intracranial vessels assessed on 3D Time of Flight MRA. The images are first visually 


























CHAPTER 8:  




1.  INTRODUCTION 
 
Cerebrovascular diseases have been increasing implicated as a cause and contributor to 
cognitive impairment and dementia.1 There is a strong association between ischemic 
strokes and white matter hyperintensities with cognitive decline. In this context, 
intracranial stenosis (ICS) has gained increasing attention due to its role in causing 
ischemic damage and hence cognitive dysfunction.2 The occurrence of ICS has been 
attributed largely to systemic vascular risk factors such as hypertension and diabetes3, 4 – 
the risk factors also associated with Alzheimer’s disease (AD) and Vascular Dementia 
(VaD). Previous post mortem studies have shown that severe arterial atherosclerosis of 
the Circle of Willis is a common finding in dementia found in 53% of VaD and 34% of 
AD patients.5  
Reports from ante mortem studies have suggested that the ICS in stroke subjects varies 
across ethnicities with a higher prevalence (30-83%) reported in Asians compared to 
Caucasians (8-10%).6, 7 This difference in prevalence might arise from different imaging 
modalities [Transcranial Doppler ultrasound (TCD) vs. Magnetic Resonance 
Angiography (MRA)] and criteria used to define ICS. Furthermore, a high prevalence of 
ICS on MRA is also reported in VaD compared to AD patients (53% vs. 18%) in a 
hospital based study consistent with the previous neuropathological findings.8 
With respect to cognition, a few studies9-12 have shown that both extra and intracranial 
arterial stenosis affects neuropsychological test performance possibly due to 
hypoperfusion and structural brain damage.13  However, the exact role of ICS in causing 
vascular pathology in preclinical cognitive impairment and different types of dementia 
has been less studied. Moreover, these studies lacked a disease free comparison group8 




present study, we examined the association of ICS in relation to cognitive impairment 
and dementia in the presence of other markers of cerebrovascular diseases. Moreover, we 
investigated its association in vascular vs. non vascular subtypes of cognitive impairment 
from a memory clinic setting in Singapore. 
2.  METHODS 
 
For the present memory clinic-based study, we employed a case-control design. Cases 
(CIND and dementia) were recruited from two study sites in Singapore (i.e. memory 
clinics from National University Hospital and Saint Luke’s Hospital). Controls were 
recruited from both memory clinics and the community (with a similar catchment area as 
cases). Controls (from memory clinic and community) were defined as those who may 
have subjective complaints of memory impairment, but were cognitively normal on 
objective neuropsychological assessment. Details of this study have been described 
previously.14 All subjects underwent physical, clinical and neuropsychological 
assessments and neuroimaging at the National University of Singapore.  
Ethics approval was obtained from the Singapore Eye Research Institute, and National-
Healthcare Group Domain-Specific Review Board. The study is conducted in accordance 
with the Declaration of Helsinki. Written informed consent was obtained in the preferred 
language of the participants by bilingual study coordinators prior to their recruitment into 
the study. 
2.1  Demographic and cardiovascular risk factor assessment  
Detailed questionnaire collecting information on age, gender, race, education and 
smoking history was described in Chapter 3. Previous medical history of hypertension, 





2.2  Neuroimaging  
MRI and three dimensional time-of-flight MRA images (3D TOF MRA) was performed 
on a 3Tesla Siemens Magnetom Trio Tim scanner, using a 32-channel head coil, at the 
Clinical Imaging Research Centre of the National University of Singapore. The MRA 
acquisition details have been described in Chapter 3.  
Intracranial stenosis on MRA 
ICS was defined based on the criteria published previously.9 Briefly, arterial narrowing 
exceeding 50% of the luminal diameter in any of the intracranial vessels were assessed on 
3D TOF MRA images and were recorded as mentioned in Chapter 3.  
Other MRI markers 
Other markers of cerebrovascular diseases (infarcts, cerebral microbleeds and white 
matter hyperintensities) and involutional changes (total intracranial volume) were also 
graded on MRI, details of which have been provided in Chapter 3.  
2.3  Diagnosis of cognitive impairment and dementia 
An extensive neuropsychological battery, which has been previously validated in 
Singaporean elderly,15 was administered to assess cognitive function. Besides the 
objective tests, the various diagnostic groups of the participants were also made at a 
weekly consensus meeting: 
- Subjects with no objective evidence of neuropsychological deficits were 
classified as having no cognitive impairment (NCI). 
- CIND was determined by clinical judgment and was defined as no significant 




the neuropsychological test battery. Participants were considered to have failed a 
test if they scored 1.5 SD below education-adjusted cut-off values on each 
individual test. Failure in at least half of the tests in each domain was considered 
as impairment in that domain.  
- The diagnosis of dementia was made according to DSM-IV criteria. The 
etiological diagnoses of dementia were based on the internationally accepted 
criteria; 
• AD was diagnosed using the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and 
Related Disorders Association (NINCDS-ADRDA). 
• VaD was defined using the National Institute of Neurological Disorders 
and Stroke and Association Internationale pour la Recherché et l' 
Enseignement en Neurosciences (NINDS-AIREN) criteria.  
- The subtypes of vascular and non-vascular cognitive impairment were defined as; 
• Vascular cognitive impairment included (VCI) (a) CIND with a history 
of ischemic stroke within the past 6–24 months or neuroimaging 
evidence of cerebral infarction, or (b) VaD, 
• Non-vascular cognitive impairment (non-VCI) included (a) CIND 
without a history of ischemic stroke or infarcts on neuroimaging or (b) 
AD.  
2.4  Statistical Analysis 
In order to compare the baseline characteristics between cases (CIND and dementia) and 
controls (NCI), analysis of covariance or chi square tests were used. In case of non-
uniform data (WMH), difference between the groups was determined using Kruskal-




distribution for further analysis. Association between ICS and CIND/dementia were 
determined initially using logistic regression models with odds ratios (OR) and 
95%Confidence interval (CI). Further regression analyses were then constructed 
separately for VCI and non-VCI and then stratified by its subtypes. All models were 
initially adjusted for age and gender and additionally for hypertension, hyperlipidemia, 
and diabetes. Finally in order to examine whether the association between ICS and 
CIND/dementia remains independent of other cerebrovascular diseases, we adjusted 
logistic models additionally for each MRI marker. P-value < 0.05 was considered 
statistically significant. Statistical analysis was performed using standard statistical 
software (Statistical Package for Social Science, SPSS V23, SPSS Inc., USA). 
3.  RESULTS 
 
Assessments of subjects were performed from August 12, 2010 to July 28, 2015. Out of 
the 462 subjects, 13 had no MRI scans and 25 had ungradable scans. Of the remaining 
424 subjects, there were 96 controls and 328 cases [177 (53.9%) CIND and 151 (46%) 
dementia]. Table 8-1 shows the baseline characteristics of the cases and controls. An 
increasing frequency of risk factors was observed from NCI to CIND and dementia. 
Compared to controls, subjects with CIND or dementia were older, had more women and 
attained lower education. A higher prevalence of hypertension and diabetes and lower 
BMI was present in the cognitively impaired subjects. Moreover, an increasing trend was 
observed for all the MRI markers whereas a decreasing trend for brain atrophy was 
observed from NCI to dementia. Among different diagnostic groups, ICS was identified 
in 8 (8.3%) NCI, 6 (5.6%) CIND, 24 (19.8%) AD, 20 (28.6%) VCIND and 17 (56.7%) 
VaD subjects.  
Table 8-2 shows the association of ICS with CIND and dementia. ICS was only related 




(age/gender adjusted OR: 2.07; 95%CI: 0.87-4.94). After adjustment for cardiovascular 
risk factors, the presence of ICS remain significantly associated with dementia (OR: 3.69; 
95%CI: 1.46-9.31). Following further adjustments with MRI markers including total 
intracranial volume, presence of cerebral microbleeds, and infarcts, the associations of 
ICS with dementia remained statistically significant. On adding WMH volume into the 
model, these associations attenuated and partly became non-significant. 
On further analysis comparing VCI vs. non-VCI groups, ICS was only associated with 
VCI in age/gender adjusted model (OR: 5.85; 95%CI: 2.52-13.56). This association 
remained independent of cardiovascular risk factors and other MRI markers. No 
association was observed with non-VCI (Table 8-3). With respect to subtypes analysis, 
ICS was related to both AD (OR: 3.51; 95%CI: 1.28-9.62) in non-VCI group and VCIND 
(OR: 3.97; 95%CI: 1.59-9.87) and VaD (OR: 11.36; 95%CI: 3.84-33.64) in VCI group in 
age and gender adjusted models (Table 8-4). These associations remain unaltered after 
including cardiovascular risk factors in the model. In terms of additional adjustment for 
total brain volume and cerebral microbleeds, similar trends were seen for both VCI and 
non-VCI subtypes.  However, these associations become non-significant after including 
WMH volume in the model in case of AD and presence of infarcts and WMH for VaD. 
An independent association was only observed for VCIND group (OR: 4.23; 95%CI: 
1.43-12.51).  
4.  DISCUSSION 
 
This study showed that the persons with ICS are more likely to have vascular cognitive 
impairment and dementia compared to the controls independent of cardiovascular risk 
factors. Additional adjustments with MRI markers revealed that the ICS induce cognitive 




Several studies have previously reported the prevalence of ICS in stroke and cognitively 
impaired individuals including dementia.16-18 The range of reported prevalence varies 
from 11-85% in stroke subjects17 to 18-53% in dementia.8 This wide difference in 
prevalence might be due to the diversities in, 1) imaging modalities, 2) measures of 
neuropsychological function and 3) limited information on degree of stenosis. The ICS 
prevalence of 19.8% in AD, 28.6% in VCIND and 56.7% in VaD in the present study – 
though towards the higher side – is in concordant with the previous findings using MRA. 
8, 19  
With respect to cognition, it has been reported that the cognitive deficits are commonly 
present in symptomatic (history of stroke) subjects with extra and intracranial arterial 
stenosis possibly through cerebral hypoxia.12,20-22 However, majority of these studies did 
not control for other relevant neurovascular variables such as cerebral infarction and 
white matter hyperintensities thus introducing heterogeneity in neurological condition of 
the patients.  Furthermore, no data exist on the association of ICS with vascular cognitive 
impairment and its subtypes. The present study extends these previous findings by 
showing that the persons with ICS are more likely to have vascular cognitive impairment 
independent of other structural MRI markers. This could be linked to the multiple cortical 
and subcortical ischemic damage (increased resistance and reduced vascular reactivity of 
the small vessels) or reduction in anatomic connectivity and perfusion deficits secondary 
to ICS. Moreover, due to the lack of underlying AD pathology, the cognitive reserve 
capacity of the brain is preserved and hence promotes recovery of cognitive function. By 
contrast, in dementia, vascular ischemic processes decrease the cognitive reserve of the 
brain to compensate for ongoing involutional changes thus preventing recovery of 
cognitive function. The similar mediating factors for both AD and VaD in this study 




disease types.23 Moreover, the pathogenesis behind AD and VaD might also involve two 
separate interaction processes. In case of AD, hypoxic injury not only accelerates 
amyloid beta deposition (especially in the hemisphere with the ICS) but also triggers 
secondary degeneration induced by inflammatory processes whereas in VaD, 
hypoperfusion interacts with the existing cerebrovascular diseases and initiates secondary 
neurodegenerative process.24 This multifactorial nature of mechanisms underlying 
cognitive impairment in patients with large-artery atheroma, may explain the link 
between ICS and dementia (AD and VaD) observed in this study. 
Our study has some limitations. First, as this data was examined cross-sectionally it is not 
possible to establish the temporal association between these ICS and the development of 
cognitive impairment. Second, cases and half of the controls were derived from two 
locations, memory clinic and community, although representative of the elderly 
population in Singapore. The control group was relatively younger and had less burden of 
vascular risk factors compared to cognitively impaired individuals which could have 
resulted in selection bias and residual confounding. Also there is a higher burden of 
vascular risk factors (hypertension, hyperlipidemia and diabetes) in our sample which 
limits generalizability of the results to the general population. Third, due to some 
overlapping symptoms and similar MRI features between AD and VaD, there is a chance 
of misclassification bias. Strengths of the study include; extensive neuropsychological 
assessment to diagnose cognitive impairment and dementia, availability of 3T MRA 
neuroimaging to grade and classify individuals with ICS which is relatively feasible to 
conduct in a large population based study.  
5.  CONCLUSION 
 
In conclusion, ICS is associated with vascular cognitive impairment and dementia in this 




marker of cerebral or generalized atherosclerosis. Further studies focusing on cerebral 
perfusion and cognitive reserve are required to determine the pathophysiological link 
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CHAPTER 8 – TABLES 
 
Table 8 – 1: Baseline demographic and clinical characteristics of the subjects (n=424) 
Characteristics NCI (n=96) CIND (n=177) Dementia (n=151) P value 
Age, years, mean (SD) 68.4 (6.1) 71.5 (8.3) 76.1 (7.9) <0.001 
Males, no. (%) 









Hypertension, no. (%) 58 (60.4) 121 (68.4) 126 (83.4) <0.001 
Hyperlipidemia, no. (%) 70 (72.9) 136 (76.8) 110 (72.8) 0.653 
Diabetes, no. (%) 20 (20.8) 63 (35.6) 64 (42.4) 0.002 
Smoking, no. (%) 









Cardiovascular disease, no (%) 8 (8.3) 31 (17.5) 28 (18.5) 0.072 
Presence of infarcts, no (%) 
White matter hyperintensities volume, ml, median (IQR) 
Total brain volume, ml, mean (SD) 
Presence of microbleeds, no. (%) 





















Abbrevations: NCI, no cognitive impairment; CIND, cognitive impairment no dementia; SD, standard deviation; No., number; IQR, interquartile 





Table 8 – 2: Association between intracranial stenosis (presence versus absence) and 
cognition 
 CIND (n=177) 
OR (95% CI) 
Dementia (n=151) 
OR (95% CI) 
Model I* 2.07 (0.87-4.94) 4.56 (1.88-11.11) 
Model II† 2.04 (0.83-5.01) 3.69 (1.46-9.31) 
Model III‡   
Total intracranial volume 2.35 (0.89-6.15) 3.89 (1.37-11.10) 
Presence of microbleeds 2.18 (0.88-5.38) 3.59 (1.42-9.12) 
Presence of infarcts 1.78 (0.71-4.46) 3.50 (1.38-8.92) 
WMH volume 2.26 (0.85-6.04) 2.86 (0.91-8.98) 
 
Abbreviation: CIND, cognitive impairment; OR, odds ratios; WMH, white matter hyperintensity 
* Model I: Adjusted for age and gender  
† Model II: Model I +hypertension, hyperlipidemia, diabetes 









Table 8 – 3: Association of intracranial stenosis with vascular vs. non vascular cognitive 
impairment 
 Non VCI (n=228) 
OR (95% CI) 
VCI (n=100) 
OR (95% CI) 
Model I* 1.67 (0.68-4.13) 5.85 (2.52-13.56) 
Model II† 1.64 (0.64-4.19) 4.49 (1.88-10.75) 
Model III‡   
Total intracranial volume 1.67 (0.59-4.75) 4.11 (1.59-10.65) 
Presence of microbleeds 1.64 (0.64-4.21) 4.39 (1.83-10.54) 
Presence of infarcts 1.63 (0.64-4.17) 4.11 (1.51-11.16) 
WMH volume 1.41 (0.49-4.07) 4.27 (1.54-11.86) 
 
Abbreviation: VCI, vascular cognitive  impairment; OR, odds ratios; WMH, white matter 
hyperintensity 
* Model I: Adjusted for age and gender  
† Model II: Model I +hypertension, hyperlipidemia, diabetes 

















Abbreviation: VCI, vascular cognitive  impairment; CIND, cognitive impairment no dementia; AD, Alzheimers disease; 
VCIND, Vascular cognitive impairment no dementia; VaD, Vascular dementia; OR, odds ratios; WMH, white matter 
hyperintensity 
 
 Non VCI (n=228) VCI (n=100) 
 CIND (n=107) 
OR (95% CI) 
AD (n=121) 
OR (95% CI) 
VCIND (n=70) 
OR (95% CI) 
VaD (n=30) 
OR (95% CI) 
Model I* 0.55 (0.17-1.82) 3.51 (1.28-9.62) 3.97 (1.59-9.87) 11.36 (3.84-33.64) 
Model II† 0.53 (0.15-1.92) 3.36 (1.17-9.65) 3.50 (1.38-8.90) 7.44 (2.33-23.77) 
Model III‡     
Total brain volume 0.55 (0.13-2.35) 3.95 (1.19-13.03) 4.31 (1.55-11.96) 9.57 (2.26-40.59) 
Presence of microbleeds 0.55 (0.15-2.01) 3.15 (1.09-9.09) 3.36 (1.31-8.63) 7.46 (2.32-24.05) 
Presence of infarcts 0.54 (0.15-1.97) 3.52 (1.23-10.08) 3.67 (1.27-10.61) 3.78 (0.92-15.63) 
WMH volume 0.56 (0.14-2.28) 3.26 (0.91-11.63) 4.23 (1.43-12.51) 4.01 (0.72-22.43) 
* Model I: Adjusted for age and gender  
† Model II: Model I +hypertension, hyperlipidemia, diabetes 
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1.  INTRODUCTION 
Neurodegeneration - a hallmark of dementia - is characterized by loss of neuronal tissue 
in both gray and white matter. This brain atrophy is not only seen in clinically manifest 
Alzheimer’s disease (AD), but may already be present in the preclinical stages [for which 
the terms cognitive impairment no dementia (CIND) or mild cognitive impairment (MCI) 
have been coined].1-4 Furthermore, it has been suggested that these brain changes may 
even be present during normal aging.5-8 
Recent advances in neuroimaging enable us to assess early age-related brain changes. Of 
particular interest is cortical thickness, which reflects the width of the cortical gray 
matter,9 and has been proposed to be a reliable marker of brain atrophy.10 Previous 
studies have shown that patients with AD have cortical thinning in frontal, temporal and 
parietal regions compared to controls, consistent with pathological patterns of atrophy 
described in AD.1,11,12 In addition, a few studies has suggested that even during the 
preclinical stages of dementia cortical thinning is associated with worse performance on 
cognitive tests.13,14 Overall, these studies were mainly limited to Caucasian populations, 
had small sample sizes, 15-17 and lacked detailed neuropsychological tests.13,14  
With respect to Asian populations, it has been proposed that – besides neurodegeneration 
- cerebrovascular disease may play a prominent role in the development of dementia, due 
to the higher prevalence of vascular risk factors among Asians compared to 
Caucasians.18-21 Nevertheless, it remains important to determine the exact role of 
involutional changes in Asian populations, particularly in the preclinical stages of 
dementia. Thus far, several studies from Korea have shown regional differences in 
temporo-parietal and prefrontal regions in both AD patients and subjects with MCI 
compared to controls.22-24 However, the association between cortical thickness and 




We, therefore, examined whether demographic and cardiovascular risk factors were 
related to cortical thickness. Furthermore, we examined in an elderly Asian population 
from Singapore the association of global and lobe-specific cortical thicknesses with 
cognitive impairment, including preclinical stages of dementia. 
2.  METHODS 
2.1.  Study Population 
The on-going Epidemiology of Dementia in Singapore (EDIS) study draws participants 
from the Singapore Epidemiology of Eye Disease (SEED) study, a multi-ethnic 
population-based study among persons aged 40 to 85 years among Chinese (Singapore 
Chinese Eye Study [SCES]), Malay (Singapore Malay Eye Study [SiMES-2]), and 
Indians (Singapore Indian Eye Study [SINDI-2]). For this study, we focused on Chinese 
25 and Malay components 26 of the EDIS Study, as the recruitment of the Indians is still 
on-going. In the first phase of the EDIS study, participants aged ≥ 60 years (n=2,666) 
were screened using the Abbreviated Mental Test and a self-report of progressive 
forgetfulness. Screen-positive subjects (n=1,097) were invited to take part in the second 
phase of this study, which included an extensive neuropsychological test battery and 
brain MRI. Of these 1,097 participants, 623 agreed to participate in phase II and hence 
were included in the present study. The details of the study methodology have been 
described elsewhere.25 Ethics approval for EDIS study was obtained from the Singapore 
Eye Research Institute, and National Healthcare Group Domain-Specific Review Board. 
The study is conducted in accordance with the Declaration of Helsinki. Written informed 
consent was obtained in the preferred language of the participants by bilingual study 
coordinators prior to their recruitment into the study. 




During a personal interview a detailed questionnaire was administered to collect relevant 
demographic and medical information. Details of all the study assessments have been 
described previously in Chapter 3.  
2.3.  Neuroimaging 
Cortical thickness was segmented throught an automated model based approach (Figure 
9 – 1). Details of cortical thickness and other quantitative MRI data (total intracranial 
volume and white matter hyperintensities volume) have been described in Chapter 3.   
2.4.  Cognitive Assessment 
An extensive neuropsychological battery, which has been previously validated in 
Singaporean elderly, was administered to assess cognitive function25 (Chapter 3). The 
diagnosis of CIND and dementia utilized in the study has been described previously in 
Chapter 3.  
2.5.   Statistical Analysis 
In order to examine differences in baseline characteristics between included and excluded 
subjects, chi-square test were used for categorical variables and student t-test for 
continuous variables. Trends in baseline characteristics across different diagnostic groups 
were examined using Analysis of Variance (ANOVA) and a p-value for the trend test was 
computed.  
Associations of potential demographic and cardiovascular risk factors with global and 
lobar cortical thicknesses were explored using multiple linear regression models. All 
continuous variables (age, mean arterial blood pressure, non-fasting blood glucose, total 
cholesterol, BMI, total intracranial volume) were standardized (by dividing each variable 
by its SD). For each continuous variable, mean differences in cortical thicknesses were 
expressed per SD increase/decrease in that variable. Model I was adjusted for age, gender 




factors were included in the same model to determine the independent effect of each 
potential factor with cortical thickness.  
Next, we examined the associations of global and lobar cortical thicknesses with clinical 
outcomes (CIND and dementia) using logistic regression models [odds ratios (OR) with 
95% confidence interval (CI)] and with composite Z score using linear regression models 
[mean difference with 95% CI]. The effect sizes of these associations with cognition were 
expressed per SD decrease in cortical thickness.  
P-values < 0.05 were considered statistically significant. In view of the multiple tests 
performed in the lobe-specific analyses, we used Bonferroni correction to obtain a 
revised statistical significance level of 0.05/6 ~ 0.008. Furthermore, we used revised 
levels of statistical significance for the cognitive domain-specific analyses: 0.05/7 ~ 
0.007 when analyzing the associations with global cortical thickness, and 0.05/7*6 ~ 
0.001 when analyzing the associations with lobar cortical thicknesses. Statistical analysis 
was performed using standard statistical software (Statistical Package for Social 
Sciences, SPSS V22, SPSS Inc., USA). 
3.  RESULTS 
Assessments of study participants were performed from August 12, 2010 to December 
21, 2013. Out of 623 subjects who participated in phase II, 36 had no MRI scans and 3 
had ungradable scans. Furthermore, 12 subjects who had a cortical infarct were excluded, 
as these infarcts may influence the cortical thickness measurements. Supplementary 
table 9-1 presents baseline data of both the included and excluded subjects. In brief, 
excluded subjects were likely to be older, were more often Chinese, had lower education 
and had higher frequency of hypertension and lower frequency of hyperlipidemia. Out of 
572 included subjects, 171 (29.9%) were diagnosed with CIND-mild, 197 (34.4%) with 




characteristics of the included participants according to the different diagnostic groups. In 
brief, increasing age, female gender, Malay ethnicity, higher proportion of hypertension, 
diabetes, and hyperlipidemia were related to severity of cognitive impairment. Also, an 
increasing frequency was observed for several MRI markers. Conversely, a decreasing 
trend was observed for education, BMI, total intracranial volume and IADL.  
Table 9-2 shows the association of potential risk factors with mean global cortical 
thickness. In fully adjusted models (Model II), the most important risk factors of cortical 
thickness were: increasing age [mean difference in cortical thickness per SD increase in 
age: -30.9μm; 95% CI: -40.2; -21.7; p<0.001], gender [women versus men: 25.4μm; 95% 
CI: 2.1; 48.7; p=0.029], Malay ethnicity [Malay versus Chinese: -57.4μm; 95% CI: -74.5; 
-40.3; p<0.001], BMI [mean difference per SD increase in BMI: -9.5; 95% CI: -18.1; -
0.8; p=0.022] and presence of lacunar infarct [presence versus absence: -25.8; 95% CI: -
48.6; -3.1; p=0.034]. A borderline significant association was observed for non-fasting 
glucose levels [mean difference per SD increase in glucose levels: -8.6μm; 95% CI: -
16.4.; 0.3; p=0.059]. 
The association between potential risk factors and lobe-specific cortical thickness are 
presented in Supplementary table 9-2. After Bonferroni correction, the most consistent 
associations with smaller cortical thicknesses across the different lobes were found for 
increasing age and Malay ethnicity. Women had thicker cortical thicknesses in particular 
in the parietal and temporal lobes. The association between higher BMI and smaller 
cortical thickness was most prominent in the frontal region [mean difference per SD 
increase in BMI: -14.7; 95% CI: -23.9; -5.45; p=0.002]. In terms of MRI markers of 
cerebral small vessel disease, WMH were associated with temporal thinning, whereas 
increasing number of microbleeds were related to insular thinning.  
With respect to clinical outcomes (Table 9-3), smaller global cortical thickness was 




p=0.004]. This association persisted even after excluding 28 dementia cases [OR: 1.69; 
95% CI: 1.18-2.43; p=0.004]. Smaller cortical thickness was also related to poorer global 
cognitive functioning as reflected by the composite Z-scores [mean difference composite 
Z-score per SD decrease in cortical thickness: -0.094; 95%CI: -0.159; -0.030, p=0.004]. 
Lobe-specific analyses showed that these associations were mainly driven by the parietal, 
occipital, temporal and limbic lobes. Specifically, the associations with the temporal and 
occipital lobes remained statistically significant after Bonferroni correction.  
Finally, in the domain-specific analyses (Table 9-4), global cortical thickness was related 
to executive function [mean difference per SD decrease in cortical thickness: -0.129; 95% 
CI: -0.207; -0.051; p=0.001], visuoconstruction [mean difference per SD decrease in 
cortical thickness: -0.099; 95% CI: -0.172; -0.027; p=0.007] and visual memory [mean 
difference per SD decrease in cortical thickness: -0.111; 95% CI: -0.183; -0.039; 
p=0.003]. In the lobe-specific analyses, the most consistent associations at the nominal 
significance level of 0.05 were found between the occipital and temporal lobes with the 
various cognitive domains. However, after applying Bonferroni correction, most of these 
associations did not remain statistically significant. 
4. DISCUSSION 
In this study, we found that persons with smaller cortical thickness – in particular in the 
temporal and occipital lobes - were more likely to have cognitive impairment, including 
the preclinical stages of dementia. More specifically, these persons performed worse on 
tasks in executive function, visuoconstruction and visual memory. Finally, the most 
important risk factors were increasing age, male gender, Malay ethnicity, increased blood 
glucose, high BMI and presence of lacunar infarction on MRI.  
Several studies reported a smaller global cortical thickness with increasing age.7, 27, 28 




largest decrease in frontal and temporal lobes,27 whereas others found the strongest 
effects in the occipital and parietal regions.6, 29 The wide age distribution of these studies 
(ranging from 18 to 82 years) may underlie these differences. Despite these variations, 
the overall trend – that increasing age was related to smaller cortical thickness – is similar 
across all these studies, which is further supported by our current findings. 
In our study women had relatively thicker cortex compared to men. This gender 
difference may be related to the protective effect of estrogen on involutional changes.30 
This is in line with other studies reporting similar gender differences in cortical thickness. 
31 In terms of ethnic differences, Malays had a thinner global and lobe-specific cortical 
thicknesses compared to Chinese. A higher prevalence of vascular risk factors 
(hypertension, diabetes and hyperlipidemia) and a higher frequency of Apoɛ4 carriers 
have been reported among Malays. These factors may lead to an increased susceptibility 
to involutional changes in Malays and hence may underlie this difference.32 
With respect to cardiovascular risk factors, we found – in accordance with other studies – 
that increased blood glucose levels were associated (borderline significantly) with global 
cortical thinning.15,31,33 The mechanisms leading to involutional changes are linked to 
episodes of hypo- and hyperglycemia, alterations to the blood-brain barrier and increased 
production of glycated endproducts.34, 35 Besides glucose levels, an independent 
association was found for BMI, especially in the frontal lobe. A previous study suggested 
that adiposity was associated with frontal gray matter atrophy in middle and old aged 
persons, possibly through increased vascular pathology and reduced blood supply 
eventually leading to brain atrophy.36 Further studies are needed to elucidate the exact 
mechanisms through which BMI and adiposity are related to cortical thinning. Finally, 




smaller global and lobe-specific cortical thicknesses, indicating an interaction between 
cerebrovascular and involutional changes.37-39 
With respect to cognition, we found that a smaller global cortical thickness is linked to 
cognitive impairment suggesting that diffuse involutional change beyond medial 
temporal lobe and hippocampus atrophy is already present in the preclinical stages of 
dementia.24 More specifically, thinner cortex in temporal and occipital lobes showed 
consistent patterns with worse performance in all cognitive domains. Patho-
physiologically, the temporal and occipital lobes may show thinning in the early stages of 
dementia, as these regions are especially susceptible to the toxic effects of neurofibrillary 
tangles and amyloid plaques,40,41 and hence are early sites for these depositions. It has 
been reported that the burden of these depositions was correlated with the extent of 
atrophy and reduced metabolism in these regions,42 and functionally with cognitive 
dysfunction. Our current findings suggest that in Asian populations, besides the 
contribution of cerebrovascular disease, involutional changes as reflected by cortical 
thickness plays an important role in cognitive impairment, including the preclinical stages 
of dementia.   
Limitations of the study include: first, 47.9% of the screened positive subjects were 
excluded from these analyses. Compared to the included participants, these excluded 
subjects were relatively older, less educated and more likely to have hypertension and 
hyperlipidemia. However, despite this non-participation we still found significant 
associations with cortical thickness. Furthermore, these excluded subjects might be more 
cognitively impaired, suggesting that the reported effect sizes in this study might be an 
underestimation. Second, due to the cross-sectional design of our study the temporal 
relationship between the presence of cortical thickness and cognitive impairment could 
not be assessed. Third, due to the small number of cases with dementia, we were not able 




effect sizes and wide confidence intervals. However, the dose-response relationship with 
the preclinical stages of cognitive impairment suggests that these findings may also be 
extendable to dementia. Strengths of the study include: subjects were selected from a 
population-based study, extensive neuropsychological tests were used to diagnose 
cognitive impairment and dementia, and automated and standardized image processing 
was used to quantify cortical thickness. 
5.  CONCLUSION 
In conclusion, persons with smaller cortical thickness – in particular in the temporal and 
occipital lobes - were more likely to have cognitive impairment, suggesting a 
contribution of diffuse cortical thinning beyond the medial-temporal lobe to cognitive 
function. These findings support the notion that cortical thinning is a biomarker of 
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CIND mild  
(n=171) 




P for trend 
Age, years, (SD) 70.5 (6.77) 67.2 (5.06) 70.1 (6.06)a 73.6 (6.58)ab 78.9 (5.11)abc <0.001 
Women, n (%) 313 (54.7) 74 (42) 83 (48.5) 132 (67)ab 24 (85.7)ab <0.001 




















Primary education >6years, n (%) 157 (27.4) 83 (47.2) 42 (24.6)a 28 (14.2)a 0 <0.001 
Instrumental activities of daily living, (SD) 8.1 (2.8) 7.2 (0.6) 7.5 (1.2) 8.6 (2.5)ab 16.5 (6.4)abc <0.001 
Hypertension, n (%) 459 (80.2) 135 (76.7) 140 (81.9) 175 (88.8)a 25 (89.3) 0.001 
Diabetes, n (%) 172 (30.1) 43 (24.4) 49 (28.7) 69 (35) 12 (42.9) 0.008 
Hyperlipidemia, n (%) 388 (67.8) 108 (61.4) 118 (69) 155 (78.7)a 20 (71.4) 0.001 
Mean arterial blood pressure, mmHg, (SD) 97.89 (10.7) 100.3 (10.4) 101.1 (10.1) 99.6 (10.9) 104.9 (13.3) 0.750 
Non-fasting blood glucose, mmol/l, (SD) 6.88 (2.92) 6.5 (2.6) 7.0 (3.2) 6.9 (2.7) 7.9 (4.2) 0.054 
Total cholesterol, mmol/l, (SD) 5.22 (1.18) 5.0 (0.9) 5.0 (1.0) 5.1 (1.3) 5.1 (1.1) 0.777 
Smoking, n (%) 76 (25.6) 54 (30.7) 57 (33.3) 52 (26.4) 2 (7.1) 0.078 
Body mass index, kg/m2, (SD) 22.2 (4.11) 19.9 (3.2) 19.9 (3.7) 19.6 (3.6) 17.7 (4.3)ab 0.019 
Total intracranial volume, ml, (SD) 1074.8 (120.9) 1108.8 (106.5) 1072.6 (131.6)a 1054.8 (102.6)a 1001.3 (195.3)ab <0.001 
Presence of lacunar infarcts, n (%) 112 (19.6) 13 (7.4) 30 (17.5) 56 (28.4)ab 13 (46.4)ab <0.001 
WMH, ml, median (IQR) 1.91 (5.27) 1.3 (3.1) 1.6 (4.2) 2.9 (7.4) 8.5 (15.6) <0.001 
Cerebral microbleeds, no. (%) 201 (35.1) 49 (27.8) 62 (36.3) 78 (39.6) 12 (42.9) 0.002 
Global cortical thickness, μm, mean (SD) 2362.0 (108.9) 2404.1 (94.3) 2366.6 (100.0)a 2334.1 (112.3)a 2266.6 (108.1)abc <0.001 
CHAPTER 9 – TABLES 
 
Table 9 – 1: Baseline characteristics of study participants 
Abbreviations: NCI, no cognitive impairment; CIND, cognitive impairment no dementia; SD, Standard deviation; n, number; mmHg, millimeter of mercury; mmol/l, millimoles 
per liters; kg/m2, kilogram per meter square; IQR, interquartile range; μm, micrometers; WMH, white matter hyperintensities  




 Global cortical thickness (μm) 
 Model I* 
Mean difference (95% CI) 
P value Model II† 
Mean difference (95% CI) 
P value 
Age (years), per SD decrease -36.7 (-45.6; -27.8)‡ <0.001 -30.9 (-40.2; -21.7) <0.001 
Gender (women vs men) 34.7 (17.4; 52.0)‡ <0.001 25.4 (2.1;48.7) 0.029 
Primary education > 6 years 16.0 (-4.8; 36.8)‡ 0.131 5.3 (-14.9; 25.5) 0.606 
Ethnicity (Malay vs Chinese) -63.1 (-79.0; -47.3) <0.001 -57.4 (-74.5; -40.3) <0.001 
Instrumental activities of daily living, per score increase -6.14 (-9.3; -2.9) <0.001 -2.43 (-5.8; 0.9) 0.161 
Mean arterial blood pressure (mmHg), per SD increase -1.3 (-9.8; 7.2) 0.758 4.8 (-3.6; 13.2) 0.242 
Non-fasting blood glucose (mmol/l), per SD increase -14.3 (-22.8; -5.8) 0.001 -8.1 (-16.4; 0.3) 0.059 
Total Cholesterol (mmol/l), per SD increase 3.6 (-5.1; 12.2) 0.418 4.4 (-4.1; 12.9) 0.322 
Smoking (Yes vs No) -1.6 (-24.3; 21.0) 0.888 -1.8 (-23.7; 20.1) 0.860 
Body mass index (kg/m2), per SD increase -15.9 (-24.4; -7.6) <0.001 -9.5 (-18.1; -0.8) 0.022 
Intracranial volume (ml), per SD increase -2.5 (-12.3; 7.3) 0.619 -2.1 (-12.0; 7.8) 0.612 
Presence of lacunar infarcts -41.6 (-63.1; -20.1) <0.001 -25.8 (-48.6; -3.1) 0.034 
WMH (ml, Log-transformed) per SD increase  -32.3 (-52.7; -11.9) 0.002 -16.5 (-38.7; 5.8) 0.169 
Per cerebral microbleed increase -0.8 (-1.6; 0.0) 0.051 -0.5 (-1.2; 0.3) 0.300 
Table 9 – 2: Multi-variable adjusted associations between potential risk factors and global cortical thickness (n=572) 
Abbreviations: μm, micrometer; CI, confidence interval; SD, standard deviation; Log, log transformed; mmHg, millimeter of mercury; mmol/l, millimoles per liters; 
kg/m2, kilogram per meter square; ml, milliliters; WMH, white matter hyperintensities 
* Model I adjusted for age, gender and education 
‡ In Model I, the effect sizes for these three variables were from a basic model containing only age, gender and education.  
† Model II fully adjusted for age, gender, education, race, non-fasting blood glucose, blood cholesterol, mean arterial blood pressure, BMI, smoking, presence of 





Abbreviations: CIND, cognitive impairment no dementia; OR, odds ratios; CI, confidence interval 
*Fully adjusted models (age, gender, education, race, non-fasting blood glucose, blood cholesterol, mean arterial blood pressure, BMI, smoking, presence of 
lacunes, white matter hyperintensities volume, number of cerebral microbleeds and intracranial volume) 
† Statistically significant after Bonferroni correction (0.05/6~0.008) 
 
Per standard deviation  decrease  
CIND mild (n=171) 
OR (95%CI)* 
CIND moderate (n=197) 
OR (95%CI)* 
CIND moderate/dementia (n=225) 
OR (95%CI)* 
Composite Z scores 
Mean difference (95%CI)* 






-0.094 (-0.159; -0.030) 
p=0.004 
Lobe-specific cortical thickness: 











-0.027 (-0.086; 0.032) 
p=0.364 






-0.083 (-0.146; -0.020) 
p=0.010 






-0.118 (-0.181; -0.054)† 
p=<0.001 






-0.135 (-0.203; -0.067)† 
p=<0.001 






-0.031 (-0.092; 0.029) 
p=0.313 






-0.080 (-0.143; -0.017) 
p=0.013 
Table  9 – 3: Multivariable-adjusted odds ratios for clinical outcomes and mean differences in global cognitive functioning per standard 






























-0.129 (-0.207; -0.051)† 
p=0.001 
 
-0.065 (-0.134; 0.004) 
p=0.065 
 
-0.059 (-0.137; 0.019) 
p=0.138 
 
-0.060 (-0.126; 0.006) 
p=0.076 
 
-0.099 (-0.172; -0.027)† 
p=0.007 
 
-0.111 (-0.183; -0.039)† 
p=0.003 
 







































0.008 (-0.062; 0.078) 
p=0.821 
Parietal  -0.142 (-0.218; -0.066)‡ 
p=<0.001 
-0.057 (-0.125; 0.011) 
p=0.098 
-0.022 (-0.098; 0.054) 
p=0.573 
-0.042 (-0.107; 0.023) 
p=0.202 
-0.078 (-0.149; -0.007) 
p=0.032 
-0.098 (-0.168; -0.027) 
p=0.007 
-0.068 (-0.143; 0.007) 
p=0.077 
Occipital  -0.138 (-0.215; -0.061)‡ 
p=<0.001 
-0.102 (-0.170; -0.034) 
p=0.003 
-0.085 (-0.161; -0.008) 
p=0.030 
-0.077 (-0.142; -0.011) 
p=0.022 
-0.110 (-0.182; -0.039) 
p=0.003 
-0.115 (-0.186; -0.043) 
p=0.002 
-0.099 (-0.175; -0.023) 
p=0.011 
Temporal -0.129 (-0.211; -0.046) 
p=0.002 
-0.107 (-0.181; -0.034) 
p=0.004 
-0.128 (-0.210; -0.046) 
p=0.002 
-0.095 (-0.165; -0.025) 
p=0.009 
-0.134 (-0.210; -0.057)‡ 
p=0.001 
-0.155 (-0.231; -0.078)‡ 
p=<0.001 
-0.081 (-0.163; -0.000) 
p=0.051 
Insula -0.008 (-0.082; 0.066) 
p=0.829 
-0.041 (-0.106; 0.024) 
p=0.213 
-0.018 (-0.091; 0.055) 
p=0.632 
-0.050 (-0.112; 0.013) 
p=0.117 
-0.045 (-0.114; 0.023) 
p=0.192 
-0.047 (-0.115; 0.021) 
p=0.178 
0.016 (-0.057; 0.088) 
p=0.668 
Limbic -0.106 (-0.183; -0.029) 
p=0.007 
-0.054 (-0.123; 0.014) 
p=0.117 
-0.061 (-0.137; 0.016) 
p=0.121 
-0.057 (-0.122; 0.008) 
p=0.085 
-0.070 (-0.141; 0.001) 
p=0.055 
-0.108 (-0.179; -0.037) 
p=0.003 
-0.037 (-0.112; 0.039) 
p=0.344 
Table  9 – 4: Multivariable-adjusted mean differences in composite and domain-specific cognitive function per standard deviation decrease in global and 
lobe-specific cortical thicknesses  
Abbreviations: CI, confidence interval ; SD, standard deviation 
* Fully adjusted models (age, gender, education, race, non-fasting blood glucose, blood cholesterol, mean arterial blood pressure, BMI, smoking, presence of lacunar infarcts, white 
matter hyperintensities volume, number of cerebral microbleeds and intracranial volume) 
† Statistically significant after Bonferroni correction (0.05/7 ~ 0.007) 





Supplementary table  9 – 1: Comparison of baseline characteristics of included and excluded 
subjects 
 
Abbreviation: SD, Standard deviation; n, number; mmHg, millimeter of mercury; mmol/l, 
millimoles per liters; kg/m2, kilogram per meter square 










Age (years) 70.5 (6.77) 71.9 (6.81) 0.001 
Women, n (%) 














Primary education > 6 years, n (%) 157 (27.4) 110 (21) 0.012 
Hypertension, n (%) 
Diabetes, n (%) 
Hyperlipidemia, n (%) 













Random blood glucose, mmol/l, (SD) 6.88 (2.92) 6.93 (3.05) 0.805 
Total cholesterol, mmol/l, (SD) 5.22 (1.18) 5.20 (1.16) 0.832 
Smoking, n (%) 76 (25.3) 40 (26.9) 0.570 






 Frontal lobe (μm) 
Beta (95%CI)* 
Parietal lobe (μm) 
Beta (95%CI)* 
Occipital lobe (μm) 
Beta (95%CI)* 









-0.39 (-14.2; 6.36) 
p=0.453 
 
-36.7 (-49.2; -24.3)† 
p=<0.001 
 
-48.4 (-60.6; -36.3)† 
p=<0.001 
 
-41.9 (-53.7; -30.3)† 
p=<0.001 
 
-12.4 (-26.6; 1.68) 
p=0.084 
 
-14.6 (-24.5; -4.67)† 
p=0.004 
Gender (Women vs men) 9.82 (-15.1; 34.7) 
p=0.438 
51.6 (21.6; 81.7)† 
p=0.001 
14.2 (-15.1; 43.5) 
p=0.341 
39.1 (10.9; 67.3)† 
p=0.007 
14.3 (-19.8; 48.4) 
p=0.411 
29.0 (5.01; 53.1) 
p=0.018 
Race (Malay vs Chinese) -45.0 (-63.6; -26.4)† 
p=<0.001 
-59.2 (-81.6; -36.7)† 
p=<0.001 
-39.3 (-61.2; -17.4)† 
p=<0.001 
-65.7 (-86.7; -44.7)† 
p=<0.001 
-75.6 (-101.2; -50.1)† 
p=<0.001 
-57.8 (-75.8; -39.9)† 
p=<0.001 
Primary education ≥ 6 years  5.42 (-16.1; 26.9) 
p=0.621 
3.29 (-22.7; 29.3) 
p=0.803 
4.86 (-20.5; 30.2) 
p=0.706 
9.08 (-15.3; 33.4) 
p=0.464 
20.2 (-9.30; 49.7) 
p=0.179 
3.72 (-17.0; 24.5) 
p=0.725 
IADL, per score increase -1.75 (-5.38; 1.88) 
p=0.343 
-3.44 (-7.82; 0.93) 
p=0.123 
-1.42 (-5.69; 2.85) 
p=0.513 
-5.98 (-10.1; -1.89)† 
p=0.004 
-1.89 (-6.87; 3.08) 
p=0.455 
-2.90 (-6.40; 0.60) 
p=0.104 
MABP, per SD increase 0.87 (-8.11; 9.85) 
p=0.849 
6.79 (-4.05; 17.6) 
p=0.219 
7.12 (-3.46; 17.7) 
p=0.187 
11.6 (1.39; 21.7) 
p=0.026 
7.19 (-5.14; 19.5) 
p=0.253 
1.09 (-7.59; 9.76) 
p=0.806 
NFBG, per SD increase -8.89 (-17.8; 0.05) 
p=0.051 
-6.22 (-17.0; 4.57) 
p=0.258 
-12.8 (-23.3; -2.26) 
p=0.017 
-9.05 (-19.1; 1.04) 
p=0.079 
-12.5 (-24.8; -0.28) 
p=0.046 
-9.34 (-17.9; -0.71) 
p=0.034 
Cholesterol, per SD increase -1.23 (-10.3; 7.84) 
p=0.789 
4.95 (-6.01; 15.9) 
p=0.376 
12.4 (1.73; 23.1) 
p=0.023 
-0.41 (-10.7; 9.85) 
p=0.937 
0.30 (-12.2; 12.8) 
p=0.962 
3.19 (-5.57; 11.9) 
p=0.474 
Smoking (Yes vs No) 
 
BMI, per SD increase 
 
TIV, (ml), per SD increase 
 
Presence of lacunar infarcts 
 
WMH (ml, Log) per SD 
increase 
Per CMB increase 
 
-4.61 (-27.9; 18.7) 
p=0.698 
-14.7 (-23.9; -5.45)† 
p=0.002 
-7.34 (-17.9; 3.27) 
p=0.174 
-11.7 (-36.0; 12.4) 
p=0.340 
-18.4 (-42.1; 5.33) 
p=0.128 
-0.36 (-1.20; 0.48) 
p=0.399 
5.39 (-22.7; 33.5) 
p=0.707 
-8.26 (-19.4; 2.88) 
p=0.146 
-8.95 (-21.7; 3.85) 
p=0.170 
-34.7 (-64.1; -5.54) 
p=0.020 
-1.88 (-30.5; 26.7) 
p=0.897 
-0.09 (-1.11; 0.92) 
p=0.854 
 
-12.7 (-40.2; 14.8) 
p=0.364 
-14.1 (-24.9; -3.17) 
p=0.011 
2.89 (-9.60; 15.4) 
p=0.650 
-31.7 (-60.2; -3.13) 
p=0.030 
-7.44 (-35.4; 20.5) 
p=0.601 
-0.21 (-1.19; 0.78) 
p=0.679 
 
-2.59 (-28.9; 23.8) 
p=0.847 
-8.79 (-19.2; 1.64) 
p=0.098 
4.76 (-7.22; 16.7) 
p=0.780 
-31.3 (-58.6; -3.89) 
p=0.025 
-38.9 (-65.7; -12.0)† 
p=0.005 
-0.46 (-1.41; 0.49) 
p=0.340 
 
-4.92 (-36.9; 27.1) 
p=0.763 
-11.4 (-24.1; 1.26) 
p=0.078 
-10.7 (-25.3; 3.83) 
p=0.148 
-23.7 (-56.9; 9.56) 
p=0.162 
-42.7 (-75.3; -10.1) 
p=0.010 
-1.67 (-2.83; -0.52)† 
p=0.005 
 
-2.26 (-24.8; 20.3) 
p=0.844 
-8.91 (-17.8; 0.01) 
p=0.050 
-11.7 (-21.9; -1.45) 
p=0.025 
-18.1 (-41.5; 5.29) 
p=0.129 
-24.9 (-47.8; -1.95) 
p=0.033 
-0.46 (-1.27; 0.35) 
p=0.267 
 
Supplementary table  9 – 2: Multi-variable adjusted associations between potential risk factors and lobe-specific cortical thicknesses 
Abbreviations: μm, micrometer; beta, mean difference; CI, confidence interval; mmHg, millimeter of mercury; SD, standard deviation; mmol/l, millimoles per liters; kg/m2, kilogram per 
meter square; ml, milliliters; Log, log transformed; no., number; BMI, body mass index; IADL, independent activities of daily living; MABP, mean arterial blood pressure; TIV, total 
intracranial volume 
* Fully adjusted models (age, gender, education, race, non-fasting blood glucose, blood cholesterol, mean arterial blood pressure, BMI, smoking, presence of lacunar infarcts, white matter 
hyperintensities volume, number of cerebral microbleeds, intracranial volume and IADL) 






CHAPTER 9 – FIGURES 
 
Figure 9 – 1: Segmentation of cortical thickness through model based automated software 
Cortical thickness is calculated on T1-weighted images at each vertex by taking the shortest distance between white matter/gray matter 
boundary and pial surface. Whole brain (global) and regional (lobar) cortical thickness are calculated using the parcellation guide on 










CHAPTER 10:  





1.  INTRODUCTION 
Loss of neuronal cell bodies and their connections - referred to as atrophy - is a hallmark 
of dementia, in particular Alzheimer’s disease (AD). AD is characterized by 
neurodegeneration of the cortex and subcortical structures including hippocampus. These 
changes are not only present in clinically manifest stages of dementia, but are already 
present in preclinical-stages [mild cognitive impairment (MCI)/cognitive impairment no 
dementia (CIND)].1,2 Several postmortem and in-vivo studies have shown that such 
atrophy may even occur during normal aging.3,4 It has been reported that pathological 
changes (amyloid, tau or iron deposition) in these structures are related to cognitive 
dysfunction in a wide range of neurological and psychiatric disorders.5 Furthermore, 
several histopathological studies have shown smaller volumes of thalamus, putamen, 
pallidum and caudate nuclei in patients with AD.6,7 Magnetic Resonance Imaging (MRI) 
acquisition and analyses tools enable accurate measurement of subcortical structural 
volumes in-vivo, including the accumbens, amygdala, caudate, pallidum, putamen, 
thalamus, hippocampus and brainstem.8 Previous studies using these techniques have 
mainly focused on AD patients,6,7,9,10 whereas the preclinical-stages of dementia have 
been less well studied.11 Furthermore, reduction of subcortical structural volumes in 
vascular compared to non-vascular subtypes of cognitive impairment remains unclear.  
In view of the paucity of epidemiological data on subcortical volume in cognitive 
impairment, we first examined the risk factors of subcortical structure volumes in a non-
demented population from Epidemiology of Dementia in Singapore study, and secondly 
their association with cognitive impairment and dementia using data from a case-control 
study in a memory clinic setting. 
2.  MATERIALS AND METHODS 




For the current analyses, subjects were drawn from two ongoing studies in Singapore. 
The first is the Epidemiology of Dementia in Singapore (EDIS) study which draws 
participants from the Singapore Epidemiology of Eye Disease (SEED) study.12,13 In the 
first phase of the EDIS study, participants aged ≥60 years (n=2,666) were screened using 
the Abbreviated Mental Test and a self-report of progressive forgetfulness. Screen-
positive subjects (n=1,097) were invited to take part in the second phase of this study, 
which included an extensive neuropsychological test battery and brain MRI. Of these 
1,097 participants, 623 agreed to participate in phase II and hence were included in the 
present study. The details of the study methodology has been further described in 
Chapter 3.12 
The second is a memory clinic-based study, which employs a case-control design. Cases 
(CIND and dementia) were recruited from two study sites in Singapore (i.e. memory 
clinics from National University Hospital and Saint Luke’s Hospital). Controls were 
recruited from both memory clinics and the community (with a similar catchment area as 
cases). Details of this study have been described previously in Chapter 3.14All subjects 
underwent physical, clinical and neuropsychological assessments and neuroimaging at 
the National University of Singapore.  
Ethics approval for both studies was obtained from the Singapore Eye Research Institute, 
and National-Healthcare Group Domain-Specific Review Board. The study is conducted 
in accordance with the Declaration of Helsinki. Written informed consent was obtained in 
the preferred language of the participants by bilingual study coordinators prior to their 
recruitment into the study. 
2.2  Demographic and Cardiovascular Risk Factor Assessment  
Detailed assessments for demographics and cardiovascular risk factors have been 
described in Chapter 3.  




Subcortical structure was segmented through an automated based model approach 
(Figure 10-1). Other quantitative MRI data (intracranial volume and white matter 
hyperintencities) together with visual gradings (lacunar infarcts and cerebral 
microbleeds) was obtained by automatic segmentation as mentioned in Chapter 3. 
2.4  Cognitive Assessment 
An extensive neuropsychological battery, which has been previously validated in 
Singaporean elderly, was administered to assess cognitive function.14 Details on subtests 
for testing cognitive function and calculation of z scores in both EDIS and case control 
study have been described in Chapter 3. 
Additionally, in the case-control study, various diagnostic groups were defined using the 
same criteria as described extensively in Chapter 8.  
2.5  Statistical Analysis 
In order to examine the differences between cases and controls, chi square test were used 
for categorical variables and t test for continuous variables. For skewed distributed 
variable (WMH), Mann-Whitney U test was utilized. All continuous variables (age, total 
intracranial volume and subcortical structures volumes) were standardized (by dividing 
each variable by its SD). For each continuous variable, mean differences in subcortical 
structures volumes were expressed as per SD increase/decrease in that variable. In the 
EDIS Study, association between risk factors and volumes of subcortical structures was 
explored using multiple linear regression models adjusting initially for age and gender. 
Subsequently, in the fully adjusted model, all potential risk factors were included in the 
same model to determine the independent effect of each factor with volumes of 
subcortical structures. Next, we examined the association of subcortical structures 
volume with composite and domain specific Z-scores [mean difference with 95% 
confidence interval (CI)]. The effect sizes of these associations with cognition were 




testing performed between specific domains and subcortical structures, we used revised 
statistical significance level of 0.05/8*7~0.0009.  
With respect to the clinical outcomes, data from the case-control study was utilized where 
the association of subcortical structures with CIND and dementia were constructed using 
logistic regression models with odds ratios (OR) and 95%CI. Lastly, in order to 
investigate whether reduction in subcortical structure volumes differ between vascular 
and non-vascular cognitive impairment, logistic regression models were used adjusting 
for all the possible confounders. Statistical analysis was performed using standard 
statistical software (Statistical Package for Social Science, SPSS V22, SPSS Inc., USA). 
3.  RESULTS 
Assessments of subjects were performed from August 12, 2010 to August 21, 2014. Out 
of 623 subjects who participated in EDIS study in phase II, 36 had no MRI scans and 7 
had ungradable scans. Out of the remaining 580 subjects from EDIS study, 30 were 
diagnosed with dementia and hence were excluded, leaving 550 subjects for analysis. In 
the case-control study, there were initially 410 subjects of whom 4 had no MRI scans and 
28 had ungradable scans. Of the remaining 378 subjects, there were 90 controls and 288 
cases [154 (40.7%) CIND and 134 (35.4%) dementia]. When subjects were classified 
based on VCI criteria, there were 86 (22.8%) VCI and 202 (53.4%) non-VCI cases. 
Table 10-1 presents baseline characteristics of the subjects in the two studies. Table 10-2 
shows the association of determinants with volumes of subcortical structures among 
EDIS participants. In multivariate adjusted models, increasing age was associated with 
smaller volumes of all subcortical structures. Women had significantly smaller amygdala, 
pallidum, putamen and brainstem volumes compared to men, whereas Malays had 
smaller amygdala, thalamus and hippocampus volumes compared to Chinese participants. 




significantly associated with several subcortical structures. Lastly, increasing total 
intracranial volume was significantly associated with larger volumes of all the subcortical 
structures.   
With respect to cognitive function, analysis of the EDIS sample showed that smaller 
accumbens [mean change in Z-score per SD decrease in volume: -0.08 (95%CI: -0.16; -
0.01)], amygdala [mean change in Z-score per SD decrease: -0.13 (95%CI: -0.21; -0.05)], 
caudate [mean change in Z-score per SD decrease: -0.07 (95%CI: -0.15;-0.00)], thalamus 
[mean change in Z-score per SD decrease: -0.08 (95%CI: -0.16; -0.01)], and brainstem 
[mean change in Z-score per SD decrease: -0.09 (95%CI: -0.17; -0.03)] were 
significantly associated with lower composite Z-scores (Table 10-3). After Bonferroni 
correction in domain-specific analysis, only smaller amygdala volume remains 
statistically significantly associated with the language domain.  
In the case-control study, a trend for increasing subcortical atrophy was observed from 
CIND to dementia (Table 10-4). In multivariate adjusted models, smaller accumbens, 
caudate, putamen and hippocampus volumes were associated with CIND whereas smaller 
volumes of all subcortical structures except for pallidum were significantly associated 
with dementia. On further analysis comparing VCI and non-VCI groups, a specific 
pattern was observed in the subcortical structures with smaller volumes of caudate and 
pallidum associated with VCI whereas smaller amygdala volume was only associated 
with the non-VCI group (Table 10-4). Smaller accumbens, putamen and hippocampus 
volumes were equally related to both VCI and non-VCI groups.  
4.  DISCUSSION 
Findings from this study suggest that important risk factors for smaller subcortical 
structures were age, female sex, ethnicity, diabetes, presence of lacunar infarcts on MRI, 




observed in dementia, but also in the preclinical stages of cognitive impairment. 
Furthermore, besides VCI, subcortical structures were also related to non-VCI. 
Several studies have shown age-related volume changes in subcortical structures.15 This 
age effect has been variable among studies with some reporting the greatest decrease in 
putamen, amygdala and accumbens in elderly subjects,16 whereas other studies report or 
small reductions in caudate, putamen, thalamus and brainstem volumes.16,17 Overall our 
findings are consistent with the majority of these studies, namely subcortical volumes of 
deep gray matter nuclei decreases with increasing age.  
Our study also shows that women had smaller volumes of amygdala, pallidum, putamen 
and brainstem compared to men which are consistent with previous studies.5 This effect 
remains even after adjustments for age and total intracranial volume. Smaller subcortical 
structure volume in women has been attributed to the loss of protective effects of 
estrogen after menopause. In terms of ethnic differences, Malays had smaller amygdala, 
thalamus and hippocampus volumes compared to Chinese. It has been reported 
previously that Malays have a higher prevalence of ApoE4 carriers.18 Moreover we also 
postulate that Malays may have a lower cognitive reserve based on lower occupational 
attainment and lower education which may explain the underlying differences.  
With respect to cardiovascular risk factors, we found that the presence of diabetes was 
associated with volume reduction in putamen,19  thalamus20 and hippocampus21,22 which is 
in line with the previous literature. Moreover, we also report an independent association 
of diabetes with smaller pallidum, and brainstem volumes. The underlying mechanism 
may be the link between diabetic vascular disease, impaired circulation and silent 
ischemic damage.23 Moreover, it has also been suggested that hyperinsulinemia may 
affect brain amyloid clearance, leading to its deposition and hence its neurotoxicity.24 
Finally, vascular pathology as reflected by cerebral small vessel diseases (lacunar infarcts 




structures. Subcortical lesions such as the lacunes and WMH may induce focal atrophy in 
the surrounding gray matter nuclei and interact with neurodegenerative process through 
disruption of white matter tracts.25, 26 However, the positive association of lacunes and 
WMH with caudate and separately of WMH with pallidum volumes in our study was 
unexpected. There could be two possible explanation to these findings; firstly, it has been 
reported that an increased neuronal hypertrophy and/or inflammation precedes clinically 
manifest AD27 giving rise to increase volumes of caudate and pallidum. Secondly, 
periventricular WMH are difficult to distinguish from gray matter especially the caudate 
nucleus on T1 sequences and hence may lead to an artificially increased volume of basal 
ganglia nuclei.16 
With respect to cognition, we found that the reduced volumes of all subcortical structures 
except pallidum and putamen were significantly associated with cognitive impairment 
reflecting that the involutional process in deep gray matter structures takes place early in 
the process of dementia. This may be explained by the fact that the amygdala, accumbens 
and thalamus are directly connected to hippocampus and reductions in these structures 
have been reported in early stages of AD.9 Pathophysiologically, amygdala, accumbens 
and hippocampus are particularly vulnerable to amyloid and tau deposition in the early 
stages of AD which then extends further to involve the thalamic nuclei and caudate. 28, 29 
Moreover, it has been reported that the anterior thalamic nuclei are directly connected to 
the medial limbic portion of the temporal lobe and cingulate gyrus,6 which controls 
language, learning and memory and hence this was reflected by the impairment in 
language and visuomotor speed domains. The association of smaller brainstem volume 
with cognitive dysfunction is inconsistent with previous findings where brainstem 
volume did not significantly change during the aging process.17, 30 This may be due to the 




segmentation of the whole brainstem difficult to achieve. However, deposition of 
neurofibrillary tangles and neurotransmitter alterations in brainstem nuclei has been 
shown previously in AD,31, 32 and thus supports our findings on the positive association 
between brainstem volume reduction and cognition. 
The association of basal ganglia nuclei (caudate and pallidum) volume with VCI further 
supports our previous findings that these nuclei are the common site for subcortical 
lesions (lacunes and WMH), which in turn induces volumes reduction secondary to 
ischemic changes.26 This is also in agreement with a prior study where it was shown that 
subjects with both mild and severe vascular cognitive impairment have similar pattern of 
shape abnormalities in lentiform and hippocampus.33  In contrast, a smaller amygdala was 
only associated with non-VCI consistent with previous literature where amygdalar 
atrophy is considered an early marker for AD type neuropathology.21 The preservation or 
lack of association of the similar nuclei (caudate and pallidum) in non-VCI cases is 
congruent with previous report where it has been suggested that such structures are only 
affected in the late stages of involutional changes.9 The association of accumbens, 
putamen and hippocampal atrophy with both VCI and non-VCI group suggests that these 
structures are equally affected in both vascular and neurodegenerative type cognitive 
impairment.  
Both samples included in this study had their limitations: first, in the EDIS study 43.2% 
of the screened positive subjects did not participate in the second phase of the study. 
These subjects were relatively older, less educated and more likely to have hypertension 
and hyperlipidemia (data not shown). Furthermore, those excluded subjects might also be 
more cognitively impaired. This exclusion may have led to an underestimation of the 
effect sizes. However, despite this non-participation we still found significant 
associations. Due to the relatively small number of cases with dementia (n=30) in the 




Second, with respect to the case-control study, controls were relatively younger 
compared to the cases, and had a lower burden of vascular risk factors, which could have 
resulted in sampling bias and residual confounding. Third, another limitation applicable 
to both samples was the cross-sectional design, which did not allow us to assess the 
temporal relationship between the subcortical volume reduction and cognitive 
impairment. Nevertheless, despite the various limitations of these two complimentary 
studies, both provided consistent associations in the same direction on the association 
between subcortical structures and cognition. Strengths of the study include: subjects for 
EDIS were selected from a population-based study, extensive neuropsychological tests 
were used to diagnose cognitive impairment and dementia, and automated and 
standardized image processing was used to quantify subcortical structure volumes.  
5.  CONCLUSION 
Smaller subcortical grey matter volume is not only observed in dementia, but also in the 
preclinical stages of cognitive impairment. Furthermore, besides VCI, subcortical 
structures were also related to non-VCI. Further prospective studies are needed to unravel 
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Abbreviations: SD= standard deviation, IQR= interquartile range; WMH= white matter hyperintensities; 
TIV= total intracranial volume, mm= millimeters  
 
*p value denotes differences between cases and controls; significant < 0.05.  
Chi square test was used for categorical variables, T-test for continuous variables, and Mann-Whitney U test 
for skewed distributed variable (white matter lesions).  
 Epidemiology of 
dementia in 
Singapore (EDIS) 









Age (years)  70.5 (6.7) 67.6 (5.6) 73.6 (8.6) <0.001 
Women, n (%) 317 (54.7) 50 (55.6) 155 (53.8) 0.773 






















Total years of education, mean 
(SD) 
6.6 (36.9) 10 (4.9) 6.6 (4.9) <0.001 
Hypertension, n (%) 466 (80.3) 51 (56.7) 215 (74.7) 0.001 
Diabetes, n (%) 175 (30.2) 19 (21.1) 116 (40.3) 0.001 
Hyperlipidemia, n (%) 394 (67.9) 64 (71.1) 212 (73.6) 0.641 
MRI markers     
Presence of lacunar infarcts, n (%) 112 (19.3) 17 (19.3) 88 (30.9) 0.035 
WMH volume, median (IQR) 2.03 (5.93) 0.99 (2.71) 4.58 (13) <0.001 
Cerebral microbleeds, n (%) 205 (35.3) 43 (47.8) 150 (52.1) 0.386 
TIV volume, mean (SD) 1075.5 (120.5) 1123.2 (115.9) 1077.7 (147.7) 0.066 
Subcortical structures     
Accumbens, mm3, mean (SD) 878.3 (183.6) 936.3 (172.1) 746.4 (198.1) <0.001 
Amygdala, mm3, mean (SD) 2652.5 (460.7) 2803.3 (483.7) 2363.5 (599.1) <0.001 
Caudate, mm3, mean (SD) 6591.1 (1050.6) 6761.9 (923.2) 6648.4 (1465.3) 0.489 
Pallidum, mm3, mean (SD) 3165.7 (460.7) 3228.9 (452.8) 3067.9 (575.3) 0.016 
Putamen, mm3, mean (SD) 9442.8 (1305.1) 9693.6 (1350.3) 8648.6 (1568.6) <0.001 
Thalamus, mm3, mean (SD) 11032.6 (1130.7) 11481.2 (1293.6) 10681.7 (1378.1) <0.001 
Hippocampus, mm3, mean (SD) 7031.0 (920.7) 7423.2 (877.4) 6173.6 (1278.6) <0.001 
Brainstem, mm3, mean (SD) 19404.8 (2422) 19982.1 (2548.3) 18620 (2422.6) <0.001 
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Age, years, per SD 
increase 
-0.39 (-0.47; -0.31) -0.39 (-0.46; -0.32) -0.11 (-0.19; -0.04) -0.19 (-0.27; -0.12) -0.32 (-0.40; -0.24) -0.24 (-0.32; -0.17) -0.44 (-0.51; -0.37) -0.12 (-0.19; -0.04) 
 p=<0.001 p=<0.001 p=0.004 p=<0.001 p=<0.001 p=<0.001 p=<0.001 p=0.004 
Gender (women vs. 
men) 
0.03 (-0.14; 0.20) -0.46 (-0.62; -0.30) -0.13 (-0.30; 0.04) -0.44 (-0.60; -0.27) -0.28 (-0.46; -0.10) -0.04 (-0.20; 0.12) 0.06 (-0.09; 0.22) -0.32 (-0.48; -0.15) 
 p=0.713 p=<0.001 p=0.124 p=<0.001 p=0.002 p=0.610 p=0.434 p=<0.001 
Race (Malays vs. 
Chinese) 
-0.06 (-0.21; 0.09) -0.18 (-0.32; -0.05) 0.03 (-0.12; 0.18) 0.08 (-0.06; 0.22) -0.04 (-0.19; 0.11) -0.24 (-0.38; -0.10) -0.24 (-0.38; -0.11) -0.13 (-0.27; 0.02) 
 
 p=0.415 p=0.009 p=0.679 p=0.252 p=0.581 p=0.001 p=<0.001 p=0.084 
Hypertension 0.10 (-0.09; 0.29) 0.00 (-0.18; 0.18) -0.13 (-0.32; 0.07) -0.17 (-0.36; 0.02) 0.02 (-0.18; 0.22) -0.13 (-0.32; 0.05) -0.14 (-0.31; 0.04) -0.23 (-0.43; -0.04) 
 p=0.304 p=0.983 p=0.206 p=0.070 p=0.864 p=0.162 p=0.138 p=0.018 
Diabetes  -0.15 (-0.31; 0.01) -0.02 (-0.17; 0.13) -0.13 (-0.29; 0.03) -0.16 (-0.31; -0.01) -0.29 (-0.44; -0.11) -0.26 (-0.41; -0.11) -0.21 (-0.35; -0.06) -0.36 (-0.51; -0.19) 
 p=0.059 0.768 p=0.103 p=0.039 p=0.001 p=0.001 p=0.006 p=<0.001 
Hyperlipidemia 0.08 (-0.08; 0.25) -0.01 (-0.16; 0.15) -0.00 (-0.16; 0.16) -0.05 (-0.21; 0.11) 0.03 (-0.14; 0.20) -0.00 (-0.16; 0.15) 0.01 (-0.14; 0.16) -0.19 (-0.36; -0.03) 
 p=0.319 p=0.923 p=0.999 p0.544 p=0.721 p=0.960 p=0.913 p=0.019 
Presence of lacunar 
infarcts 
-0.26 (-0.47; -0.06) -0.11 (-0.29; 0.08) 0.23 (0.03; 0.43) -0.23 (-0.42; -0.03) -0.22 (-0.43; -0.01) -0.23 (-0.42; -0.04) -0.02 (-0.21; 0.16) -0.22 (-0.42; -0.02) 
 p=0.011 p=0.261 p=0.026 p=0.022 p=0.038 p=0.018 p=0.817 p=0.030 
WMH volume (ml, 
log), per SD increase 
-0.48 (-0.68; -0.29) -0.29 (-0.47; -0.11) 0.56 (0.37; 0.76) 0.25 (0.06; 0.43) 0.09 (-0.10; 0.29) 
 
-0.17 (-0.35; 0.01) -0.19 (-0.37; -0.01) -0.23 (-0.42; -0.04) 
 p=<0.001 p=0.001 p=<0.001 p=0.009 p=0.350 p=0.067 p=0.034 p=0.017 
Cerebral microbleeds,  -0.01 (-0.02; 0.01) 0.00 (-0.01; 0.01) 0.00 (-0.01; 0.02) -0.01 (-0.02; 0.00) 0.00 (-0.01; 0.01) -0.00 (-0.02; 0.01) 0.00 (-0.01; 0.01) -0.00 (-0.01; 0.01) 
 p=0.374 p=0.958 P=0.643 p=0.159 p=0.942 p=0.499 p=0.832 p=0.791 
TIV, ml, per SD 
increase 
0.16 (0.07; 0.25) 0.29 (0.21; 0.38) 0.35 (0.26; 0.44) 0.42 (0.34; 0.51) 0.25 (0.16; 0.35) 0.48 (0.39; 0.56) 0.32 (0.23; 0.39) 0.38 (0.29; 0.47) 
 p=0.001 p=<0.001 P=<0.001 p=<0.001 p=<0.001 p=<0.001 p=<0.001 p=<0.001 
Abbreviations: SD= standard deviation; CI= confidence interval; WMH= white matter hyperintensities; ml= milliliters; TIV= total intracranial volume 
*Multivariate adjusted linear regression model with 95% confidence interval using risk factors as determinant and each subcortical structures as outcome. The values provided in 
each column refer to the mean difference in volume of subcortical structure with respect to the risk factors. All models are adjusted for age, gender, race, hypertension, diabetes, 
hyperlipidemia, presence of lacunar infarcts, white matter hyperintensities volume, cerebral microbleeds, total intracranial volume.  
 
































Accumbens  -0.08 (-0.16; -0.01) -0.09 (-0.18; -0.00) -0.07 (-0.14; 0.01) -0.10 (-0.19; -0.01) -0.08 (-0.16; -0.01) -0.05 (-0.13; 0.02) -0.08 (-0.16; 0.01) -0.01 (-0.09; 0.07) 
 
p=0.019 p=0.047 p=0.072 p=0.025 p=0.020 p=0.177 p=0.066 p=0.740 
Amygdala  -0.13 (-0.21; -0.05) -0.08 (-0.18; 0.01) -0.09 (-0.18; -0.01) -0.19 (-0.28; -0.09)† -0.05 (-0.13; 0.03) -0.11 (-0.19; -0.02) -0.13 (-0.22; -0.04) -0.08 (-0.17; 0.01) 
 p=0.001 p=0.085 p=0.024 p=<0.001 p=0.199 p=0.014 p=0.003 p=0.072 
Caudate  -0.07 (-0.15; -0.00) -0.05 (-0.14; 0.04) -0.05 (-0.13; 0.03) -0.04 (-0.13; 0.05) -0.08 (-0.15; -0.01) -0.08 (-0.15; 0.00) -0.08 (-0.16; 0.01) -0.06 (-0.14; 0.03) 
 p=0.047 p=0.297 p=0.200 p=0.422 p=0.034 p=0.062 p=0.071 p=0.187 
Pallidum  -0.04 (-0.11; 0.04) -0.04 (-0.13; 0.06) -0.04 (-0.12; 0.04) -0.01 (-0.10; 0.09) -0.06 (-0.14; 0.01) -0.05 (-0.13; 0.03) -0.02 (-0.10; 0.07) -0.02 (-0.10; 0.07) 
 p=0.354 p=0.436 p=0.353 p=0.884 p=0.110 p=0.215 p=0.713 p=0.696 
Putamen  -0.06 (-0.13; 0.01) -0.07 (-0.16; 0.01) -0.03 (-0.11; 0.04) -0.05 (-0.14; 0.04) -0.04 (-0.11; 0.03) -0.03 (-0.11; 0.04) -0.06 (-0.14; 0.02) -0.05 (-0.13; 0.03) 
 p=0.115 p=0.095 p=0.390 p=0.242 p=0.308 p=0.385 p=0.134 p=0.249 
Thalamus  -0.08 (-0.16; -0.01) -0.00 (-0.09; 0.09) -0.07 (-0.15; 0.02) -0.11 (-0.21; -0.02) -0.11 (-0.19; -0.04) -0.07 (-0.15; 0.02) -0.06 (-0.15; 0.03) -0.07 (-0.16; 0.02) 
 p=0.037 p=0.973 p=0.107 p=0.024 p=0.004 p=0.112 p=0.192 p=0.108 
Hippocampus  -0.06 (-0.14; 0.02) -0.06 (-0.16; 0.04) -0.03 (-0.11; 0.05) -0.14 (-0.23; -0.04) -0.03 (-0.10; 0.05) -0.05 (-0.13; 0.04) -0.06 (-0.15; 0.03) -0.02 (-0.11; 0.07) 
 p=0.120 p=0.226 p=0.474 p=0.007 p=0.510 p=0.280 p=0.215 p=0.692 
Brainstem  -0.09 (-0.17; -0.03) -0.04 (-0.13; 0.05) -0.06 (-0.14; 0.02) -0.11 (-0.19; -0.01) -0.12 (-0.19; -0.05) -0.07 (-0.15; 0.02) -0.09 (-0.17; -0.01) -0.12 (-0.20; -0.04) 
 p=0.008 p=0.346 p=0.125 p=0.024 p=0.001 p=0.110 p=0.036 p=0.004 
Table 10 – 3: Multivariate adjusted estimated change in cognitive performance (mean difference) per standard deviation change in volumes of subcortical 
structures (EDIS) 
Abbreviations: SD= standard deviation; CI= confidence interval 
* Multivariate adjusted linear regression model with 95% confidence interval using each subcortical structure volume as determinant and composite/domain specific Z-scores as outcome. 
The values provided in each column refer to the mean difference in Z-score per SD decrease in volume of subcortical structure. All models are adjusted for age, gender, race, hypertension, 
diabetes, hyperlipidemia, presence of lacunar infarcts, white matter hyperintensities volume, cerebral microbleeds, total intracranial volume. 




Table 10 – 4: Multivariate adjusted estimated change in cognitive performance (ratios) per 
standard deviation change in volumes of subcortical structures (case control study) 
 
Abbreviations: CIND= cognitive impairment no dementia; VCI= vascular cognitive impairment; OR= odds 
ratios; CI= confidence interval; SD= standard deviation 
* Multivariate adjusted logistic regression model with 95% confidence interval using each subcortical 
structure volume as determinant and clinical categories of cognitive impairment as outcome. All models are 
adjusted for age, gender, race, hypertension, diabetes, hyperlipidemia, presence of lacunar infarcts, white 
matter hyperintensities volume, cerebral microbleeds, total intracranial volume. 
Per SD 
decrease  






Non VCI (n=202) 
OR (95% CI)* 
Accumbens 
volume 
1.64 (1.12-2.41) 3.57 (1.81-7.03) 2.00 (1.15 – 3.49) 1.83 (1.23 – 2.72) 
 p=0.011 p=<0.001 p=0.014 p=0.003 
Amygdala 
volume 
1.40 (0.96-2.06) 4.73 (2.13-10.48) 1.44 (0.78 – 2.65)   1.87 (1.23 – 2.86) 
 p=0.085 p=<0.001 p=0.241 p=0.004 
Caudate 
volume 
1.74 (1.09-2.78) 1.94 (1.04-3.59) 1.94 (1.07 – 3.52) 1.55 (0.98 – 2.45) 
 p=0.020 p=0.036 p=0.030 p=0.063 
Pallidum 
volume 
0.97 (0.66-1.43) 1.22 (0.72-2.06) 1.84 (1.04 – 3.24)  0.79 (0.52 – 1.21) 
 p=0.870 p=0.467 p=0.036 p=0.796 
Putamen 
volume 
1.66 (1.13-2.46) 1.92 (1.10-3.34) 1.61 (1.00 – 2.60) 1.79 (1.19 – 2.69) 
 p=0.010 p=0.021 p=0.053 p=0.005 
Thalamus 
volume 
1.16 (0.77-1.75) 2.22 (1.18-4.19) 1.64 (0.96 – 2.81)  1.11 (0.71 – 1.75) 
 
 p=0.483 p=0.014 p=0.070 p=0.640 
Hippocampus 
volume 
2.06 (1.29-3.29) 10.05 (4.02-25.15) 2.76 (1.39 – 5.48) 2.86 (1.75 – 4.69) 
 p=0.003 p=<0.001 p=0.004 p=<0.001 
Brainstem 
volume 
1.06 (0.72-1.55) 2.07 (1.14-3.76) 1.46 (0.88 - 2.43) 1.16 (0.78 - 1.72) 




CHAPTER 10 – FIGURE 
 
Figure 10– 1: Volumes of subcortical structures segmented through model based automated procedure 
Each voxel of the MRI volumes on T1 sequence was labeled automatically as a corresponding brain region based on a parcellation guide. The volumes of 
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1.  INTRODUCTION 
In addition to Alzheimer’s disease (AD), cerebrovascular disease is an important cause 
and contributor to cognitive decline and dementia.1 Magnetic resonance imaging (MRI) 
has become increasingly important in unraveling the role of vascular pathology involved 
in cognitive impairment and dementia. Improvements in MR scanner hard- and software 
have made it possible to visualize brain pathology more accurately. Recently, cerebral 
microbleeds (CMB) detected on MRI have been suggested as another manifestation or 
marker of cerebral small vessel disease, in addition to traditional markers such as white 
matter lesions (WML) and lacunar infarcts.2  
However, direct in vivo visualization of the involvement of cerebral small vessels is 
difficult to achieve. As the retinal and cerebral microvasculature share several anatomical 
and physiological features,3 the retina may provide a non-invasive “window” into the 
status of these small cerebral vessels. Previous studies have shown that the clinically 
visible retinopathy signs are associated with an increased risk of clinical cerebrovascular 
disease, including stroke and dementia, and subclinical markers of cerebral small vessel 
disease.4 Furthermore, quantitative changes in retinal vessel width, such as narrower 
arteriolar caliber and wider venular caliber, have been shown to be associated with these 
subclinical and clinical age-related brain pathologies.5  
More recently, a series of novel quantitative retinal vascular parameters such as fractal 
dimension and tortuosity have been proposed to provide information on the cerebral 
microvasculature even before the appearance of retinopathy signs. It has been shown that 
both patients with ischemic stroke and those with AD have a sparser and more tortuous 
microvascular network in the retina,6,7 suggesting that AD and stroke may share similar 
underlying microvascular pathology. However, data on the association between these 




are largely lacking. Therefore, we investigated whether there was a link between these 
novel quantitative retinal parameters and cerebral small vessel disease on MRI. 
2.  MATERIALS AND METHODS 
2.1  Study Population 
The Epidemiology of Dementia in Singapore (EDIS) study draws participants from the 
Singapore Epidemiology of Eye Disease (SEED) Study, which is a population-based 
study among Chinese, Malays and Indians.2 In the present study we restricted analysis to 
the Chinese component of EDIS, the description of which has been described in Chapter 
3.  
2.2  Retinal Photography 
Retinal vascular parameters were extracted through fundus photographs and included 
retinal vascular caliber, fractal dimension, and tortuosity.6,7 Details of these parameters 
and reliability assessment have been described in Chapter 3. 
2.3  Neuroimaging 
Markers of cerebrovascular diseases (lacunes, CMB and WML) and involutional changes 
(total brain and intracranial volume) were collated for each subject using the same 
protocol as described previously in Chapter 3.  
2.4  Assessment of Other Vascular Risk Factors 
The details of vascular risk factors assessment have been described in Chapter 3. 
2.5  Statistical Analyses  
Quantitative retinal vascular measures (retinal vascular caliber, fractal dimension, and 
tortuosity) from arterioles and venules were used as determinants and expressed as per 
standard deviation (SD) increase or decrease, whereas markers of cerebral small vessel 
disease were taken as outcomes. To examine the associations with lacunar infarcts and 




values were log-transformed. Linear regression was used to model log-transformed WML 
volumes. These models were initially adjusted for age and sex, additionally for smoking, 
body mass index, mean arterial blood pressure, fasting blood glucose and total 
cholesterol; and finally for other MRI markers. In order to examine the robustness of any 
association with CMB, we decided to use different categorizations for CMB, as described 
previously2: (a) multiple (≥2) versus none/single (<2) CMB, (b) multiple categories of 
CMBs (0, 1 or ≥ 2) and (c) CMB counts using Poisson regression. For the Poisson 
regression models, outliers were excluded to satisfy the goodness-of-fit criterion assessed 
with the Pearson’s Chi-square statistic. For all the models, association measures were 
expressed with the corresponding 95% confidence intervals (CI). All statistical analyses 
were performed on standard statistical software (SPSS Version 17, SPSS Inc., USA). 
3.  RESULTS  
Out of the 300 subjects who participated in the second phase of the EDIS Study, 39 
subjects were excluded from the analysis: 18 had no MRI scans (due to claustrophobia, or 
contraindications), and 21 subjects did not have gradable retinal photographs. Baseline 
characteristics of the remaining 261 subjects are shown in Table 11-1. With respect to 
qualitative MRI markers, 46 subjects (17.6%) had evidence of ischemic stroke on their 
MRI scan, of whom 36 (13.8%) had lacunes; while 83 subjects (31.8%) had CMB 
present, of whom 33 (12.6%) had multiple CMB, including 2 subjects who had more than 
20 CMB (23 and 43 CMBs). Among these 33 subjects, 22 had isolated multiple lobar 
CMBs, 9 isolated multiple deep or posterior fossa CMBs and 2 combination of lobar, 
deep or posterior fossa CMB. With respect to quantitative MRI markers, mean total brain 
volume was 895.6 ml (standard error of the mean [SEM]: 5.4) and mean total intracranial 
volume 1096 ml (SEM: 6.1). As WML volume showed a skewed distribution, the median 




of these markers of cerebral small vessel disease stratified according to 5-year age 
categories. All MRI lesions showed a higher prevalence with increasing age. CMBs were 
more prevalent in the younger age categories compared to lacunes, whereas in those aged 
≥80 years, the prevalence of CMB and lacunes were comparable. Although WML 
volume is not directly comparable across age categories with the other markers, the 
median WML volume in the youngest category was relatively small and showed a steep 
increase at older age. 
Table 11-2 describes age and sex-adjusted associations of retinal vascular parameters 
with log-transformed WML volumes, and the presence of lacunes and multiple CMB. 
The presence of lacunes was not associated with any retinal vascular parameters. WML 
volume was initially associated with increasing venular caliber in age and sex-adjusted 
models (Table 11-2), while multiple CMB was associated with narrower arteriolar 
caliber, wider venular caliber and reduced arteriolar fractal dimensions. However, 
associations with WML were attenuated when adjusted for cardiovascular risk factors. 
Associations with multiple CMB remained consistent, after adjustment for vascular risk 
factors and MRI markers (Table 11-3). Similar associations were observed when 
different categorizations of CMBs were used. In addition to narrower arteriolar caliber, 
wider venular caliber, and smaller arteriolar fractal dimension, analyses using Poisson 
regression models showed that higher arteriolar tortuosity was also associated with an 
increasing number of CMBs (Table 11-3). Figure 11-2 shows examples of subjects with 
CMB who had relatively smaller fractal dimension and higher tortuosity compared to 
subjects without CMB. 
4.  DISCUSSION 
In this study, persons with a sparser and more tortuous retinal vascular network were 




markers such as WML and lacunes. These data suggest that early retinal changes may 
provide insight into specific early markers of cerebral small vessel disease, such as 
CMBs. 
Thus far there have been no data from population-based studies examining the link 
between these novel retinal changes and CMBs. Though, using the same latest computer-
assisted method to measure the retinal microvasculature, we did recently observe similar 
retinal microvascular network changes (a sparser and more tortuous retinal network) in 
patients with stroke and Alzheimer’s disease.6,7 Furthermore, there are several reports 
describing rare hereditary conditions involving both retinal and cerebral microvessels 
including cerebroretinal vasculopathy, hereditary endotheliopathy with retinopathy, 
nephropathy and stroke (HERNS), cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leucoencephalopathy (CADASIL) and hereditary retinal arteriolar 
tortuosity. For example, persons with CADASIL have a decreased retinal vascular fractal 
dimension compared to healthy controls.8 In patients with hereditary retinal arteriolar 
tortuosity, besides the presence of retinal arteriolar tortuosity and retinal hemorrhages, 
CMBs have been observed on MRI.9 Although these studies in rare hereditary conditions 
affecting the retinal and brain microvessels consists of small numbers or case series, these 
data do provide initial evidence that these novel retinal parameters such as fractal 
dimension or tortuosity may be early markers of microvascular pathology in the brain as 
reflected on MRI, such as CMBs. Taken together, findings from our current study further 
support data from histopathological studies that CMBs are a marker of microvascular 
pathology.10 
Most studies that have examined the link between retinal changes and cerebral small 
vessel disease have focused on clinically visible retinopathy signs and on WMH and 
lacunar infarcts. Data from both the Atherosclerosis Risks in Communities Study and the 




likely to have both WML and subclinical infarcts.4,11 More recently, the AGES-Reykjavik 
Study reported that retinopathy signs were also associated with the presence of multiple 
CMB.12 Taken together, these studies provided evidence that microvascular lesions in 
both the retina and the brain may occur concomitantly as part of generalized 
microvascular disease resulting from common pathophysiological mechanisms. 
Retinopathy signs are, however, relatively late indicators of target organ damage in the 
eye and probably reflect advanced stages of structural microvascular damage including 
breakdown of the blood-retina barrier (Figure 11-3; blue line).  
Initial studies using the computer analysis techniques focused on earlier markers such as 
generalized arteriolar narrowing and venular dilatation. Longitudinal data from the 
Rotterdam Study showed that specifically wider venular caliber was associated with 
progression of both periventricular and subcortical white matter lesions, and incident 
lacunar infarcts on MRI.5 However, in the cross-sectional analyses from this study there 
was no statistically significant association between retinal calibers and these markers of 
cerebral small vessel disease. The lack of an association in the cross-sectional analyses 
may suggest that early changes in the retinal microvasculature (e.g. venular dilatation) do 
not reflect the actual severity of cerebral small vessel disease, but may precede the 
development of WMH and lacunes. Furthermore, in our cohort we found that in contrast 
to WMH and lacunes, prevalence of CMB was already high at a younger age, suggesting 
that CMBs may manifest before the appearance of the other cerebral small vessels 
disease markers. These data are in accordance with observations made in the 
spontaneously hypertensive stroke-prone (SHRSP) rat model showing that the 
development of CMBs as an important early milestone in the pathogenesis of cerebral 
small vessel disease.13 Overall, our current analyses showed that these early novel retinal 
parameters such as fractal dimension and tortuosity showed a significant cross-sectional 




disease (Figure 11-3; green line). Finally, our findings suggest that although these MRI 
lesions can occur concomitantly and increase with advancing age, there may be 
differences in pathophysiology underlying these lesions.  
Several methodological issues need to be discussed. Firstly, nearly 50% of screen-
positive subjects did not participate in the second phase of the EDIS study.2 Those 
(n=312) who did not participate were relatively older and had higher mean arterial blood 
pressure. This might have led to an underestimation of the prevalence of MRI markers of 
cerebral small vessel disease. Secondly, also due to small numbers, we were not able to 
study in detail the associations with the specific location of CMB. Strengths of our study 
include quantitative assessment of retinal photographs using standardized protocols, and 
quantitative measurement of MRI markers such as white matter lesion volume. 
5.  CONCLUSION 
In conclusion, we report that elderly persons with early retinal changes such as a sparser 
and more tortuous retinal microvascular network are more likely to have CMBs on MRI 
independent of cardiovascular risk factors and other markers of small vessel disease on 
MRI. This provides further evidence that CMB may be an early manifestation of cerebral 
small vessel disease.  
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CHAPTER 11 – TABLES 
 
Table 11 – 1: Baseline characteristics of study participants (n=261) 
 
Baseline characteristics Mean / N  
Age, years  70 (0.4) 
Males,  122 (46.7) 
BMI, kg/m2  24.1 (0.2) 
Hypertension, 196 (75.1) 
Diabetes,  69 (26.4) 
Hyperlipidemia,  154 (59.0) 
Systolic blood pressure, mmHg  147.0 (1.2) 
Diastolic blood pressure, mmHg  76.7 (0.7) 
Mean arterial blood pressure, mmHg  100.2 (0.7) 
Fasting blood glucose, mmol/l  5.1 (0.09) 
Fasting total cholesterol, mmol/l  4.9 (0.05) 
Ever smokers,  76 (29.1) 
 
Abbreviations: BMI= body mass index; kg/m2= kilogram per meter square;  
mmHg= millimeters of mercury; mmol/l= millimoles per liter 





Table  11 – 2: Age-sex adjusted regression models of retina vascular parameters for white 
matter hyperintensities (WMH) volume, and multiple cerebral microbleeds (CMB≥2)  
 
 




OR (95% CI) 
(n=36/261) 
Multiple CMBs† 
OR (95% CI) 
(n=33/261)  
Caliber 
Arteriolar, per SD 
decrease‡ 
0.32 (-0.05; 0.69) 1.26 (0.65; 2.45) 2.10 (1.06; 4.15) 
Venular, per SD increase‡  0.38 (0.02; 0.75) 1.57 (0.83; 2.98) 2.29 (1.19; 4.40) 
Fractal dimension, per SD decrease 
Arteriolar  0.06 (-0.16; 0.27) 1.31 (0.90; 1.91) 1.89 (1.27; 2.82) 
Venular  -0.10 (-0.32; 0.12) 1.11 (0.95; 1.64) 1.30 (0.88; 1.92) 
Tortuosity, per SD increase 
Arteriolar  -0.05 (-0.27; 0.16) 0.78 (0.52; 1.17) 1.07 (0.73; 1.56) 
Venular  0.12 (-0.09; 0.33) 0.99 (0.67; 1.46) 0.94 (0.63; 1.40) 
 
Abbreviations: WMH= white matter hyperintensities; CMB= cerebral microbleeds; OR= odds ratios; 
CI= confidence interval; SD= standard deviation 
 
∗Linear regression models with log-transformed WMH volumes as the dependent variable. 
 
†Logistic regression models with the presence of lacunes or multiple CMB as the dependent 
variable. 
 




Table 11 – 3: Multivariable-adjusted odds ratios (ORs) for the presence of multiple cerebral microbleeds (CMBs) and rate ratios 
(RRs) for the CMB counts (with 95% confidence intervals) presented as per standard deviation difference in retinal parameters 
 ORs for presence of multiple CMB∗  RRs for CMB counts† 
Retinal Parameter 
Model I‡ 
OR (95% CI) 
(n=32/258) 
Model II§ 
OR (95% CI) 
(n=32/258) 
 Model I‡ 
RR (95% CI) 
(n=256) 
Model II§ 
RR (95% CI) 
(n=256) 
Caliber      
Arteriolar, per SD decrease# 2.17 (1.04; 4.51) 2.07 (0.98; 4.38)  1.48 (1.01; 2.17) 1.42 (0.98; 2.05) 
Venular, per SD increase# 2.40 (1.20; 4.77) 2.23 (1.09; 4.56)  1.39 (1.00; 1.93) 1.31 (0.93; 1.84) 
Fractal dimension, per SD decrease     
Arteriolar  1.84 (1.22; 2.78) 1.79 (1.17; 2.73)  1.39 (1.08; 1.80) 1.37 (1.06; 1.78) 
Venular  1.22 (0.82; 1.83) 1.24 (0.82; 1.88)  1.15 (0.91; 1.45) 1.15 (0.91; 1.46) 
Tortuosity, per SD increase      
Arteriolar  1.17 (0.80; 1.38) 1.29 (0.87; 1.93)  1.25 (1.01; 1.55) 1.29 (1.03; 1.61) 
Venular  0.96 (0.64; 1.45) 0.96 (0.64; 1.44)  0.99 (0.76; 1.29) 0.98 (0.76; 1.27) 
 Abbreviations: OR=odds ratios; RR= rate ratios; CMB= cerebral microbleeds; SD= standard deviation 
*Multivariable-adjusted odds ratios for the presence of multiple cerebral microbleeds (with 95% confidence intervals) 
†Multivariable-adjusted rate ratios for the cerebral microbleed counts (with 95% confidence intervals). Additionally, 2 outliers 
(subjects with 23 and 43 CMBs) were excluded to satisfy the goodness-of-fit criterion for Poisson regression models 
‡Model I: Adjusted for age, sex, smoking, body mass index, mean arterial blood pressure, fasting blood glucose and cholesterol  
§Model II: Adjusted for confounders from model I, and total white matter volume, total brain volume/total intracranial volume, and 
presence of stroke 
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Figure 11 – 2: MRI scans and corresponding retinal photographs of study subjects 
 
MRI scans (A-D) showing absence (left column) or presence (right column) of cerebral 
microbleeds (CMB; white arrows) and retinal fundus photos graded by computer software (A'-D') 
showing vessel path tracing of images from participants, with red for arterioles and blue for 
venules. In a subject with CMB retinal arteriolar fractal dimension (C,C’) is smaller compared to a 
subject without CMB (A,A'). In another subject with CMB, retinal arteriolar tortuosity (D,D’) is 















Figure 11 – 3:  Representation of postulated timeline of preclinical imaging markers in 
cognitive impairment 
 
Among preclinical imaging markers for cognitive impairment, white matter lesions and lacunar 
infarcts may be relatively “late” markers as they are related to retinopathy signs (blue line), 
whereas cerebral microbleeds are related to “early” retinal parameters such as fractal dimension 
and tortuosity (green line) and hence may be early manifestation of cerebral small vessel disease.  



































CHAPTER 12:  






1.  INTRODUCTION 
An increasing amount of evidence suggests that vascular pathology is an independent and 
important contributor to the development of dementia, including Alzheimer’s disease and 
its preclinical stages.1 In particular, cerebral small vessel disease has been associated with 
increased risk of cognitive decline and dementia.2,3 Although modern neuroimaging 
modalities have contributed immensely to our understanding of microvascular pathology 
in dementia and cognitive impairment, it remains difficult to directly observe the cerebral 
microvasculature in vivo. As the retinal and cerebral microvasculature share many 
anatomical and physiological aspects, the retina provides a viable window to directly 
observe changes to the cerebral microvasculature.4 
Thus far, studies have shown that traditional signs of retinal microvascular damage, such 
as retinopathy signs (e.g. retinal hemorrhage) are associated with both dementia and its 
earlier preclinical stages.5-7 However, retinopathy signs are relatively late indicators of 
damage in the eye, and indicate advanced stages of structural microvascular damage, 
such as breakdown of the blood-retina barrier, and are not commonly seen. With recent 
advances in digital retinal imaging and analysis techniques, we are now able to quantify 
objectively the structure and pattern of the retinal microvascular network, which may 
reflect earlier and more subtle changes before the appearance of overt signs. Novel retinal 
vascular parameters such as fractal dimensions, which reflect the optimality of the 
vascular network, are of particular interest, as they have recently been found to be 
associated with both stroke and dementia.8,9 In view of these associations with clinical 
disease, we hypothesized that these early retinal vascular network changes may also be 
present even in the preclinical stages of dementia. In this study, we examined the 
association between retinal vascular network parameters, particularly vascular fractal 





2.  METHODS  
2.1  Study Population  
The Epidemiology of Dementia in Singapore (EDIS) study draws participants from the 
Singapore Epidemiology of Eye Disease (SEED) Study, which is a population-based 
study among Chinese, Malays and Indians.2 In the present study we restricted analysis to 
the Chinese component of EDIS, the description of which has been described in Chapter 
3.  
2.2  Assessment of Retinal Vascular Parameters 
Retinal fundus photographs were taken from each eye after pupil dilation and graded 
according to a standardized protocol as described in Chapter 3. The following retinal 
vascular parameters were extracted and used for analysis: retinal vascular fractal 
dimension, tortuosity, and caliber. Details of these parameters and reliability assessment 
have been described in the previous Chapter 3. 
2.3  Neuropsychological Assessment 
Detailed neuropsychological assessments with subtests and Z-score calculation has been 
described in detail in Chapter 3. 
2.4  Diagnosis of Cognitive Impairment and Dementia 
Weekly consensus meetings were held with study clinicians, neuropsychologists, clinical 
research fellows, research coordinators, and research assistants. Details from the clinical 
assessment, blood investigations, neuropsychological testing and MRI scans were 
reviewed. Diagnostic criteria for CIND and dementia have been described in detail in 
Chapter 3. Seven participants who were diagnosed with dementia were excluded from 
final analysis. 
2.5 Assessment of Other Risk Factors 
Details on the demographic and vascular risk factors assessment have been described in 




the neuropsychological and clinical data for the presence of stroke and cerebral 
microbleeds (Brain Observer Microbleed Scale). White matter lesions (WML) volume, 
total brain volume, and total intracranial volume were quantified by automatic 
segmentation as described in Chapter 3 at the Erasmus University Medical Center 
Rotterdam, The Netherlands.16-18 
2.6  Statistical Analysis  
For the comparison of baseline demographic and risk factors between participants with 
gradable and ungradable retinal fundus images, and between the different diagnostic 
groups, Pearson’s chi-square test was used for categorical variables with independent t-
tests and analysis of variance (ANOVA) for continuous variables. Kruskal-Wallis one-
way analysis of variance was used to compare WML volumes, MMSE scores, and MoCA 
scores as they were not normally distributed. Multinomial logistic regression models 
were constructed to calculate odds ratios (OR) and their 95% confidence intervals (CI) 
for CIND-mild and CIND moderate by per standard deviation (SD) increase or decrease 
in retinal vascular parameters. Models were firstly adjusted for age and sex, then 
additionally for risk factors of education level, socioeconomic status, mean arterial blood 
pressure, fasting blood glucose, serum cholesterol, smoking status, and MRI brain 
imaging markers. Similarly adjusted linear regression models were also constructed for z-
scores from individual domains and the composite Z-score for all domains to test for 
linear relationships between retinal vascular parameters and cognitive performance. All 
statistical analysis was performed using SPSS Version 17.0 (SPSS Inc., USA).  
3.  RESULTS  
Of the 300 Chinese participants recruited into the EDIS study, 7 participants diagnosed 
with clinical dementia were excluded from this study. From the remaining 293 




from the analysis were similar in baseline characteristics compared to the included 
participants, except for education level (less with Primary education and above, p=0.045), 
socioeconomic status (lower, p=0.006), and presence of any previous stroke on 
neuroimaging (higher, p=0.043). In the 268 eligible participants, 121 participants were 
NCI, 78 CIND-mild, and 69 CIND-moderate. In general, participants who were CIND-
mild or CIND-moderate were more likely to be women, older, had lower education and 
socioeconomic status, higher diastolic blood pressures, prevalent stroke, higher WML 
volume, and lower total brain volume/intracranial volume ratio (Table 12-1).  
In multinomial age-sex adjusted logistic regression models, reduced retinal arteriolar 
fractal dimension was associated with higher risk of being CIND-moderate, while 
reduced venular fractal dimension was associated with higher risk of being CIND-mild 
and CIND-moderate (Table 12-2). After further adjustment for other risk factors such as 
socioeconomic status, blood pressure, glucose, cholesterol levels, and MRI markers, 
reduced fractal dimensions remained associated with both clinical outcomes of CIND-
mild and CIND-moderate (Table 12-3).  
In age-sex adjusted linear regression models for global cognitive function as expressed as 
composite VDB Z-scores in the entire cohort showed that both reduced arteriolar and 
venular fractal dimensions and reduced arteriolar vessel tortuosity was associated with 
poorer cognitive performance (Table 12-2). However, the association of cognitive 
impairment with arteriolar tortuosity was attenuated after additional adjustment for other 
risk factors and MRI markers (Table 12-3).  
As there were significant associations between fractal dimensions and global cognitive 
function, associations with specific cognitive domains were also investigated in this 
cohort. Reduced fractal dimensions were associated with lower scores in verbal memory, 




4.  DISCUSSION 
In this Chinese population, persons with a sparser vascular network in the retina were 
more likely to have poorer global cognitive performance, and have significant cognitive 
impairment, independent of traditional risk factors and MRI markers. In particular, they 
performed worse in specific cognitive domains of verbal memory, visuoconstruction and 
visuomotor speed. 
Thus far, previous studies examining the relationship between retinal microvascular 
changes and cognitive dysfunction have mainly focused on clinically visible retinopathy 
signs. In the Atherosclerosis Risk in Communities (ARIC) study,10 classic retinopathy 
lesions were clearly associated with cognitive impairment. However, findings from other 
studies, including the Los Angeles Latino Eye Study (LALES), the Cardiovascular 
Health Study (CHS), the Blue Mountain Eye Study (BMES), and the AGES-Reykjavik 
Study, have been less clear.11-13 For example, in the BMES,13 these associations were 
only present among subjects with hypertension, whereas in the AGES-Reykjavik Study,6 
retinopathy combined with the presence of cerebral microbleeds was associated with 
cognition. These discrepancies could partly be due to not only differences in the cognitive 
tests used, such as the Mini Mental State Examination, or the Abbreviated Mental 
Test,11,13,14 but also differences in the specific cognitive domains tested such as 
psychomotor speed, executive function, and verbal memory.10,11 Finally, retinopathy 
signs are considered relatively late indicators of vascular damage in the eye, and indicate 
advanced stages of structural microvascular damage. Recent advances in digital retinal 
imaging have enabled us to quantify early changes in the retinal microvasculature. 
In this present study, we focused on retinal vascular fractal dimensions. In addition to its 
potential to reflect earlier and more subtle changes before the appearance of overt signs, 
fractal dimensions in particular have the advantage of being parameters that do not vary 




fractal dimensions was related to cognitive dysfunction.14 However, in the study only a 
brief 10-point screening test (Abbreviated Mental Test) was employed. In the current 
study, an extensive neuropsychological test battery was employed to assess a range of 
cognitive domains, allowing us to not only study individual domains, but also 
comprehensively stage our subjects into categories with increasing severity of 
impairment. Our data provide additional support that these changes in the retinal vascular 
network are associated with cognitive impairment. Furthermore, our findings that reduced 
arteriolar and venular fractal dimensions are associated with preclinical stages of 
dementia are in line with previous studies showing that these retinal parameters are 
linked to not only clinical outcomes such as acute ischemic stroke and dementia, but also 
markers of cerebral small vessel disease such as lacunar infarcts and cerebral 
microbleeds.8,9,15-17 Pathophysiologically, a sparser network as reflected by a reduced 
fractal dimension is a consequence of retinal vessel rarefaction and collapse, which may 
lead to hypoxia in the retina.18 Similarly in the brain, destruction and occlusion of the 
small perforating vessels have been observed,19 suggesting that there may be parallel 
pathological mechanisms at work in the brain and retina leading to microvascular 
changes. Taken together, these morphological changes in the retinal microvasculature 
suggest that subtle microvascular changes may already be present in the preclinical stages 
of dementia, further providing evidence for vascular disease as an important contributor 
to the development of cognitive impairment and dementia. 
Some methodological issues need to be discussed. Since approximately half of the screen 
positive subjects declined to take part in phase II of the study (cognitive assessment and 
neuroimaging phase), eligible subjects who refused to participate may have had poorer 
cognitive function leading to an underestimation of the effect sizes.20 Nevertheless, we 
still found a consistent association between retinal vascular network complexity and 




our study include comprehensive and standardized assessment of cognitive ability over a 
range of domains, and quantitative assessment of retinal photographs using standardized 
semi-automated protocols. 
5. CONCLUSION 
In conclusion, our study found that a sparser retinal microvascular network is associated 
with cognitive impairment and poorer performance on cognitive scores, independent of 
cardiovascular risk factors and MRI markers of cerebral small vessel disease. This 
provides additional evidence for the importance of microvascular pathology in the 
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CHAPTER 12 – TABLES 
 




Abbreviations: BMI= body mass index; MMSE= mini mental status examination; MoCA= 
montreal cognitive assessment; CMB= cerebral microbleeds; TBV= total brain volume; ICV= 
intracranial volume, NCI= no cognitive impairment; CIND= cognitive impairment no dementia 
 
*Chi-square test was used for categorical variables and Student’s t-test for continuous variables 
unless stated otherwise 
 
†Kruskal-Wallis test was used for white matter lesion volume, MMSE score and MoCA score 
  







Female, n (%)  53 (43.8) 42 (53.8) 47 (68.1) 0.005 
Age, mean (SD)  67.3 (4.8) 71.1 (6.3) 74.1 (5.4) <0.001 
Above primary education, n (%)  110 (90.9) 61 (76.9) 41 (59.4) <0.001 
Low socioeconomic status, n (%)  58 (48.7) 52 (71.2) 57 (83.8) <0.001 
BMI, mean (SD)  23.9 (3.2) 23.8 (3.3) 24.5 (4.1) 0.456 
Systolic blood pressure, mean (SD)  146.3 (19.1) 145.4 (17.9) 149.1 (21.6) 0.477 
Diastolic blood pressure, mean (SD)  78.9 (10.1) 75.2 (10.1) 74.8 (10.9) 0.010 
Hypertension, n (%)  88 (72.7) 59 (75.6) 61 (88.4) 0.040 
Random blood glucose, mmol/L (SD)  6.41 (2.50) 6.61 (3.09) 6.65 (2.44) 0.810 
Diabetes, n (%)  26 (21.5) 19 (24.4) 22 (31.9) 0.278 
Serum total cholesterol, mmol/L (SD)  5.32 (1.01) 5.06 (0.97) 5.33 (1.05) 0.493 
Hyperlipidemia, n (%)  67 (55.4) 48 (61.5) 48 (69.6) 0.154 
Ever smokers, n (%)  35 (28.9) 24 (30.8) 22 (31.9) 0.906 
MMSE score, median (IQR)  27 (2) 25 (4) 21 (5) <0.001† 
MoCA score, mean (IQR)  24 (4) 20 (5) 16 (6) <0.001† 
MRI markers 
Presence of stroke, n (%)  5 (4.1) 14 (17.9) 21 (30.4) <0.001 
Presence of CMB, n (%)  33 (27.3) 24 (30.8) 23 (33.3) 0.510 
WML volume, median ml (IQR)  1.37 (3.19) 1.82 (4.26) 3.28 (10.39) 0.002† 





Table 12 – 2: Age-sex adjusted associations of retinal vascular parameters with global 
cognitive performance, expressed as mean differences (95%CI) in normalized test scores, 




Abbreviations: B= mean difference; OR= odds ratios; CI= confidence interval; CIND= cognitive 
impairment no dementia; VDB= vascular dementia battery; SD= standard deviation  
 
*Expressed as mean differences with 95% confidence intervals  
 








Age-sex adjusted (268) 
B (95%CI)* OR (95%CI) 







Arteriolar, per SD decrease†  0.072 (-0.091, 0.234) 0.70 (0.39-1.24) 0.81 (0.43-1.53) 
Venular, per SD increase†  -0.080 (-0.240, 0.081) 0.99 (0.57-1.72) 1.17 (0.63-2.16) 
Fractal Dimension 
Arteriolar, per SD decrease  -0.165 (-0.247, -0.073) 1.37 (0.99-1.89) 1.73 (1.19-2.53) 
Venular, per SD decrease  -0.151 (-0.242, -0.061) 1.38 (1.00-1.90) 1.79 (1.24-2.60) 
Tortuosity 
Arteriolar, per SD increase  0.143 (0.053, 0.234) 0.86 (0.63-1.17) 0.73 (0.51-1.05) 




Table 12 – 3: Multivariable adjusted associations of retinal vascular parameters with global cognitive performance, expressed as mean differences 
(95%CI) in normalized test scores, and with diagnosis of cognitive impairment status expressed as odds ratios (95% CI) 
 
Abbreviations: B= mean difference; OR= odds ratios; CI= confidence interval; VDB= vascular dementia battery; CIND= cognitive impairment no dementia; 
SD= standard deviation  
 
* Adjusted for age, gender, race, education level, low socioeconomic status, mean arteriolar blood pressure, random blood glucose, total cholesterol and presence 
of stroke  
 
† Adjusted for age, gender, race, education level, low socioeconomic status, mean arteriolar blood pressure, random blood glucose and total cholesterol, presence 
of stroke and cerebral microbleeds, total white matter lesion volume, and total brain volume/intracranial volume 
 










Model I* (244)  Model II† (243) 
B (95%CI)         OR (95% CI)            B (95%CI) OR (95% CI)  
Composite VDB score‡  











Fractal Dimension   
Arteriolar, per SD 
decrease  
-0.119 (-0.200, -0.037)  1.40 (0.98-2.01)  1.86 (1.20-2.88)  -0.103 (-0.187, -0.020) 1.46 (1.01-2.12) 1.86 (1.17-2.93) 
Venular, per SD 
decrease  
-0.108 (-0.190, -0.026)  1.52 (1.05-2.21)  2.09 (1.35-3.22)  -0.109 (-0.191, -0.028) 1.54 (1.06-2.25) 2.15 (1.38-3.34) 
Tortuosity  
Arteriolar, per SD 
increase  




Table 12 – 4: Associations between retinal vascular fractal dimensions with specific cognitive domain scores expressed as mean differences (95%CI) 
 
 
Abbreviations: B= mean difference; CI= confidence interval; SD= standard deviation  
 
∗ Adjusted for age, gender, race, education level, mean arteriolar blood pressure, fasting blood glucose, total cholesterol, and presence of stroke 
  
†Adjusted for age, gender, race, education level, mean arteriolar blood pressure, fasting blood glucose, total cholesterol, presence of stroke, cerebral microbleeds, 
total white matter lesion volume, and total brain volume/intracranial volume 
 
                               Executive Function  Attention Language Visual Memory Verbal Memory Visuoconstruction Visuomotor speed 
         B (95%CI) B (95%CI) B (95%CI) B (95%CI) B (95%CI) B (95%CI) B (95%CI) 
Arteriolar fractal dimension per SD decrease  




























Venular fractal dimension per SD decrease 








































CHAPTER 13:  
Retinal Neurodegeneration on Optical Coherence Tomography 





1.  INTRODUCTION  
Alzheimer’s disease is characterized by brain atrophy in the cortical and subcortical grey 
and white matter especially the hippocampus and entorhinal cortex. Structural 
neuroimaging has shown that diffuse atrophy is present even in the early stages of 
dementia.1-3 Advanced automated segmentation techniques, such as voxel based 
morphometry, allow quantification of grey and white matter volumes using magnetic 
resonance imaging (MRI).4 Grey matter loss is related to progressive mild cognitive 
impairment (MCI) and conversion to dementia in the MCI group.5-7 Global and regional 
grey matter volume measurements are now crucial biomarkers in detecting neuronal loss 
and progression of cognitive decline. However, MRI remains a time-consuming and 
expensive technique. Moreover, some patients have contraindications for undergoing 
MRI such as claustrophobia, cardiac pacemakers, and inability to tolerate the procedure.  
As the retina shares developmental, physiological and anatomical features with the 
brain,8,9 retinal imaging is now increasingly used in studying neurodegenerative disease. 
Both histopathological and clinical studies have shown that patients with Alzheimer’s 
disease have functional visual deficits and anatomical changes in retinal structures.10,11  
Structural changes to the optic nerve can be non-invasively measured in vivo using 
techniques such as spectral domain-optical coherence tomography (SD-OCT). Recent 
advances in SD-OCT have made it possible to automatically measure the retinal nerve 
fiber layer (RNFL) and the ganglion cell-inner plexiform layer (GC-IPL). Unmyelinated 
axons of the retinal ganglion cells form the RNFL, while the GC-IPL contains the cell 
bodies and dendrites of these cells. Previous studies have linked RNFL thinning to a 
number of brain diseases, such as Alzheimer’s disease,12-14 Parkinson’s disease, and 
multiple sclerosis.15-17 However, studies have not examined if neuronal changes in the 




Therefore, we examined the relationship of RNFL and GC-IPL thickness, with cerebral 
white and grey matter volumes on MRI in an elderly population from Singapore. 
2.  METHODS  
2.1  Study Population  
The on-going Epidemiology of Dementia in Singapore (EDIS) study draws participants 
from the Singapore Epidemiology of Eye Disease (SEED) study, a multi-ethnic 
population-based study among persons aged 40 to 85 years. For this study, we focused on 
participants drawn from the first follow-up examination of the Singapore Malay Eye 
Study (SiMES) component of the SEED study who had OCT data available.18 In order to 
use the limited MRI imaging resources efficiently, it was decided to focus on those 
subjects who were most likely to have cognitive problems. Hence, in the first phase of the 
EDIS-SiMES Study, participants from SiMES aged ≥ 60 years (n=1014) were screened 
using the Abbreviated Mental Test (AMT) and a self-report of progressive forgetfulness. 
Screen-positive subjects (n=448) were invited to take part in the second phase of this 
study, which included an extensive neuropsychological test battery and brain MRI. Of 
these 448 participants, 307 agreed to participate in phase II and hence were included in 
the present study. Cognitively impaired no dementia (CIND) was defined as impairment 
in one or more domains in the neuropsychological test battery, as described previously.19 
Dementia was diagnosed in accordance to the Diagnostic and Statistical Manual of 
Mental Disorders-IV criteria. The details of the study methodology have been described 
elsewhere.19 Ethics approval for the EDIS study was obtained from the SingHealth 
Institutional Review Board and the National Healthcare Group Domain-Specific Review 
Board. The study was conducted in accordance with the Declaration of Helsinki. Written 
informed consent was obtained prior to recruitment.  




Intracranial volume (ICV), grey matter and white matter volumes were quantified by 
automatic segmentation at the Erasmus University Medical Center Rotterdam, The 
Netherlands as mentioned in Chapter 3. 
2.3  Assessment of Retinal Neuronal Layers  
SD-OCT (Cirrus HD-OCT; Carl Zeiss Meditec) macular and optic disc cube scans were 
obtained from study participants and assessed according to standardized protocol 
described in Chapter 3. Participants were also excluded if they had a diagnosis of 
glaucoma from study ophthalmologists. Macular GC-IPL thickness and peripapillary 
RNFL thickness measurements were taken from a randomly selected eye from each 
participant for analysis. Figure 13-1 shows detailed cross-sectional image of the retinal 
layers centered at the macula using a SD-OCT. 
2.4  Assessment of Other Vascular Risk Factors  
Other vascular risk factors assessment has been described in detail in Chapter 3. Axial 
length for study eyes was measured using IOL Master V3.01 (Carl Zeiss; Meditec AG 
Jene, Germany). 
2.5  Statistical Analysis 
Grey and white matter volumes were used as determinants and expressed as per standard 
deviation (SD) decrease, whereas GC-IPL and RNFL thickness were taken as outcomes. 
Linear regression models were used to estimate mean change [95% confidence intervals 
(CI)] in GC-IPL and RNFL thickness per SD decrease in total brain volume, grey matter, 
and white matter volumes. Models were initially adjusted for age and sex, additionally 
MABP, blood glucose, serum cholesterol, with axial length and OCT scan signal strength 
from the eye chosen, and total intracranial volume to correct for head size. RNFL models 
were additionally adjusted for optic disc area. Separate linear regression models were 




statistical analyses were performed on standard statistical software (SPSS Version 17, 
SPSS Inc., USA). 
3.  RESULTS 
Screening and assessments of the Malay cohort was performed from February 2011 to 
July 2013. Of the 307 subjects who participated in the second phase of the EDIS Study, 
143 were excluded from the analysis: 21 had no MRI scans (due to claustrophobia, or 
contraindications), 14 were diagnosed with glaucoma, 87 did not complete OCT 
scanning, while 34 had ungradable OCT scans. Comparison of the 164 participants 
included and 143 participants excluded are shown in Table 13-1. In summary, excluded 
participants were more likely to be older, have diabetes, lower BMI, and more likely to 
be CIND or dementia. Mean total brain volume was 863.5ml (SD, 89.1ml), mean grey 
matter volume 507.2ml (SD, 53.2ml), mean white matter volume 357.9ml (SD, 42.1ml) 
and mean total intracranial volume 1056.0ml (SD, 100.1ml). Mean RNFL thickness was 
90.6 μm (SD, 10.3 μm), while mean GC-IPL thickness was 78.8 μm (SD, 7.2 μm). 
Decreasing total brain volume was weakly associated with GC-IPL thinning (mean 
change in GC-IPL per SD decrease in brain volume: -1.26 μm, 95%CI -2.53 to 0.01μm), 
while decreasing total grey matter volume was more strongly associated with GC-IPL 
thinning (mean change in GC-IPL per SD decrease in grey matter volume: -1.40μm, 
95%CI -2.66 to -0.14μm) in age-sex adjusted models. In contrast, reduction in white 
matter volume was not significantly associated with GC-IPL thinning (mean change in 
GC-IPL per SD decrease in white matter volume: -0.80μm, 95%CI -2.02 to 0.41μm). 
However, these associations became non-significant after additional adjustment for 
MABP, blood glucose, plasma cholesterol levels, smoking, axial length, OCT scan signal 




for RNFL thickness were not statistically associated with total brain, grey or white matter 
volume. 
Region-specific analyses (Table 13-2 and Table 13-3) showed that decreasing grey 
matter volume in both occipital and temporal lobes was associated with GC-IPL thinning 
in both age-sex and multivariable-adjusted models, whereas only decreasing temporal 
lobe grey matter volume was associated with RNFL thinning independent of risk factors, 
axial length and intracranial volume. Reduction in grey and white matter volumes in the 
frontal, parietal lobes and central regions were not significantly associated with GC-IPL 
or RNFL thickness changes. 
When participants with dementia (n=3; all Alzheimer’s Disease) were further excluded 
from analysis, these associations remained unaltered. 
4.  DISCUSSION 
In this study, we found that reduction in grey matter volume in the occipital and temporal 
lobes was associated with GC-IPL thinning in the retina, independent of systemic 
vascular risk factors, in elderly persons without glaucoma or clinical retinal diseases. 
However, there was no evidence of an association between global grey and white matter 
volumes or regional white matter volumes with GC-IPL and RNFL thickness. This 
suggests that thinning in the retinal neuronal layers may provide insight into region-
specific grey matter atrophy in elderly persons at risk of cognitive decline. 
Thickness measurements of the GC-IPL and RNFL are both markers of retinal ganglion 
cell structural integrity, with the RNFL being mainly composed of retinal ganglion cell 
axons, whereas the GC-IPL is composed of both the cell bodies and dendrites of the 
retinal ganglion cells. As reduction in dendritic complexity and area occurs prior to 
retinal ganglion cell death and loss,20 this suggests that the GC-IPL may be more 




Our findings that reduction in grey matter volumes in the occipital and temporal lobes is 
linked to RNFL and GC-IPL thinning suggest the presence of a neurodegenerative 
pathway linking these regions of the brain directly to the eye. The visual association 
cortex in the inferior temporal lobe and the occipital lobes are particularly susceptible to 
neurofibrillary tangles and amyloid plaque deposition,21,22 and this correlates with atrophy 
and reduced metabolism especially in the occipital and temporoparietal regions.23 As a 
result, these pathological depositions disrupt connections within the visual tract, 
potentially causing retrograde neuronal degeneration down the optic nerve,21 resulting in 
region-specific relationships between the temporal and occipital lobe atrophy with retinal 
neuronal damage. Retrograde damage to the optic nerve, and hence retinal ganglion cells, 
would then be reflected as RNFL and GC-IPL thinning, as shown in a number of clinical 
studies in mild cognitive impairment and Alzheimer’s disease.12, 14, 24 
The association of occipital and temporal lobe grey matter atrophy with GC-IPL thinning 
was present in persons with no dementia. In conjunction with how the occipital and 
adjacent temporal lobes appear to be an early site of amyloid and neurofibril 
accumulation,21, 22, 25 this suggests that GC-IPL thinning may reflect involutional changes 
in these regions of interest even before the onset of dementia. Hence, the GC-IPL shows 
promise as a novel early biomarker of involutional changes in the brain. Future studies 
are warranted to further assess if the GC-IPL is useful in tracking grey matter volume 
changes longitudinally, and if this association is related to cognitive performance and 
decline.  
There are a few limitations to our study. Firstly, about 33.6% of screen-positive subjects 
did not participate in the second phase of the EDIS study, and of those who participated, 
nearly 40% of them either did not successfully complete OCT scanning or had scans 
unsuitable for analysis. Therefore, the generalizability of our study results may be 




results with respect to the cause and effect. Third, visual fields were not tested in our 
subjects. Hence, we were unable to examine whether retinal thinning was correlated to 
visual field defects. Fourth, as is the case with any technology (including OCT and MRI), 
each has its own limitations and contraindications. For OCT, ocular co-morbidities and 
any inability to undergo OCT assessment form the most important limitations. In terms of 
prognostic utility, we do not think that OCT on its own will be sufficient to assess 
involutional changes in the brain. Different and complementary imaging modalities such 
as the OCT and MRI should be combined to obtain a thorough assessment of involutional 
changes in the brain. In terms of limitations, this means that subjects with prominent 
ocular co-morbidities may benefit more from a brain MRI, while subjects with 
pacemakers, claustrophobia, who cannot undergo MRI, may benefit more from OCT to 
get an impression of the extent of neurodegneration. The main strengths of our study 
include direct in vivo quantitative assessment of neuronal damage in the retina and the 
brain using OCT and MRI, and a cohort spanning varying degrees of cognitive 
impairment status.  
5.  CONCLUSION 
In conclusion, retinal neuronal damage, as reflected by GC-IPL thinning, is 
independently associated with grey matter loss in the occipital and temporal lobes. In 
contrast, there was no evidence of an association between global grey and white matter 
volumes or regional white matter volumes with GC-IPL and RNFL thickness. These 
findings suggest that changes in retinal ganglion cells as assessed by high-resolution OCT 
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CHAPTER 13 – TABLES 
 
Table  13 – 1: Comparison of baseline characteristics of included and excluded participants 
of this study  
 
Baseline characteristics Included (n=164) Excluded (n=143) p-value* 
Age, years (SD) 69.0 (6.5) 73.3 (6.8) <0.001 
Males, n (%) 70 (42.7) 69 (48.3) 0.359 
BMI, kg/m2 (SD) 21.0 (4.1) 20.0 (4.0) 0.045 
Hypertension, n (%) 138 (84.1) 131 (91.6) 0.056 
Diabetes, n (%) 44 (26.8) 59 (41.3) 0.008 
Hyperlipidemia, n (%) 133 (81.1) 112 (78.3) 0.571 
Systolic blood pressure, mmHg (SD) 150.1 (19.5) 154.1 (21.6) 0.091 
Diastolic blood pressure, mmHg (SD) 79.7 (11.6) 78.4 (12.0) 0.352 
Mean arterial blood pressure, mmHg (SD) 101.7 (11.3) 102.8 (11.5) 0.435 
Random blood glucose, mmol/l (SD) 6.86 (3.02) 7.51 (3.04) 0.073 
Total cholesterol, mmol/l (SD) 5.27 (1.31) 5.17 (1.35) 0.531 
Ever Smokers, n (%) 46 (28.0) 44 (30.8) 0.617 
Cognitive status    
Not cognitively impaired, n (%) 36 (22.0) 22 (15.4) <0.001 
CIND, n (%) 125 (76.2) 101 (70.6)  
Dementia, n (%) 3 (1.8) 20 (14.0)  
 
Abbreviations: SD= standard deviation; BMI= body mass index; kg/m2= kilogram per meter 
square; mmHg= millimeters of mercury; mmol/l= millimoles per liter; CIND= cognitive 
impairment no dementia 
 





Table 13 – 2: Age-sex-adjusted estimated mean change in GC-IPL and RNFL thicknesses 
(95%CI) per standard deviation change in MRI markers 
 
 
 GC-IPL thickness  
B (95%CI), µm 
RNFL thickness  
B (95%CI), µm 
per SD decrease in Occipital lobe   
Grey+White matter volume -1.83 (-3.05, -0.61) -2.33 (-4.16, -0.51) 
Grey matter volume -2.04 (-3.20, -0.88) -2.46 (-4.20, -0.71) 
White matter volume -0.80 (-2.04, 0.45) -1.23 (-3.08, 0.62) 
per SD decrease in Temporal  lobe   
Grey+White matter volume -2.32 (-3.52, -1.11) -2.77 (-4.58, -0.96) 
Grey matter volume -2.55 (-3.71, -1.40) -3.03 (-4.78, -1.28) 
White matter volume -1.14 (-2.35, 0.06) -1.40 (-3.20, 0.39) 
per SD decrease in Frontal lobe   
Grey+White matter volume -0.97 (-2.22, 0.28) -1.35 (-3.20, 0.50) 
Grey matter volume -0.95 (-2.19, 0.30) -0.99 (-2.84, 0.87) 
White matter volume -0.71 (-1.90, 0.48) -1.41 (-3.17, 0.35) 
per SD decrease in Parietal  lobe   
Grey+White matter volume -1.12 (-2.30, 0.06) -1.18 (-2.94, 0.58) 
Grey matter volume -1.23 (-2.39, 0.08) -1.19 (-2.91, 0.53) 
White matter volume -0.73 (-1.91, 0.44) -0.90 (-2.65, 0.85) 
per SD decrease in Central  lobe   
Grey+White matter volume -1.17 (-2.43, 0.09) -1.76 (-3.63, 0.11) 
Grey matter volume -1.50 (-2.74, -0.27) -1.94 (-3.78, -0.10) 
White matter volume -0.51 (-1.70, 0.67) -1.03 (-2.79, 0.73) 
 
Abbreviations: GC-IPL= ganglion cell inner plexiform layer; RNFL= retinal nerve fiber layer; B= 





Table 13 – 3: Multivariable-adjusted estimated mean change in GC-IPL and RNFL 
thicknesses (95%CI) per standard deviation change in MRI markers  
 




per SD decrease in Occipital lobe   
Grey+White matter volume -1.77 (-6.55, 0.01) -1.87 (-4.44. 0.69) 
Grey matter volume -1.78 (-3.20, -0.36) -1.72 (-3.79, 0.34) 
White matter volume 0.07 (-1.68, 1.81) -0.27 (-2.79, 2.25) 
per SD decrease in Temporal  lobe   
Grey+White matter volume -3.45 (-5.40, -1.49) -2.70 (-2.61, 0.21) 
Grey matter volume -2.94 (-4.46, -1.41) -2.56 (-4.85, -0.27) 
White matter volume -0.55 (-2.57, 1.46) 0.14 (-2.76, 3.05) 
per SD decrease in Frontal lobe   
Grey+White matter volume 0.05 (-2.67, 2.76) 1.16 (-2.72, 5.03) 
Grey matter volume -0.34 (-3.20, 1.53) 0.59 (-2.09, 3.26) 
White matter volume 0.81 (-1.51, 3.14) 0.56 (-2.69, 3.82) 
per SD decrease in Parietal  lobe   
Grey+White matter volume -0.24 (-2.72, 2.23) 2.83 (-0.75, 6.43) 
Grey matter volume -0.88 (-2.79, 1.03) 0.93 (-1.85, 3.71) 
White matter volume 0.67 (-1.27, 2.61) 2.18 (-0.56, 4.93) 
per SD decrease in Central  lobe   
Grey+White matter volume -0.06 (-2.56, 2.44) -0.57 (-4.16, 3.03) 
Grey matter volume -1.10 (-2.80, 0.60) -1.28 (-3.73, 1.16) 
White matter volume 1.02 (-0.80, 2.83) 0.77 (-1.85, 3.39) 
 
Abbreviations: GC-IPL= ganglion cell inner plexiform layer; RNFL= retinal nerve fiber 
layer; B= mean difference, CI= confidence interval; µm= micrometer; SD= standard 
deviation 
 
*Adjusted for age, sex, age, gender, mean arterial blood pressure, plasma blood glucose, 
serum cholesterol, smoking, axial length, OCT signal strength and total intracranial volume. 
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CHAPTER 14:  






One of the main goals of this thesis was to explore markers of cerebrovascular diseases 
and involutional changes on MR and retinal imaging and to subsequently link them with 
cognitive dysfunction. A range of cerebral markers and retinal parameters were identified 
and evaluated using visual and automated approaches in a large population based cohort 
and in a diseased population. A schematic representation of these markers identified 
through visual and quantitative techniques are summarized in Figure 14 – 1 and 2.  
Subsequently, these markers/parameters were applied to study several other 
manifestations of brain changes in the context of aging, cerebrovascular diseases and 
cognitive impairment. A summary of these findings and their link with cognition is 
shown in figure 14 – 3.  In the following sections, I will first synthesize my main findings 
from chapters 4 – 13 and will show their joint effects using Principle Component 
Analysis (PCA). I will also suggest a cerebrovascular disease burden score and will 
assess its clinical correlates with respect to cognitive impairment and dementia. Finally, I 
will expand on the implications of these markers which are then followed by future 
perspectives and recommendations. 
1.  SYNTHESIS OF MAIN FINDINGS 
The main findings described in the chapters above are discussed in the same order in 
which they appear in this thesis; first the MRI markers of cerebral small and large vessel 
diseases, followed by markers of involutional changes and their effects on cognition and 
finally retinal microvascular and neuronal markers of cerebrovascular diseases and 
involutional changes. A summary of these imaging markers has been presented in Figure 
14 – 4.  




Findings from both EDIS and memory clinic studies have shown that the cerebral small 
vessel disease as reflected by cerebral microbleeds and cortical microinfarcts (CMIs) 
were not only related to clinical outcomes (cognitive impairment and dementia) but were 
also associated with the worse performance on cognitive testing. This high lights the 
importance of microvascular pathology in cerebrovascular disease related cognitive 
decline. This is in line with other findings on established markers of cerebrovascular 
diseases such as lacunes and white matter hyperintensities which often co-exist in 
Alzheimer’s pathology and in vascular dementia.  
Age, gender, cardiovascular risk factors (hypertension, hyperlipidemia and diabetes), 
stroke and atrial fibrillation were the major risk factors of CMIs. The most striking 
findings were that CMIs which were previously reported to be a manifestation of small 
vessel disease were also related to large vessel disease. This shows that CMIs represent 
proxies for either small or large vessel infarcts or even diffuse cerebral injury through 
arteriosclerosis, microembolism and hypoperfusion. Using a detailed neuropsychological 
assessment, we further showed that the reduced performance in global cognitive scores 
together with domains of executive function, language, visuomotor speed, verbal and 
visual memory were associated with cerebral small vessel disease markers. However, in 
the memory clinic setting, this association was attenuated in the presence of atrophy 
suggesting common pathways involved in CMIs and atrophy. Our study findings from 
both EDIS and case control studies, therefore supports a major step in developing the 
non-invasive means of detecting CMIs on MRI scans during life and further unravel their 
role in aging and dementia. 




In the population based study (EDIS), we reported that the intracranial stenosis influence 
cognition through ischemic changes in the brain. On the formal neuropsychological tests, 
we found that the persons with ICS were more likely to have significant cognitive 
impairment and performed worse in the domains of executive function, language, 
visuomotor speed, verbal and visual memory albeit in the presence of infarcts. From the 
memory clinic study, we also showed that intracranial stenosis was associated with 
vascular cognitive impairment, and with dementia subtypes i.e. AD and Vascular 
dementia (VaD). The association with dementia became attenuated in the presence of 
white matter hyperintensities and infarcts. This suggests that the cerebral ischemia 
(through possible perfusion deficits) remains the common mechanism behind ICS and 
cognition. Moreover, despite having different etiologies, the association of ICS with 
different subtypes of dementia suggests that similar underlying micro- and macrovascular 
pathologies exist in both AD and cerebrovascular disease related cognitive decline. 
Hence, in summary both studies have shown that ICS effects cognition through cerebral 
ischemic damage.  
1.3  Markers of involutional changes 
We have used quantitative MRI techniques to segment cortical thickness and subcortical 
structure volumes and have reported their risk factors and relation to cognitive 
impairment and dementia. The major common risk factors were found to be age, gender, 
Malay ethnicity, diabetes and lacunar infarcts thus, high lighting the fact that these 
cortical and subcortical structures are sensitive to increasing age, hormonal effects, ethnic 
differences, systemic diseases and small vessel diseases. Moreover, we have also reported 
independent association of global and lobar specific region thinnings and subcortical 
structural volumes with severe cognitive impairment (CIND moderate and dementia). 




involutional changes in the gray matter (cortex and deep gray matter nuclei) takes place 
early in the process of dementia due to the possible progression of tau and amyloid 
pathology from the hippocampus to the rest of the brain. 
Our most interesting finding was a specific pattern of subcortical volume reduction in 
vascular vs. non vascular cognitive impairment. Smaller caudate and pallidum were 
specific to vascular cognitive impairment as they are the common sites of subcortical 
lacunes whereas the amygdala was particularly affected in non-vascular cognitive 
impairment due to increased sensitivity to AD type neuropathology. However, the 
association of other subcortical structures with cognitive impairment has suggested that 
subcortical structures are equally affected in both vascular and non-vascular cognitive 
impairment.   
1.3  Retinal markers 
Microvascular Markers 
Besides the visual assessment of retinopathy signs which have been extensively studied 
previously, we have utilized the automated image analysis technique which can quantify 
subtle changes in the retinal microvasculature by identifying changes in retinal vessel 
calibers, fractal dimension and tortuosity. We have found that the retinal venular 
widening, smaller arteriolar fractals and increased arteriolar tortuosity were associated 
with cerebral microbleeds on the MRI scans. Compared with previous studies where 
lacunes and white matter hyperintensities were linked to retinopathy, we also found the 
association of cerebral microbleeds with retinal microvascular changes suggesting that 
microbleeds may be a possible early marker of cerebrovascular disease. 
In terms of the clinical outcome, we have also reported an association of reduced 




neuropsychological assessment, we also showed that reduced retinal arteriolar and 
venular fractals were related to worse performance on verbal memory, visuoconstruction 
and visuomotor speed domains, thus further confirming that the retinal microvascular 
changes occur in preclinical cognitive impairment.  
Neuronal Markers 
Spectral domain optical coherence tomography was used to quantify retinal nerve fiber 
layer (RNFL) and ganglion cell inner plexiform layer (GC-IPL) and hence these were 
examined in relation to cognitive impairment. We found that the GC-IPL thinning was 
independently associated with cerebral atrophy in the occipital and temporal region 
whereas RNFL was related only to temporal atrophy. These findings suggest that the GC-
IPL show promise as an early and sensitive marker of involutional changes in the brain.  
2. LINKING MARKERS OF CEREBROVASCULAR DISEASES 
As mentioned previously, the aim of the work described in this thesis was to focus on 
markers of CeVD and involutional changes using both cerebral and retinal imaging and 
assess the clinical correlates of these lesions with cognitive impairment and dementia. 
Interestingly, all the markers showed a dose response relationship with increasing 
severity of cognitive impairment. The consistent pattern observed in the association of 
CeVD markers with cognitive function specifically in the domains of executive function, 
visuoconstruction, language and memory reflects underlying vascular mechanisms in 
cognitive dysfunction. 
Although my previous chapters (4-13) were concentrated on individual marker of CeVD, 
there is a need to explore the joint effect of all markers of CeVD on cognitive 
dysfunction. Previous data has suggested that small vessel diseases such as WMH, 




impairment. As these CeVD markers produce similar features of brain damage on 
imaging, it is appropriate to explore the inter-correlations between these variables. It is 
likely that markers with similar underlying pathology might co-exist and affect cognitive 
ability in the elderly. 
Principle component analysis  
Validated visual scores of MRI markers for CeVD (lacunes, WMH, microbleeds, 
intracranial stenosis, cortical infarcts and CMIs) were used to identify the clusters of MRI 
markers in the Epidemiology of Dementia In Singapore study (EDIS). We first performed 
principal component analysis (PCA) to reduce the selected six MRI markers into 
principal components (PCs). PCA revealed two PCs: PC1 was mainly driven by CMIs, 
cortical infarcts, and intracranial stenosis whilst PC2 by WMH, lacunes and microbleeds. 
The largest variance in PC1 was contributed by CMIs whereas in PC2, it was mainly 
driven by WMH. After identifying these components, we further performed regression 
analysis with cognition. In multivariate adjusted models, both PC1 and PC2 were 
independently linked with cognition (Table 14 – 1 and 14 – 2). On adding the two 
components into the same model, an independent association was observed with CIND-
moderate/dementia for both PC1 [Odds ratios (OR): 2.39; 95%CI: 1.26-4.56] and PC2 
[OR: 1.77; 95%CI: 1.11-2.81]. A similar association was also observed with composite Z 
scores (Table 14 – 3). 
Based on the above findings, a total CeVD measure may therefore better account for the 
global effect of CeVD on brain than the individual MRI features. Hence, it would be 
ideal to provide not only an efficient measure to assess the global CeVD burden but also 




using a weighted assessment which can be feasibly administered in a clinical and 
research setting. 
CeVD burden score 
In order to explore whether a weighted assessment of total CeVD burden can improve 
understanding of the cognitive consequences of CeVD, we first performed regression 
analysis between different markers of CeVD. The results showed that the presence of 
WMH was significantly correlated with multiple lacunes (φ=0.28; P<0.001) and multiple 
microbleeds (φ=0.27; P<0.001). In addition, multiple lacunes were associated with 
multiple microbleeds (φ=0.27; P<0.001) and cortical infarcts (φ=0.28; P<0.001). 
Intracranial stenosis was associated solely with cortical infarcts (φ=0.30; P<0.001). 
Moderate-to-severe WMH was independently associated with lower global cognition (β 
[SE]=−0.21 [0.16]; P<0.001).  Other CeVD markers did not show an independent 
association with global cognition. Moreover, the presence of any ≥2 CeVD indicators 
was found to be significantly associated with worse global cognitive performance (β 
[SE]=−0.09 [0.18]; P<0.01), independent of WMH. 
On the basis of linear regression coefficient established between CeVD indicators and 
cognitive performance as above, we devised a weighted CeVD burden score with 2 points 
awarded when moderate or severe WMH was present and one point awarded when at 
least 2 CeVD markers were present. 
Hence, a 4-category CeVD burden score was generated as suggested below: 
None/very mild CeVD burden score, 0= none/mild WMH and <2 other CeVD indicators. 
Mild CeVD burden score, 1= none/mild WMH and ≥2 other CeVD indicators. 
Moderate CeVD burden score, 2= moderate/severe WMH and <2 other CeVD indicators. 




An inverse association of CeVD burden score with global cognitive score and domain-
specific cognitive performance is shown in figure 14 – 5. Poor cognitive score was 
associated with moderate CeVD, whilst severe CeVD showed further compromised 
cognitive performance in language (p=0.003) and visuomotor speed (p=0.007) domains. 
Moreover, a more impaired visual memory score was found in cases with severe CeVD 
compared to moderate CeVD (p=0.006). The association of the total CeVD burden score 
with cognition suggests that there is a threshold effect: when moderate CeVD burden is 
reached, global cognitive dysfunction begins to occur.  
In summary, we provided two measures of MRI burden. First from the PC analysis which 
showed two components comprising MRI markers of small and large vessel diseases are 
equally important in cognitive dysfunction and secondly from the simple and pragmatic 
CeVD burden score, defined by a combination of WMH and other small and large vessel 
disease markers, which is inversely related to global cognitive status. This further 
confirms that the individual MRI markers are jointly indicative of an underlying CeVD 
and hence might be useful in tracking their impact on cognition and disease over time. 
Our results imply a cumulative effect of different CeVD markers on general cognitive 
ability, possibly reflecting more extensive vascular pathology in the brain that can be 
estimated using a CeVD burden score.  
These results are promising and have already provided valuable clues on the role of 
microvascular changes in CeVD and cognitive dysfunction.   
3.  IMPLICATIONS OF STUDY FINDINGS 
This thesis has highlighted the brain imaging biomarkers of cerebrovascular disease and 
involutional changes involved in cognitive impairment and dementia. Moreover, I have 




microvascular and involutional changes in the cerebral vascular and degenerative 
diseases. 
3.1  Cerebrovascular Disease Markers 
As mentioned in chapters 1 and 2, cerebrovascular diseases are a major cause and 
contributors to cognitive impairment and dementia. However, the exact mechanism 
underlying cerebrovascular disease pathology and its functional consequences (cognitive 
impairment) remains unknown. Currently, there are no adequate treatment options 
available. Furthermore, it is also unclear why some patients with cerebrovascular diseases 
develop cognitive dysfunction while others do not. Moreover, as Asian populations are 
reported to have a higher burden of vascular risk factors and cerebrovascular diseases 
compared to Caucasians, it is imperative to identify reliable markers of cerebrovascular 
diseases before an individual develop dementia in order to facilitate development of new 
treatments and prevention strategies. 
Brain Markers of Vascular Changes 
Cerebral microbleeds and CMIs have emerged as new imaging markers of cerebral small 
vessel disease besides the other conventional MRI visible lesions (lacunes and white 
matter hyperintensities). The development of higher resolution and sensitive sequences 
has sparked scientific and clinical interests in these lesions due to their possible link with 
cognitive dysfunction. It has previously been argued that established cerebrovascular MR 
lesions did not fully capture the burden of the total cerebrovascular disease pathology as 
the observed associations with clinical outcomes are often inconsistent and weak.1 Hence, 
microbleeds and CMIs could potentially account for the unexplained variances observed 
in the previous studies. Furthermore, as both these lesions can be feasibly detected on 




relevance of these lesions in research settings. As described in this thesis, we were able to 
describe their prevalence and demonstrated their link with cognitive dysfunction 
independent of other cerebrovascular disease markers. Hence, microbleeds and CMIs are 
potentially early markers of cerebrovascular diseases and are related to cognitive decline 
and dementia. 
Besides the cerebral small vessel diseases, intracranial stenosis (ICS) secondary to large 
artery atherosclerosis has been reported to be highly prevalent in Asians due to higher 
prevalence of vascular risk factors. The prevalence of ICS in Chinese is much higher (40-
50%) compared to Caucasians (8-10%).2 In this context, both EDIS and case control 
studies provide an ideal platform to study the prevalence of ICS not only in asymptomatic 
Chinese subjects but also in vascular cognitive impairment, AD, Vascular dementia. We 
have already shown that ICS leads to cognitive dysfunction in the presence of cerebral 
ischemic changes (infarcts and white matter hyperintensities). The cognitive deficits 
develop as a result of microcirculation defects, increased resistance in the small blood 
vessels and reduced vascular reactivity leading to cerebral hypoperfusion. This 
hypoperfusion not only triggers but may also accelerate neurodegenerative process by 
facilitating amyloid beta deposition.3 This further suggests that the ICS does not directly 
reduce cognitive functioning but in fact is a marker of cerebral or generalized 
atherosclerosis.4  
Retinal Markers of Vascular Changes 
We have demonstrated retinal imaging to be a simple and feasible tool for studying 
microvascular changes in cerebrovascular diseases and cognitive impairment. Semi-
automated techniques for analyzing retinal photography are able to quantify subtle 




tortuosity are of particular interest as they are not affected by pulse wave velocity unlike 
vessel calibers. The association of reduced fractal dimension with cerebral microbleeds in 
our study suggests that this might be an early and sensitive marker of cerebrovascular 
damage in the brain. Retinal vascular changes mirror changes in the cerebral 
microvasculature through impaired vascular perfusion, vessel wall dysfunction and blood 
retinal-brain damage. Moreover, the association of smaller fractal density with preclinical 
cognitive impairment suggests that cerebral hypoperfusion occurs relatively early in the 
course of cognitive dysfunction. This further confirms that microvascular damage is 
common in both cerebrovascular diseases and cognitive impairment. 
Hence, based on our results on brain and retinal vascular markers, we have 
consistently shown that vascular pathology is indeed an important contributor to 
cognitive impairment and dementia. This further suggests that cerebrovascular 
diseases should be accounted for in all the studies focusing on cognitive impairment, 
AD and vascular dementias.  
3.2  Markers of involutional changes 
Neurodegeneration remains the pathological hall mark of AD and is even observed in 
preclinical cognitive impairment and normal aging. This process encompasses neuronal 
loss in both cortical and subcortical structures. Although atrophy is generally considered 
a late biomarker for AD, it is the most versatile and prominent marker of neuronal 
changes in the brain. Hence it is viable to detect subtle changes in the brain which could 
potentially serve as useful markers for tracking diseases progression.  
Brain Markers of Neuronal Loss 
Robust, automated procedures have made it possible to segment gray matter in brain 




sex, race, cardiovascular risk factors and other cerebrovascular disease markers, all 
triggers and affects the involutional changes as shown by our findings from the 
population based study. Moreover, pathological changes possibly induced by risk factors 
in both cortical and subcortical structures gives rise to wide range of cognitive deficits as 
reflected by reduced cognitive performance. The improved techniques of detecting subtle 
cortical thinning and subcortical structure volumes offer insight into early degenerative 
damage and further confirm that these changes are indeed taking place much earlier in the 
dementia cascade. Moreover, the association of subcortical atrophy in both vascular and 
non-vascular cognitive impairments suggests vascular insufficiency promoting 
neurodegeneration or vice versa, thus shedding light onto an additive or synergistic 
effects between AD pathology and cerebrovascular diseases.   
Retinal Marker of Neuronal Loss 
Development in the Optical Coherence Tomography (OCT), has resulted in the 
segmentation of two key neuronal layers; Retinal Nerve Fiber Layer (RNFL) and 
Ganglion Cell Inner Plexiform Layer (GC-IPL). Thinning of the GC-IPL was related to 
both the occipital and temporal atrophy in the brain, suggesting that the GC-IPL is a 
sensitive marker for involutional changes. By using OCT, we have demonstrated that 
cerebral atrophy, measurement of which requires expertise and depends on expensive 
technique, is now easily accessible. Hence, changes in the retinal ganglion cell can serve 
as biomarkers for region specific involutional changes in the brain.   
Thus, these sensitive cerebral and retinal neuronal markers can reflect underlying 
cerebral neuronal damage resulting from AD or cerebrovascular disease related 




4.  STRENGTHS AND LIMITATIONS 
Strengths and limitations pertaining to EDIS and case-control studies have been 
described in detail in each chapter. In the following sections, I highlight the common 
strengths and limitations relevant to the two studies.  
4.1  Strengths 
The major strengths of the studies include use of the large population based sample 
(EDIS), detailed neuropsychological assessment to diagnose cognitive impairment and 
dementia and availability of 3T MRI scans to grade and classify individuals based on the 
cerebrovascular diseases. Both studies had standardized protocols to assess MRI and 
retinal quantitative changes using semi-automated and automated techniques which 
ensured direct comparison between the two studies. All the final analyses were adjusted 
for possible confounders to show independent effects of imaging markers with cognition.  
4.2  Limitations  
Although efforts were made to minimize the potential source of bias in the two studies, 
there still remain some common limitations which can contribute to following errors: 
Temporal Relationship 
In both the EDIS (cross-sectional) and case control studies, it was difficult to determine 
the temporal relationship between MRI and retinal imaging markers with cognitive 
dysfunction which limits the interpretation of the study findings.  
Selection Bias 
In the EDIS study, 47.2% of the screened positive subjects did not participate in the 




relatively older, less educated, and more likely to have hypertension. Hence it is likely 
that they might have had poor cognitive function and/or had higher prevalence of 
cerebrovascular diseases which could lead to underestimation of effect sizes. Moreover, 
of those who participated, nearly 40% did not complete OCT scanning or had ungradable 
scans for analysis. Therefore, the generalizability of our results may be limited. Moreover 
it would have been ideal to perform the MR imaging in individuals who were cognitively 
normal (passed AMT and PFQ).  This would have allowed us to report on the prevalence 
of incidental findings of cerebrovascular diseases in cognitively asymptomatic 
individuals.  
In relation to case control study, cases and half of the controls were recruited from two 
locations i.e. memory clinic and the community. The control group consisted of relatively 
younger subjects who had less burden of cerebrovascular diseases on their MRI 
compared to cognitively impaired individuals. Also there was a higher burden of vascular 
risk factors (hypertension, hyperlipidemia and diabetes) in this sample which limited the 
generalizability of our results to the general population. 
Information Bias 
The classification of cognitive outcomes (CIND and dementia) together with functional 
loss was corroborated using clinical history which was subjected to underreporting from 
both the patients and caregivers, leading to information bias. In terms of retinal imaging, 
as only one eye was randomly selected without taking into account the severity of the 
disease in either of the eye, this may have led to misclassification bias.  
Confounding 
Even though standardized procedures were used for assessments (collection of risk 




differences in the definition of cardiovascular risk factors (medical history vs. single 
measurement of blood pressure, cholesterol and blood sugar) which could have resulted 
in residual confounding. Other possible causes of residual confounding include 
adjustment for categorical variables instead of the continuous ones and the presence of 
unknown confounders which might not have accounted for in both the studies.  
5.  FUTURE PERSPECTIVES AND RECOMMENDATIONS 
Throughout the thesis, I have consistently demonstrated that both the brain and retinal 
imaging markers can provide novel insights into the pathophysiology of cerebrovascular 
disease and cognitive impairment. However, there are still other areas that need to be 
explored and requires attention. 
5.1 Structural to Functional Parameters 
Our present findings were based on the structural changes on both MR and retinal 
imaging which usually indicate irreversible damage. Future studies focusing on the 
functional or dynamic biomarkers would be able to help uncover early pathological 
mechanisms behind cerebrovascular diseases and involutional changes. The future 
directions and recommendations of each biomarker are given below; 
Magnetic Resonance Imaging (MRI) 
Cerebral Microbleeds and Susceptibility Mapping Images 
Susceptibility weighted imaging which is extensively used to grade microbleeds is 
limited by undesirable artifacts created by veins and calcium depositions. Addition of 
MR phase data or quantitative susceptibility mapping images which identify true iron 
containing lesions, can provide better tool for diagnosing microbleeds.5, 6 They could also 




(PiB-PET)6 which better identifies amyloid deposition and hence might be able to 
provide the clinical relevance of these lesions in relation to CAA. 
Cerebral Microinfarcts, Perfusion and White Matter Integrity 
Our findings provide clues that CMIs are possible expressions of both small vessel and 
large vessel diseases which can be the result of a) small vessel changes, b) microemboli 
secondary to atrial fibrillation or stenosis in an upstream vessel, or c) hypoperfusion. 
Future studies can benefit from the use of transcranial doppler (TCD) or arterial spin 
labeling (ASL) technique with brain density maps to help unravel the perfusion deficits in 
the whole brain and in area surrounding the lesion. Another interesting aspect to explore 
the link between CMIs and heart would be to determine its link with cardiac biomarkers 
(brain natriuretic peptide, troponin T and growth differentiation factor 15) of ischemic 
heart disease, atrial fibrillation and congestive heart failure in conjunction with TCD and 
echo cardiogram. 
Moreover, the eventual outcome of CMIs on cognition remains mixed as evident from 
our samples and previous study.7 Do CMIs directly disrupt neuronal connections or co-
occur in parallel with other cerebrovascular diseases to produce cognitive dysfunction 
remains unknown? A combination of structural sequences together with its effect on 
white matter integrity using diffusion tensor imaging (DTI) or functional connectomes 
can help unravel the true meaning of these lesions. Moving on from cortical to 
subcortical microinfarcts might be another useful strategy to understand complete burden 
of cerebrovascular diseases in cognitive impairment and dementia.  
Intracranial Stenosis and Cerebral Hemodynamics 
We have demonstrated the effects of intracranial stenosis on cognitive performance 




from functional imaging such as perfusion techniques (ASL) which is able to detect  
alterations in the cerebrovascular reactivity in both the symptomatic and asymptomatic 
individuals. Detection of cerebral hemodynamics through perfusion may serve as a useful 
strategy in the management of subjects with carotid stenosis even in the absence of signs 
or symptoms of cerebrovascular disease.8 However, the contemporary medical therapy 
(antiplatelet and statin therapy) vs. surgical endarterectomy as means of treatment for 
asymptomatic carotid stenosis remains inconclusive.  Other valuable methods to identify 
high-risk asymptomatic carotid stenosis besides MRA is the transcranial Doppler 
embolus detection, advanced carotid imaging and plaque characterization.9 These various 
imaging parameters can be combined to estimate the individual risk of ischemia.10, 11 
However, their added value needs to be confirmed in large, multicenter studies. 
Cortical Thickness, Subcortical Structural Volumes and White Matter Integrity 
The automated segmentation tool has the advantage of being stable due to the 
cytoarchitectural features of the gray matter and thus is a desirable measure of disease 
related subtle alterations.12 Mesaures of cortical thinning and decreasing subcortical 
structure volume can serve as reliable tools to identify MCI from AD and it can even 
detect, at risk patients, of converting into dementia. Future studies can reliably use these 
techniques in conjunction with tractography and voxel based methods utilizing multiple 
novel analysis approaches. These will include remote effects of cortical thinning in 
relation to subcortical infarcts,13 localization of white matter hyperintensities on white 
matter tracts and their effects on cognitive domains using lesion symptom mapping 
approach14 and relation of cortical thickness and subcortical structure volume with white 





Retinal imaging has the potential to study cerebrovascular diseases and involutional 
changes in the brain. We have demonstrated the association of structural retinal imaging 
in relation to cerebral small vessel and degenerative changes and preclinical cognitive 
impairment. The potential of retinal imaging biomarkers for screening, prognostic and 
assessment purposes need to be further evaluated in future prospective studies. 
Retinal Microvascular Changes and Cerebral Hemodynamics 
Using combined retinal vascular parameters (calibers, fractal dimension and tortuosity) 
instead of individual marker, might be better in providing specificity and etiologies for 
different subtypes of dementia and other diseases (cardiovascular and kidney diseases). 
Moreover, utilizing functional biomarkers from retinal vascular imaging which includes 
dynamic vessel analyzer,16 doppler flowmetry17 and retinal oximeter17 may be able to 
provide insights into cerebral hemodynamics in cerebrovascular diseases and dementia. 
Retinal Neuronal Changes and Cerebral Involutional Changes 
According to our findings, GC-IPL thinning was more related to cerebral gray matter loss 
compared to RNFL. The latter comprises axonal processes of the ganglion cell and hence 
may be more related to white matter changes. This might be better assessed at the 
microstructural level i.e. white matter integrity using DTI and functional connectome. 
Adaptive optics in combination with OCT may be able to provide detailed retinal 
structural images (nerve bundle layers, capillaries and photoreceptors) and hence can be 
used to study amyloid plaque deposition and dynamics.18  
5.2  Longitudinal Design  
As mentioned in the paragraph of limitations, our findings were based on the cross 




imaging markers and cognitive impairment. Future population based studies using a 
prospective longitudinal design can provide more insights on the temporal relationship of 
these MRI (microbleeds, microinfarcts and ICS) and retinal defined structural changes 
(microstructural and neuronal layer chnages) with the risk of other cerebrovascular 
diseases, cognitive decline and conversion of MCI to dementia.  
5.3  Composite CeVD markers 
Integrating results from PCA and joint CeVD burden score can direct studies towards a 
better understanding of CeVD and should be validated across cohorts with wide age 
ranges, longitudinal design and in animal models. Specifically, studies across a wider age 
range may provide insights into the temporal sequence of CeVD markers, whilst 
longitudinal studies are necessary to demonstrate causality. Animal models are required 
to investigate mechanisms and targets for therapies which will eventually justify 
interventional clinical trials.  
5.4 Furture extension of current work 
Apart from above recommendations, I also suggest the following as future extension of 
the current work:   
1. Determine  interaction between markers of cerebral small vessel diseases and 
explore their synergistic effect on cognitive dysfunction,  
2. A meta-analysis on the previous literature based on these markers and how they 
differ from current findings, 
3. Evaluation of the causal link between markers of cerebrovascular 
diseases/neurodegeneration and cognition using Structural Equation Modelling 




4. Longitudinal extension of the current work by repeating followup of the study 
participants 
5. Adding markers of involutional changes and retinal imaging in both PCA and 
CeVD burden score whihc might be useful to capture complete CeVD burden.   
5.5 Translating Imaging Biomarkers into Clinical Practice 
As cerebrovascular diseases remains the most common cause of cognitive impairment 
and dementia, it seems prudent that, its detection during life requires attention. Due to 
availability of 3T MRI scans in clinical settings, I recommend that the detection of 
micobleeds, microinfarcts and intracranial stenosis should routinely be conducted in 
patients presenting in the clinics with symptoms of cognitive impairment, besides the 
infarcts and white matter hyperintensities. Moreover, they should also be screened in 
subjects who are at risk of cognitive decline and dementia. In addition to MR scanning, 
retinal imaging could potentially be used as a research tool to provide a better picture of 
the underlying cerebrovascular diseases and involutional changes. Lastly, both cerebral 
and retinal imaging markers can provide new clues for the implementation of therapeutic 
and preventive interventions in clinical trials. In particular, these imaging biomarkers can 
be used as a “surrogate” for preclinical brain diseases to show efficacy of a drug in a trial 
setting and to identify and select individuals who will gain most from the use of 
particular drugs or interventions. 
5.  CONCLUSION 
Cerebrovascular diseases are a collective term including both small and large vessel 
alterations and cerebral atrophy. In this thesis, I have investigated the MRI manifestation 
of cerebrovascular diseases (microbleeds and intracranial stenosis) and uncovered clinical 




impact of the cerebrovascular disease markers on cognition and also identify their major 
risk factors. Furthermore, I have also shown that the retinal imaging is an additional 
imaging tool in aiding our understanding of the mechanism behind cerebrovascular and 
involutional changes. Future studies should be directed towards understanding the 
longitudinal implications of these cerebrovascular disease markers, to the 
pathophysiological mechanism that drives the formation of these markers, and their 
impact on structure and function of aging brain. This will direct the studies towards the 






CHAPTER 14 – REFERENCES 
  
1. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: 
the invisible lesions. Lancet Neurol. 2012;11:272-82. 
2. Li H, Wong KS. Racial distribution of intracranial and extracranial 
atherosclerosis. Journal of clinical neuroscience : official journal of the Neurosurgical 
Society of Australasia. 2003;10:30-4 
3.  Thiel A, Cechetto DF, Heiss WD, Hachinski V, Whitehead SN. Amyloid burden, 
neuroinflammation, and links to cognitive decline after ischemic stroke. Stroke. 2014;45: 
2825-9. 
4. Mathiesen EB, Waterloo K, Joakimsen O, Bakke SJ, Jacobsen EA, Bonaa KH. 
Reduced neuropsychological test performance in asymptomatic carotid stenosis: The 
Tromso Study. Neurology. 2004;62:695-701. 
5. Klohs J, Deistung A, Schweser F, et al. Detection of cerebral microbleeds with 
quantitative susceptibility mapping in the ArcAbeta mouse model of cerebral 
amyloidosis. Journal of cerebral blood flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow and Metabolism. 2011;31:2282-92. 
6. McAuley G, Schrag M, Barnes S, et al. Iron quantification of microbleeds in 
postmortem brain. Magnetic resonance in medicine. 2011;65:1592-1601. 
7. van Veluw SJ, Heringa SM, Kuijf HJ, Koek HL, Luijten PR, Biessels GJ. 
Cerebral cortical microinfarcts at 7Tesla MRI in patients with early Alzheimer's disease. 
Journal of Alzheimer's disease : JAD. 2014;39:163-7. 
8. Fearn SJ, Hutchinson S, Riding G, Hill-Wilson G, Wesnes K, McCollum CN. 
Carotid endarterectomy improves cognitive function in patients with exhausted 
cerebrovascular reserve. European journal of vascular and endovascular surgery : the 




9. Singh TD, Kramer CL, Mandrekar J, Lanzino G, Rabinstein AA. Asymptomatic 
Carotid Stenosis: Risk of Progression and Development of Symptoms. Cerebrovasc Dis 
2015;40:236-43. 
10. Naylor AR. Time to rethink management strategies in asymptomatic carotid 
artery disease. Nature reviews Cardiology. 2012;9:116-24. 
11. Naylor AR, Schroeder TV, Sillesen H. Clinical and imaging features associated 
with an increased risk of late stroke in patients with asymptomatic carotid disease. 
European journal of vascular and endovascular surgery : the official journal of the 
European Society for Vascular Surgery. 2014;48:633-40. 
12. Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial 
patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain. 
2006;129:2885-93. 
13. Duering M, Righart R, Wollenweber FA, Zietemann V, Gesierich B, Dichgans 
M. Acute infarcts cause focal thinning in remote cortex via degeneration of connecting 
fiber tracts. Neurology. 2015;84:1685-92. 
14. Biesbroek JM, Kuijf HJ, van der Graaf Y, et al. Association between subcortical 
vascular lesion location and cognition: a voxel-based and tract-based lesion-symptom 
mapping study. The SMART-MR study. PloS one. 2013;8,e60541. 
15. Bennett IJ, Madden DJ. Disconnected aging: cerebral white matter integrity and 
age-related differences in cognition. Neuroscience. 2014;276:187-205. 
16. Frost S, Kanagasingam Y, Sohrabi H, et al. Retinal vascular biomarkers for early 
detection and monitoring of Alzheimer's disease. Translational psychiatry. 2013;3,e233. 
17. Harazny JM, Raff U, Welzenbach J, et al. New software analyses increase the 
reliability of measurements of retinal arterioles morphology by scanning laser Doppler 




18. Lombardo M, Serrao S, Devaney N, Parravano M, Lombardo G. Adaptive optics 
























Table 14 - 1: Association of component 1 with cognition 
 
Model I: included age, gender and education 
Model II: included age, gender, education, race, mean arterial blood pressure, total cholesterol, 
random blood glucose, smoking, BMI, peripheral arterial disease 
Model III: included age, gender, race, mean arterial blood pressure, total cholesterol, random 
blood glucose, smoking, BMI, peripheral arterial disease, total intracranial volume, gray matter 
volume, white matter volume, hippocampus volume 
  









Composite Z scores 
(n=579) 
Mean difference (95%CI) 
Model I 1.53 (0.92 - 2.53) 3.06 (1.64 – 5.69) 3.17 (1.71 – 5.87) -0.16 (-0.23; -0.10) 
Model II 1.24 (0.75 - 2.04) 2.50 (1.31 – 4.79) 2.55 (1.33 – 4.88) -0.14 (-0.19; -0.07) 





Table 14 - 2: Association of component 2 with cognition 
 
Model I: included age, gender and education 
Model II: included age, gender, education, race, mean arterial blood pressure, total cholesterol, 
random blood glucose, smoking, BMI, peripheral arterial disease 
Model III: included age, gender, race, mean arterial blood pressure, total cholesterol, random 
blood glucose, smoking, BMI, peripheral arterial disease, total intracranial volume, gray matter 
volume, white matter volume, hippocampus volume 
  









Composite Z scores 
(n=579) 
Mean difference (95%CI) 
Model I 1.52 (1.09 – 2.10) 1.74 (1.22 – 2.47) 1.78 (1.26 – 2.51) -0.18 (-0.25; -0.11) 
Model II 1.44 (1.00 - 2.07) 1.50 (1.00 – 2.25) 1.54 (1.03 – 2.31) -0.09 (-0.17; -0.03) 





Table 3: Association of components 1 and 2 with cognition 
 
Model I: included age, gender and education 
Model II: included age, gender, education, race, mean arterial blood pressure, total cholesterol, 
random blood glucose, smoking, BMI, peripheral arterial disease 
Model III: included age, gender, race, mean arterial blood pressure, total cholesterol, random 
blood glucose, smoking, BMI, peripheral arterial disease, total intracranial volume, gray matter 
volume, white matter volume, hippocampus volume 
  









Composite Z scores 
(n=579) 
























-0.16 (-0.22; -0.10) 
 
























-0.14 (-0.20; -0.08) 
 























-0.14 (-0.21; -0.08) 
 












CHAPTER 14 – FIGURES 
 
Figure 14 - 1: MR qualitative and quantitative markers of cerebrovascular diseases and 
involutional changes 
Schematic representation of MRI qualitative (visible) and quantitative (invisible) markers of 
cerebrovascular disease and involutional changes. It is now possible to detect the subtle changes in the 
brain parenchyma through the automated software. This has led to the better understanding of the 
association between qualitative and quantitative markers of cerebrovascular diseases/involutional 




Figure 14 - 2: Retinal qualitative and quantitative markers of cerebrovascular diseases and 
involutional changes  
Schematic representation of retinal qualitative and quantitative cerebrovascular disease and 
involutional changes markers. It is now possible to detect the subtle changes in the retinal 
microvascular and neuronal layers through the automated software. This has led to the better 
understanding of the association between qualitative and quantitative markers with 









Figure 14 - 3: Summary of the cerebral and retinal markers of cerebrovascular diseases and neurodegeneration and their link with cognition 
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Figure 14 - 5: Global and domain-based neurocognitive performance in different CeVD severity groups with error bars 
Summary of Publications 
337 
 
SUMMARY OF PUBLICATIONS 
 
Aims Studies Main findings/ High lights Status Authorship 
Aim 1: Brain markers of small vessel disease     
a. Cerebral microbleeds (CMB) EDIS CMB is associated with worse performance on cognitive 
testing (executive function, attention and visuoconstruction) 
Alzheimer Dis Assoc Disord. 
2014; 28(2):106-12 
1st 
b. Cerebral cortical microinfarcts (CMIs) Case control  CMIs are novel marker of cerebrovascular disease and 
associated with worse performance in language and 
visuoconstruction.  
Alzheimers Dement. 2015; 
S1552-5260(15):00123-5 
2nd 
c. Cerebral cortical microinfarcts (CMIs) EDIS CMIs are associated with severe cognitive impairment and 
worse performance in the domains of executive function, 
verbal and visual memory 
Revision for Neurology 1st 
Aim 2: Brain marker of large vessel disease     
a. Intracranial stenosis (ICS) EDIS ICS is associated with severe cognitive impairment and in 
domains of executive function, language, visuomotor speed, 
verbal and visual memory.  
Alzheimer Dis Assoc Disord. 
2015;29(1):12-7 
1st 
b. Intracranial stenosis (ICS) Case control ICS is associated with vascular cognitive impairment and 
dementias (AD and VaD).  
In preparation. Submit to 
Journal of cerebral blood 
flow and metabolism 
1st 
Aim 3: Brain markers of involutional changes     
a. Cortical thickness EDIS Decreasing global and regional cortical thickness is 
significantly associated with cognitive impairment and 
dementia 
Medicine 2015; 94(23):e852 1st 
b. Subcortical structure volumes EDIS and case 
control 
Subcortical volume reduction is related to cognitive 
impairment and dementia. Subcortical structures are equally 
affected in both vascular and non vascular cognitive 
impairment 
J Alzheimers Dis. 2015; 
48(3): 813-23 
1st 
Aim 4: Retinal markers of cerebrovascular 
diseases and involutional changes 
    
a. Retinal microvascular changes EDIS Smaller arteriolar and wider venular calibers and smaller 




b. Retinal microvascular changes EDIS Reduced fractal dimension associated with worse performance 
on verbal memory, visuoconstruction 
and visuomotor speed 
Dement  geriatr cogn disord 
extra. 2014; 4:305-13 
2nd 
c. Retinal neuronal changes EDIS Smaller occipital and temporal gray matter volumes are 
associated with GC-IPL thinning whereas smaller temporal 
gray matter volume associated with RNFL thinning 
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APPENDIX 1 – LIST OF ABBREVIATIONS 
 
Abbreviation Term 
AD Alzheimer's Disease 
AGES-Reykjavik Age, Gene/Environment Susceptibility-Reykjavik 
AIBL Australian Imaging, Biomarker & Lifestyle 
aMCI Amnestic Mild Cognitive Impairment 
AMT Abbreviated Mental Test 
ARIC Atherosclerosis Risk in Communities 
AV nicking Arteriovenous nicking 
BMES Blue Mountains Eye Study 
BMI Body Mass Index 
BOMBS Brain Observer Microbleed Scale 
CAA Cerebral Amyloid Angiopathy 
CADASIL Cerebral Autosomal-Dominant Arteriopathy with Subcortical 
Infarcts and Leukoencephalopathy 
CASI-S Cognitive Abilities Screening Instrument-Short 
CDR Clinical Dementia Rating scale 
CERAD Consortium to Establish a Registry for Alzheimer’s Disease 
CeVD Cerebrovascular diseases 
CHS Cardiovascular Health Study 
CI Confidence interval 
CIND  Cognitive Impairment No Dementia 
CMB Cerebral microbleeds 
CMIs Cerebral microinfarcts 
CRAE Central Retinal Arteriolar Equivalent 
CRVE Central Retinal Venular Equivalent 
CT Computed Tomography 
DSM Diagnostic and Statistical Manual of Mental Disorders 
DSRB Domain-Specific Review Board 
DSC Dice Similarity Coefficient 
EDIS Epidemiology of Dementia In Singapore study 
EOAD Early Onset Alzheimer's Disease 
FLAIR Fluid Attenuated Inversion Recovery 






GC-IPL Ganglion cell-Inner Plexiform Layer 
GDS Geriatric Depression Scale 
GE Gradient Echo 
HD-OCT High Definition-Optical Coherence Tomography 
HERNS Hereditary Endotheliopathy with Retinopathy, Nephropathy and 
Stroke 
HR Hazard Ratio 
IADL Instrumental Activities of Daily Living 
ICC Intraclass Correlation Coefficient 
ICS Intracranial stenosis 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
LALES Los Angeles Latino Eye Study 
LOAD Late Onset Alzheimer's Disease 
MABP Mean Arterial Blood Pressure 
MCA Middle Cerebral Artery 
MCI Mild cognitive impairment 
MMSE Mini Mental Status Examination 
MoCA Montreal Cognitive Assessment 
MPRAGE Magnetization Prepared Rapid Gradient Recalled Echo 
MRA Magnetic Resonance Angiography 
MRI Magnetic Resonance Imaging 
NCI No Cognitive Impairment 
NINDS-ADRDA National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and Related Disorders 
Association 
NINDS-AIREN National Institute for Neurological Disorders and Stroke-
Association Internationale pour la Recherche et l'Enseignement en 
Neurosciences 
OCT Optical Coherence Tomography 
OR Odds Ratios 
PF Progressive Forgetfulness 
RNFL Retinal Nerve Fiber Layer 
RR Relative Risk 
  
RSS Rotterdam Scan Study 
RUN-DMC Radboud University Nijmegen Diffusion tensor and MRI 
Cohort 
SCES Singapore Chinese Eye Study 
SD Standard Deviation 






SEED Singapore Epidemiology of Eye Disease 
SiMES Singapore Malay Eye Study 
SINDI Singapore Indian Eye Study 
SIVA Singapore I Vessel Analysis 
STRIVE STandards for ReportIng Vascular changes on nEuroimaging 
SVD Small Vessel Disease 
SWI Susceptibility-weighted imaging 
T Tesla 
TBV Total Brain Volume 
TCD Transcranial Doppler  
TD-OCT Time Domain-Optical Coherence Tomography 
TE Time to Echo 
TIV Total Intracranial volume 
ToF Time of Flight 
TR Repetition Time 
VaD Vascular dementia 
VCI Vascular Cognitive Impairment 
WAIS Wechsler Adult Intelligence Scale  
WHO World Health Organization 
WMH White Matter Hyperintensities 






APPENDIX 2 – SUMMARY OF WORK DONE 
 
Epidemiology of Dementia In Singapore study (EDIS) 
• Subject assessments (questionnaire, physical examination, clinical history) 
• Neuroimaging gradings 
• Participation in consensus for clinical diagnosis of subjects  
• Study coordination (retinal imaging, neuroimaging segmentations) with 
multi-disciplinary teams which includes; 
- Singapore Eye Research Institute 
- Erasmus Univerity Medical Center 
- Utrecht Medical Center 
• Data cleaning and data management 
• Data analysis 
• Manuscript writing 
Case control study 
• Subject assessments (questionnaire, physical examination, clinical history) 
• Neuroimaging gradings 
• Participation in consensus for clinical diagnosis of subjects  
• Study coordination (neuroimaging segmentations) with multi-disciplinary 
teams which includes; 
- Erasmus Univerity Medical Center 
- Utrecht Medical Center 
• Data cleaning and data management 
• Data analysis 
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